Document:

Exhibit 10.2

 

INTELLECTUAL
PROPERTY LICENSE AGREEMENT

 

This
Intellectual Property License Agreement (“Agreement”) is made, entered into, and effective as of April 2, 2021 (the
“Effective Date”) by and between Medovex Corp., a Nevada corporation having an address at 201 E. Kennedy Blvd,
Suite 700, Tampa, Florida 33602 (“Licensor”) and Medovex, LLC, a Delaware limited liability company (“Licensee”).

 

Background

 

Medovex
owns certain personal property that the Licensee believes would be useful for or in the conduct of its business. The parties have entered
into that certain Contribution Agreement of even date herewith that contemplates a transaction in which Medovex will assign and contribute
such personal property and related rights, constituting all of the tangible assets of Medovex relating to the DenerveX® rotational
ablation denervation device (the “DenerveX Device”) to the Licensee in exchange for the Consideration described in
the Contribution Agreement. The contributed assets exclude all Intellectual Property (defined below) in or to the DenerveX Device, and
Licensor retains ownership of all such Intellectual Property. Licensee would like to license the Intellectual Property for use in commercializing
the DenerveX Device, and Medovex is willing to grant such a license to Licensee subject to the terms and conditions of this Agreement.

 

Now
therefore, in consideration of the mutual promises and benefits stated herein, the receipt and sufficiency of which consideration is
hereby acknowledged, the parties, intending to be legally bound, agree as follows:

 

ARTICLE
1 – DEFINITIONS

 

1.1.
“Base Applications” means the pending patent applications identified in Exhibit “A,” attached hereto and
incorporated herein by this reference. The term “Base Applications” also includes all divisionals, continuations, reissues,
re-examinations, continuation-in-part applications, and any other applications claiming priority to or the benefit of any of the Base
Applications or any applications from which any Patent issues or grants.

 

1.2.
“Improvements” means all inventions, developments, modifications, or improvements of an invention, component, method,
process, material, or design, whether or not patentable, relating to the Patents, Base Applications, Technology, Intellectual Property,
or Licensed Product that are made or acquired by Licensor or Licensee during the Term of this Agreement.

 

1.3.
“Intellectual Property” means all intellectual property rights in or to the DenerveX Device, including, without limitation:
(i) all Patents and Base Applications; (ii) the Technology and all other inventions (whether patentable or not in any country), invention
disclosures, trade secrets, proprietary information, know-how, technical data, and claimed and unclaimed subject matter disclosed in
any of the Patents or Base Applications; (iii) copyrights, mask works, copyright registrations, mask work registrations, and applications
therefor in any country, and all other rights corresponding thereto throughout the world; (iv) the Trademarks; (v) other proprietary
rights in technology, including, without limitation, design history files, sterilization plans, specifications, recipes of systems and
subsystems, data, reports and records, software (in source code and object code), algorithms, architecture, databases, development tools,
and all documentation and media constituting, describing, or relating to the above, including, without limitation, manuals, memoranda,
business information, anywhere in the world, and all updates, upgrades, corrections, modifications, translations, releases, versions,
and derivative works and improvements of each of the foregoing items; (vi) Improvements to any of the foregoing; and (vii) any applications,
registrations, provisional applications, or other filings for, or to obtain, protect, perfect, or secure any of the foregoing, anywhere
in the world.

 

    	 

     

    

 

1.4.
“Key Patent Nonenforceability Event” means if at any time during the Term, one or more of the patents identified on
Exhibit “B” to this Agreement become invalid or unenforceable in courts of competent jurisdiction within the European Union
and all appeals and opportunities for appeals are finally exhausted, and Licensor does not cure such occurrence within sixty (60) days
of its receipt of notice thereof of such invalidity or unenforceability.

 

1.5.
“Licensed Field” means all uses in all areas, both commercial and non-commercial, without any exclusions or exceptions.

 

1.6.
“Licensed Product” means, collectively, the DenerveX Device and any other article, device, method, process, or activity
exploited by Licensee, including, without limitation, any making, using, selling, importing, and offering for sale that (i) would otherwise
infringe any one or more claims of any Patent in the absence of a right or license; or (ii) uses, incorporates, or otherwise employs,
in whole or in part, any Intellectual Property other than the Patents.

 

1.7.
“Gross Sales” means the total revenues derived by Licensee from the sale of the Licensed Product without deductions
or set-offs of any kind or nature.

 

1.8.
“Patent” means the patents identified in Exhibit “A,” any and all patents issuing during the Term within
the Territory claiming priority to or the benefit of any one or more of the Base Applications.

 

1.9.
“Royalties” means, collectively, all Patent Royalties and all IP Royalties, which terms are defined in Sections 3.1(b)
and 3.1(c) below, respectively.

 

1.10.
“Sale of the Company” means (a) the closing of the sale, transfer or other disposition, in a single transaction or
series of related transactions, or all or substantially all of Licensee’s assets or (b) a transaction or series of related transactions
in which a person or entity, or a group of related persons or entities, acquires from the equityholders of Licensee’s securities
representing more than fifty percent (50%) of the outstanding voting power of Licensee. For the avoidance of doubt, a transaction will
not constitute a “Sale of the Company” if its sole purpose is to change the state of Licensee’s formation or to create
a holding company that will be owned in substantially the same proportions by the persons who held Licensee’s securities immediately
prior to such transaction.

 

1.11.
“Technology” means all trade secrets, and all other data, discoveries, inventions, technical information, manufacturing
processes, and know-how that are not publicly or generally known and that are disclosed to Licensee by or on behalf of Licensor under
this Agreement for the use in the commercialization of the DenerveX Device.

 

1.12.
“Term” means the term of this Agreement as set forth in Section 9.1 below.

 

    	2

     

    

 

1.13.
“Territory” means worldwide.

 

1.14.
“Trademarks” means all of Licensor’s trademarks related to the DenerveX Device, whether registered or unregistered,
including, without limitation, the trademarks identified in Exhibit “A,” and all similar trademarks, service marks, trade
dress, trade names, logos, internet domain names, and registrations and applications for registration thereof, together with all of the
goodwill associated therewith.

 

ARTICLE
2 - GRANT OF LICENSE

 

2.1.
Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, personal, non-transferable,
limited license to make, use, sell, offer for sale and import the Licensed Products in the Licensed Field and throughout the Territory
using the Intellectual Property during the Term (hereinafter the “License”). Licensee shall not have the right to
grant sublicenses, without the express permission of the Licensor. Any rights not expressly granted to Licensee in this Agreement are
retained by and reserved to Licensor.

 

ARTICLE
3 - PAYMENTS UNDER THE LICENSE

 

3.1.
Royalties. Licensee agrees to pay to Licensor the following royalties:

 

3.1.1.
During the Patent Royalty Period (defined below), a royalty of six percent (6%) of the Gross Sales of all Licensed Products sold by Licensee
in the Licensed Field within the Territory (the “Patent Royalties”), provided, however, that the Licensee’s
first $666,666.67 of Gross Sales shall be exempt from the Patent Royalties; and

 

3.1.2.
Upon expiration of the Patent Royalty Period and for the remainder of the Term, a royalty of two percent (2%) of the Gross Sales of all
Licensed Products sold by Licensee in the Licensed Field within the Territory after the Term (the “IP Royalties”).

 

3.2.
Patent and IP Royalties. Licensee acknowledges and agrees that it is paying two separate and independent Royalties (Patent Royalties
and IP Royalties) under this Agreement for activities relating to the Licensed Product.

 

3.3.
Payment of Royalty. Royalties will be computed quarterly on a calendar year basis. Beginning on the Effective Date, the Royalties
will begin to accrue immediately and will be paid quarterly based upon the following schedule:

 

3.3.1.
For the period of January 1st through and including March 31st, payment shall be due on or before April 15th;

 

3.3.2.
For the period of April 1st through and including June 30th, payment shall be due on or before July 15th;

 

3.3.3.
For the period of July 1st through and including September 30th, payment shall be due on or before October 15th; and,

 

3.3.4.
For the period of October 1st through and including December 31st, payment shall be due on or before January 15th of the following year.

 

    	3

     

    

 

For
purposes of this Section, the term “Royalty Year” shall mean each consecutive twelve (12) month period beginning on
the Effective Date and ending on the anniversary of the Effective Date.

 

3.4.
Patent Prosecution and Maintenance Fees. Beginning on the Effective Date and continuing until the end of the Patent Royalty Period,
Licensee shall be responsible for all costs, fees, expenses, and amounts, including, without limitation, all maintenance fees, annuities,
and attorneys’ fees, incurred by Licensor for the prosecution and maintenance of the Patents and Base Applications in all jurisdictions
throughout the Territory.

 

3.5.
Unpaid Amounts. Any payments not timely made under this Agreement and any underpayments of previously owed amounts shall bear
interest from the time such payment was due at the rate of one and one-half percent (1.5%) per month or the highest rate permissible
by law if less.

 

3.6.
Currency. Royalty payments will be made in U.S. Dollars regardless of where the Licensed Product is made or sold and notwithstanding
currency restrictions or regulations in any country where the Licensed Product is sold. Sales made in any currency other than U.S. Dollars
will be converted at the applicable rate of exchange published in the Wall Street Journal on the last day of the accounting period
in which the Royalty payments accrue. Each such payment will include the Royalties which have accrued during the calendar quarter immediately
preceding.

 

3.7.
Royalty Period.

 

3.7.1.
Patent Royalty Period. Licensee’s obligation to pay Patent Royalties shall commence upon the Effective Date and shall continue
until the earlier of (i) termination or expiration of this Agreement; (ii) the fifteen (15) year anniversary of this Agreement; and (iii)
upon the occurrence of a Key Patent Nonenforceability Event, the later of (A) the date of such Key Patent Nonenforceability Event and
(B) the five (5) year anniversary of this Agreement (“Patent Royalty Period”). Notwithstanding the foregoing, if a
Sale of the Company occurs following the occurrence of a Key Patent Nonenforceability Event, the Patent Royalty Period shall be deemed
to have expired upon the closing of such Sale of the Company event. All such Patent Royalties shall be paid during the full Patent Royalty
Period in the manner set forth in this Article 3.

 

3.8.
Taxes. In addition to the charges due under this Agreement, and even if Licensee shall provide a tax exemption number or affidavit
of exemption or other evidence of exemption, the Licensee shall be responsible for and reimburse Licensor for any taxes, including without
limitation, sales, use, property, excise, VAT, value added and gross receipts levied on this Agreement, any payments hereunder and any
activities subject to the License, except for taxes based solely on Licensor’s income (“Tax”). If necessary
this Tax, when being collected, shall be paid by Licensee in the name of Licensor. Licensee shall not withhold any Tax or other amounts
from any Royalties or other payments owing to Licensor under this Agreement.

 

ARTICLE
4 – TRADEMARKS

 

4.1.
Trademark Use Approval. Licensor shall have the right to approve any products, services, advertisements, or other materials exhibiting
or otherwise using the Trademarks (the “Materials”). Licensor’s approval shall not be unreasonably withheld.
Such approval may be given orally or implied based upon a review of Materials by Licensor’s personnel working for Licensee without
objection or based upon Licensor’s participation in the design and creation of Materials. Any Materials submitted to Licensor shall
be deemed approved unless Licensor notifies Licensee to the contrary within thirty (30) days after receipt of such Materials. Any product
developed, manufactured, distributed, sold, and advertised by Licensee shall conform to the Materials approved or deemed approved by
Licensor. Licensor shall have the right to terminate the License and this Agreement upon Licensee’s failure to have any Materials
approved after having received written notice from Licensor of such failure and a reasonable opportunity to cure.

 

    	4

     

    

 

4.2.
Acknowledgment and Marking. Licensee acknowledges and agrees that: (i) Licensor is the sole and exclusive owner of all rights,
title, and interest in and to the Trademarks and of the right to use the Trademarks and to grant the Licenses for use of the Trademarks
by Licensee; (ii) Licensee will never claim or assert any claim of ownership or title to the Trademarks; (iii) Licensee will never claim
any right to use the Trademarks except for the License expressly granted by Licensor under this Agreement; and (iv) Licensor at all times
has retained ownership of the Trademarks and has made no transfers thereof to Licensee under any other agreement. Licensee shall prominently
display the Trademarks in connection with commercialization of the DenerveX Device and shall include all notices and legends with respect
to Licensor’s Trademarks as are or may be required by applicable federal, state, and local trademark law or which may be reasonably
requested by Licensor.

 

4.3.
Use of Similar Marks. Licensee shall at no time adopt or use, without Licensor’s prior written consent, any variation of
the Trademarks, including translations, or any mark likely to be similar to or confusing with the Trademarks. In the event that Licensor
consents to any variation of the Trademarks, Licensee herby agrees that Licensor shall own such new mark and Licensor shall have the
right to file and obtain in Licensor’s name all United States and international trademark registrations. Licensee agrees to give
Licensor reasonable assistance, including execution and delivery of all documents required by Licensee, in filing such applications for
trademark registration.

 

4.4.
Trademark Validity. Licensee shall not contest or deny the validity or enforceability of any or all of the Trademarks or oppose
or seek to cancel any registration thereof by Licensor, or aid or abet others in doing so, either during the Term of this Agreement or
at any time thereafter.

 

4.5.
Good Faith Business. Licensee agrees that it shall conduct its business in a dignified manner, consistent with and enhancing the
general reputation of the Trademarks and Licensor, and in accordance with good trademark practice.

 

4.6.
Goodwill. Any and all goodwill arising from Licensee’s use of the Trademarks and attributable to the Trademarks shall inure
solely to the benefit of Licensor, and neither during the Term or following the termination, cancellation or expiration of this Agreement
and the License granted hereunder shall Licensee assert any claim to the Trademarks or such goodwill. Licensee shall not take any action
that could be detrimental to the goodwill associated with the Trademarks or with Licensor.

 

ARTICLE
5 – RECORDS UNDER THE LICENSE

 

5.1.
Records and Accounting. During the Term of this Agreement and for seven (7) years thereafter, Licensee and shall keep complete
and accurate records of its Gross Sales under the License and all activities under this Agreement in sufficient detail to enable the
Royalties and other amounts payable hereunder to be determined and in accordance with generally accepted accounting principles. Licensee
agrees to permit Licensor and its accountants, agents, and other designees with five (5) business days written notice, to periodically
examine its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report
required under this Agreement and to conduct an audit (hereinafter referred to as the “Audit”). Licensor shall pay
its own costs associated with the Audit unless the Audit results reflect an underpayment by Licensee of five percent (5%) or more of
any payment due hereunder. In such instance Licensee shall pay all of Licensor’s costs and expenses associated with the Audit.

 

    	5

     

    

 

ARTICLE
6 - PATENT PROSECUTION AND ENFORCEMENT

 

6.1.
Filing and Prosecution of Patent Applications. The right to file, prosecute, and control all Patents, Base Applications, and other
Intellectual Property rights rests solely with the Licensor. Licensor, in its sole discretion, will control the decision to file and
the prosecution of all Patents and other Intellectual Property throughout the Territory.

 

6.2.
Patent and Trademark Maintenance and Renewal. Licensee shall have sole responsibility for all post-grant and post-issuance maintenance
of the Patents and Trademarks, including, without limitation, by timely paying all maintenance fees and annuities in each jurisdiction
where the Patents and Trademark subsist, and by timely filing all affidavits, evidence, and other documents for the purpose of maintaining
enforceability of the Patents and Trademarks throughout the full extent of the Term. Licensee acknowledges and agrees that this obligation
is undertaken as a reasonable allocation of expense to Licensee in its role under the exclusive License in the Territory. Licensee’s
discharge of this responsibility in no way shall be construed as transferring any ownership interest in or to the Patents or Trademarks
from Licensor to Licensee.

 

6.3.
Enforcement. Licensee has a duty to notify Licensor of any known and/or suspected infringement of the Licensed Product occurring
within the Territory. The right to institute such a suit for infringement of the Licensed Product occurring within the Territory rests
solely with the Licensee, provided that if Licensee fails to promptly institute such suit for infringement or informs the Licensor that
it does not plan to institute such suit for infringement, Licensor shall have the option, exercisable upon written notice to Licensee
to assume and control the institution of such suit. Licensee will provide full cooperation and assistance in any actions brought by Licensor,
including Licensee’s joining the suit as a party.

 

6.4.
Validity Challenges by Licensee.

 

6.4.1.
Licensee shall not institute or actively participate as an adverse party in, or otherwise provide material support to, any legal action
or administrative proceeding to obtain a ruling that any Patent claim is invalid, unenforceable, or not patentable or that any Licensed
Product does not infringe one or more claims of any Patent (“Patent Challenge”) until the expiration of sixty (60)
days after Licensee serves on Licensor written notice of such Licensee’s intention to bring or participate in a Patent Challenge.
Licensee shall also provide to Licensor a complete written disclosure of each and every basis then known to Licensee for the Patent Challenge
and shall provide Licensor with a copy of any document or publication that such Licensee may use in connection with the Patent Challenge.

 

6.4.2.
Upon the commencement of a Patent Challenge, (by the Licensee only) the Licensor, it its sole discretion, may either (i) immediately
terminate this Agreement; or (ii) immediately terminate the exclusivity of the license granted in Section 2.1 of this Agreement, and
Licensee’s continued exploitation of all Licensed Products thereafter shall be on a non-exclusive basis.

 

    	6

     

    

 

6.4.3.
Any Patent Challenge asserted by Licensee shall be brought solely and exclusively in the U.S. District Court for the Middle District
of Florida, Tampa Division, in Hillsborough County, Tampa, Florida. Licensee shall not file any Patent Challenge in the Patent Trial
and Appeal Board of the U.S. Patent & Trademark Office, or in any equivalent or counterpart administrative tribunal in any jurisdiction
in the Territory.

 

6.4.4.
Licensee’s failure to comply with the provisions of this Section 6.4 shall constitute a material breach of this Agreement.

 

ARTICLE
7 - WARRANTIES AND OBLIGATIONS OF LICENSEE

 

7.1.
Warranties to Licensor. Licensee represents and warrants to Licensor and each purchaser or customer of Licensed Products that:
(1) all services, manufacturing and other activities under the License and this Agreement shall be performed in a professional workmanlike
manner; (2) Licensee has good title to all Licensed Products sold or delivered hereunder, free and clear of all liens and encumbrances;
(3) Licensee shall use best efforts to ensure that all Licensed Products and related services and activities under the License are performed
and delivered free of material defects in manufacture, design, and workmanship; and (4) Licensee shall manufacture and use the Licensed
Products with the same quality as manufactured by the Licensor. Licensor shall have the right to control the agreed-upon quality and
to stop the sale of Licensed Products which are below standard. Licensor may exercise this right to control by personal inspection of
the production. The foregoing representations and warranties are material obligations placed upon Licensee.

 

7.2.
Indemnification. Notwithstanding any provision of this Agreement to the contrary, Licensee agrees to defend, hold harmless, and
indemnify Licensor, its officers, employees, and agents from and against any claims, loss, damage, injury demands, or causes of action
whatsoever (“Losses”) including, without limitation, those arising on account of: (i) any injury or death of persons
or damage to property of Licensor or any third party caused by, or arising out of, or relating to any intentional, reckless or negligent
act or omission; (ii) strict liability or product liability of Licensee or its employees, sub-licensees, agents, or invitees in performing
any and all obligations or services under this Agreement; (iii) Licensee’s manufacture, use, distribution, or sale of Licensed
Products, including, without limitation, the use thereof by any third party; (iv) any breach of this Agreement; or (v) Licensee’s
exercise or practice of the License granted hereunder; provided, however, that Licensee’s obligations under (i), (iii), and (iv)
above shall not apply to Losses occurring prior to the Effective Date.

 

7.3.
Marking. The Licensee shall comply with all patent marking requirements under all applicable laws within the Territory including,
without limitation, placing in a conspicuous location on all Licensed Products a patent notice in accordance with the United States patent
laws, including 35 U.S.C. § 287 and the laws of all other jurisdictions within the Territory. The Licensee agrees to mark any products
made using a process covered by a Patent with the number of each such Patent. 

 

7.4.
Compliance With Laws. Licensee shall comply at all times at its sole expense with all applicable state and federal laws, rules,
licensing and regulations pertaining to its business and operations and its performance of the Services including, without limitation,
compliance with all state and federal laws, and the laws of all other jurisdictions within the Territory.

 

    	7

     

    

 

7.5.
Trade Secrets. Licensee acknowledges and agrees that: (a) the Technology is comprised of trade secrets and confidential and proprietary
information that is not publicly or generally known, is not readily ascertainable by proper means, possesses substantial and significant
economic value by remaining secret, and has been the subject of reasonable efforts to maintain its secrecy; (b) the Technology cannot
be derived from the Base Applications; (c) Licensor is the sole and exclusive owner of the Technology; and (d) Licensee does not possess
the Technology or any related know how to implement a production process or to manufacture products that achieve the advantages of the
Technology. Licensee agrees that during the term of this Agreement and thereafter it shall not take any present or future direct or indirect
action to challenge, attack, or otherwise contest the validity, ownership, or rights of Licensor in or to the Technology’s status
as trade secrets protected from disclosure and use under all applicable laws, or to enjoin, oppose or otherwise interfere with Licensor’s
full enjoyment and use of the Technology as trade secrets in any manner whatsoever world-wide. Nor shall Licensee aid any third party
in connection with the foregoing. 

 

ARTICLE
8 - DEFENSE AND INSURANCE

 

8.1.
Defense. In the event a third party brings an action to obtain a declaration of invalidity of one or more Patents, (a “DJ-Action”)
against the Licensor and/or the Licensee, then the Licensor shall have the first right to defend said action at its own costs and expense
and to control the ensuing litigation. If the Licensor elects not to defend the DJ-Action, then Licensee may defend the DJ-Action at
its own cost and expense and to control the ensuing litigation. If a litigating party finally prevails, it shall retain all damages which
it may collect.

 

8.2.
Insurance. Licensee shall maintain Comprehensive General Liability and Property Damage Insurance (including completed operations
and product liability coverage) of not less than $2,000,000 per person, $2,000,000 per occurrence for bodily injury, and $1,000,000 per
occurrence for property damage as protection against all risks of damage to or destruction of property or bodily injury, sickness, or
disease (including death resulting at any time therefrom) of persons, wherever located, resulting from Licensee’s or its sub-licensee’s
negligence, strict liability, product liability, or failure to exercise reasonable care in performing the obligations hereunder in accordance
with applicable law. Licensor shall be named as an additional insured on all such policies, and Licensee shall provide Licensor with
evidence of the same in the form of an endorsement. All insurance coverage required hereunder shall be issued in a form reasonably acceptable
to Licensor. All insurance coverage procured hereunder shall provide that no material change or cancellation in insurance shall be made
by Licensee without thirty (30) days prior written notice to Licensor. Compliance or failure to comply by Licensee with the foregoing
requirements, as to carrying insurance and furnishing certificates, shall not relieve Licensee of its liabilities and obligations under
this section.

 

8.3.
Limitation on Liability. EXCEPT FOR CASES OF LIABILITY FOR INTENTION, IN NO EVENT SHALL LICENSOR BE LIABLE TO LICENSEE OR LICENSEE’S
SUCCESSORS, ASSIGNS, OFFICERS, DIRECTORS, EMPLOYEES, CONTRACTORS, OR AGENTS FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL DAMAGES, OR LOST
PROFITS, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR TO THE PERFORMANCE OR BREACH THEREOF, EVEN IF LICENSOR HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.

 

    	8

     

    

 

ARTICLE
9 - TERM OF LICENSE AND TERMINATION

 

9.1.
Term. Unless terminated in accordance with Section 9.2 or 9.3 below, the term of this Agreement shall begin on the Effective Date
and shall continue until Licensee ceases all commercial use or exploitation of the Licensed Products in the Territory (“Term”).

 

9.2.
Default by Licensee. Except as set forth in Section 9.3, Licensor has the right to terminate this Agreement and the License granted
to Licensee hereunder: (i) pursuant to Section 6.4.2, or (ii) if the Licensee at any time defaults in any material obligation under this
Agreement, and such default is not cured within sixty (60) days after written notice from Licensor to Licensee specifying the nature
of the default, and such termination will become effective at the close of business on the thirtieth day after giving such notice. For
purposes of this Section 9.2, it shall be a material breach of this Agreement by Licensee if Licensee becomes bankrupt or insolvent and/or
if the business of Licensee is placed in the hands of a receiver, assignee for the benefit of creditors, or trustee, whether by voluntary
act of Licensee or otherwise, and Licensor shall have the right to terminate if not cured by Licensee after Licensor has provided Licensee
with notice and sixty (60) days to cure as set forth above in Section 9.2(ii).

 

9.3.
Termination for Nonpayment. This Agreement will terminate sooner than as set forth in Section 9.2 above if the Licensee shall
at any time default under any obligation under this Agreement relating to a failure to make any Report, pay any Royalty payments, or
permit the inspection of its books and records upon proper notice as herein-above required, and such default is not cured within ten
(10) days after written notice to Licensee specifying the nature of the default.

 

9.4.
Effects of Termination. If this Agreement is terminated, cancelled, or expires for any cause or reason whatsoever:

 

9.4.1.
Nothing herein shall relieve Licensor or Licensee of any obligations or liability accrued hereunder prior to such termination, nor rescind
or give rise to any rights or rescind anything done or any payments made or other consideration given hereunder prior to the effective
time of such termination and shall not effect in any manner the rights of either party arising out of the Agreement prior to such termination;
and

 

9.4.2.
After the effective date of the termination, Licensee will provide Licensor with a report for all Royalties due as of the date of termination
and a written inventory of all Licensed Products in process of manufacture or in stock. Provided Licensee is not in default under this
Agreement, Licensee may sell any such remaining Licensed Product inventory within ninety (90) days following such termination provided
all Royalties are paid thereon within five (5) business days of all such sales. Otherwise all such inventory shall be delivered to Licensor
at no charge; and

 

9.4.3.
The License shall be immediately and automatically revoked without notice. Except as expressly permitted by Section 9.4.2, Licensee shall
immediately cease all use of the Licensed Product, and all rights and privileges granted to Licensee hereunder shall immediately and
automatically revert to Licensor. Licensee shall also immediately return to Licensor all Confidential Information in Licensee’s
possession, custody, or control.

 

    	9

     

    

 

ARTICLE
10 - OBLIGATIONS AND DUTIES OF THE LICENSOR

 

10.1.
Ownership/Conveyance Warranty. Licensor warrants to the Licensee that it is the sole owner of all Patents and Intellectual Property
rights being licensed hereunder.

 

10.2.
No Interfering Rights Warranty. Licensor is not aware of any conflicting third party property rights, including blocking patents,
copyrights, or any other rights of third parties, that may interfere with any of Licensee’s activities under this Agreement or
diminish the rights conveyed to Licensee by this Agreement. However, Licensor makes no warranties that: (a) the Technology or disclosures
in the Patents are accurate, correct, defect-free, or error free, or that the use of the foregoing information is adequate for the production
or use of the Licensed Products or that the technical information is complete; (b) the use of the License, the Licensed Product or any
activities under this Agreement does not infringe third parties’ rights or does not cause damages to third parties; or (c) any
of the Patents now issued or later issued are valid or enforceable.

 

ARTICLE
11 - COMMUNICATIONS AND NOTICES

 

11.1.
Mode and Manner. Any payment, notice, or other communication required or permitted to be made or given to either party hereto
pursuant to this Agreement will be in writing and will be sufficiently made or given on the date of service if sent to such party by
overnight delivery or by certified or registered mail, postage pre-paid, addressed to it at its address set forth above or to such other
address as it designates by written notice delivered to the other party.

 

ARTICLE
12 - OWNERSHIP OF IMPROVEMENTS

 

12.1.
Licensor Improvements. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
by Licensor or its employees, all inventions entitled to any patent or patents maturing therefrom will be owned by Licensor (a “Licensor
Invention”).

 

12.2.
Joint Invention Rights. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
under which the Licensor and the Licensee or any of their respective employees may be a joint inventor, all inventions entitled to any
patent or patents maturing therefrom will be owned solely by Licensor, and Licensee hereby irrevocably and unconditionally assigns to
Licensor all rights, title, and interest therein worldwide and to any and all Patents thereon.

 

12.3.
Licensee Improvements. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
solely by Licensee or its employees, agents, or contractors, all inventions entitled to any patent or patents maturing therefrom will
be owned solely and exclusively by Licensee (a “Licensee Invention”). Licensee shall promptly disclose to Licensor
each Licensee Invention and shall offer Licensor a license to use the same and the parties shall negotiate in good faith.

 

ARTICLE
13 – CONFIDENTIALITY

 

13.1.
Confidential Information. For purposes of this Agreement the term “Confidential Information” includes any information
disclosed by one party to another under this Agreement that is not publicly or generally known including, but not limited to, ideas,
inventions, discoveries, improvements, algorithms, formulas, computer programs, Technology, Improvements, the contents of unpublished
patent applications, product plans, products, product updates and upgrades, services, pricing information, developments, processes, designs,
drawings, engineering, development information, trial and clinic tests, research and development, customer lists, customer information,
marketing, advertising, business and marketing plans, business and financial information, whether protectable under applicable patent
or copyright law or otherwise. Licensee represents, acknowledges, and agrees that the Technology contains highly valuable and proprietary
trade secrets of the Licensor and that Licensee receives a competitive advantage in the Territory marketplace by receiving a license
to these trade secrets from Licensor on the terms and conditions set forth in this Agreement.

 

    	10

     

    

 

13.2.
Restrictions on Confidential Information. During the term of this Agreement and thereafter until such time as that portion of
the Confidential Information no longer qualifies for protection as trade secrets or confidential or proprietary business information
under all applicable laws, each party will maintain the other party’s Confidential Information in strict confidence and will not
directly or indirectly use the Confidential Information except during the term of this Agreement in connection with each party’s
performance under this Agreement, and neither party will disclose the Confidential Information to any third parties. Upon the termination
or expiration of this Agreement or at the request of either party at any time, each party will return the other party’s Confidential
Information to that party.

 

13.3.
Exclusions. The confidentiality obligation in Section 13.2 shall lapse if Confidential Information: (i) becomes a part of the
public domain without breach of this Agreement by the receiving party; or (ii) is legitimately obtained by the receiving party without
a commitment of confidentiality from a third party. Either party may provide Confidential Information to an authorized body pursuant
to judicial action or government regulations, provided that the party required to disclose Confidential Information shall promptly notify
the other party in writing, who may seek to obtain suitable protective orders to maintain the confidentiality of Confidential Information
before the disclosing party actually makes such disclosure.

 

ARTICLE
14 - CONSENT AND COOPERATION

 

14.1.
Consent. Any party who is required to give consent under this Agreement will not unreasonably withhold it. Each party will execute
any instruments reasonably necessary to implement the provisions of this Agreement.

 

14.2.
Non-Assignability. The parties agree that this Agreement imposes personal obligations upon Licensee and, without Licensor’s
prior written consent, which consent shall not be unreasonably withheld, Licensee will not assign or transfer any rights under this Agreement,
whether by agreement, merger, reorganization, or in connection with the sale of all or substantially all of the assets or equity interest
in Licensee, or by operation of law or otherwise. Any attempted assignment in breach of this Section 14.2 shall be void and of no force
or effect.

 

14.3.
Buy-Out. In the event that a third party acquires Licensor by agreement, merger, reorganization, or in connection with the sale
of all or substantially all of the assets or equity interest in Licensor, or by operation of law or otherwise, all Intellectual Property
rights held by Licensor and subject to the License shall be transferred to Licensee for reasonable consideration as part of such transaction.

 

    	11

     

    

 

14.4.
Benefits and Burdens. This Agreement and each and every covenant, term, and condition herein is binding upon and inures to the
benefit of the parties hereto and their respective successors and permitted assigns. This Agreement is binding upon any third parties
that acquire all ownership or control of one of the parties hereto through a transfer and ownership interest or as a part of the sale
of all or substantially all of one of the party’s assets.

 

14.5.
No Benefit to Others. The representations, warranties, covenants, and agreements contained in this Agreement are for the sole
benefit of the parties hereto and their heirs, executors, administrators, legal representatives, successors, and permitted assigns, and
they will not be construed as conferring any rights on any other persons. The parties agree there are no express or intended third party
beneficiaries of this Agreement.

 

14.6.
Cooperation. Licensee shall, during the Term of this Agreement and following the termination, cancellation, or expiration thereof,
execute such documents and provide such cooperation as Licensor may reasonably request from time to time to ensure that all right, title,
and interest in and to the Intellectual Property reside with Licensor.

 

ARTICLE
15 - GOVERNING LAW

 

15.1.
Governing Law. This Agreement shall be governed by, and interpreted under, the laws of the State of Delaware applicable to contracts
made and to be performed therein, without giving effect to the principles of conflicts of law. Except in respect to an action commenced
by a third party in another jurisdiction and actions under Section 6.4.3, the parties hereto hereby agree that any legal suit action,
or proceeding arising out of or relating to this Agreement must be exclusively instituted in a federal or state court in Hillsborough
County, Tampa, Florida, and the parties hereto hereby irrevocably submit to the jurisdiction of any such court and waive any objection
to the laying of venue in, jurisdiction over their person in, or the inconvenience of, such forum.

 

15.2.
Venue for Equitable Relief. Notwithstanding Section 15.1 above, in the event Licensee is in breach of any obligation under this
Agreement, Licensor shall have the right to institute suit in any state or federal court of competent jurisdiction located within the
Territory to obtain equitable, emergency, or provisional relief under this Agreement including, without limitation, a temporary or preliminary
injunction or specific performance and the parties agree that such court shall retain jurisdiction throughout the entirety of the proceedings
through entry of final judgment or adjudication of all issues.

 

ARTICLE
16 - ADDITIONAL TERMS

 

16.1.
Counterparts and Translations. This Agreement may be prepared in two identical and original counterparts. If a counterpart shall
be prepared in a language other than English, then the English language version shall control and the non-English counterpart shall be
for convenience only and shall not affect the performance or interpretation of the Agreement. Likewise, the exchange of a fully executed
Agreement by electronic transmission (whether by separately executed counterparts or otherwise) shall be fully binding on the parties
with respect to the terms and conditions of the Agreement.

 

16.2.
Headings, Persons, and Plurals. All section headings contained in this Agreement are for convenience of reference only, do not
form a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. Words used herein, regardless
of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other
gender, masculine, feminine, or neuter, as the context requires. Any reference to a “person” herein shall include an individual,
firm, corporation, partnership, trust, governmental authority or body, association, unincorporated organization, or any other entity.

 

    	12

     

    

 

16.3.
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and
valid under applicable law. However, if any provision of this Agreement or the application of any provision to any party or circumstance
shall be prohibited by or invalid under applicable law, such provision shall be reduced to such scope as is reasonable and enforceable
if possible. Otherwise, such provision shall be ineffective to the extent of such prohibition or invalidity without it invalidating the
remainder of the provisions of this Agreement or the application of the provision to the other parties or other circumstances.

 

16.4.
Attorneys’ Fees. In connection with any legal, arbitration, and/or other proceedings arising out of or relating to this
Agreement, including appeal and enforcement, the prevailing party shall be entitled to recover its reasonable attorneys’ fees,
costs, and expenses from the other party.

 

16.5.
No Other Rights. Except as otherwise provided herein by the License, no license or other rights, express or implied, are granted
to either party. The relationship of Licensor to Licensee is that of an independent contractor and neither Licensee nor its agents or
employees shall be considered employees of Licensor. This Agreement does not constitute and shall not be construed as constituting a
partnership or joint venture or grant of a franchise between Licensor and Licensee. This Agreement shall not be construed as authority
for either party to act for the other party in any agency or other capacity or to make commitments of any kind for the account of or
on behalf of the other, except to the extent and for the purposes provided herein.

 

16.6.
Integration. This Agreement and any attached exhibits constitute the entire and only agreement between the parties regarding the
subject matter of hereof, and all prior negotiations, representations, agreements, and understandings are superseded hereby. No agreements
altering or supplementing the terms hereof may be made except by a written document signed by both parties. No terms or provisions in
any subsequent shipping documents, bills of lading, purchase orders, or other similar documents that are materially different from these
terms and conditions shall be binding upon either party unless evidenced in writing by a duly authorized officer of each party. Such
terms or provisions not in compliance with this section shall be of no force or effect.

 

16.7.
Equitable Relief. The parties stipulate that a breach of Article 13 or of Sections 12.2 or 12.3 above will cause immediate and
irreparable harm and significant injury, for which there is no adequate remedy at law and that Licensor shall be entitled, in addition
to any other rights and remedies it may have, to specific performance and other equitable remedies to restrain any threatened, continuing
or further breach of this Agreement without proof of actual damages sustained by Licensor and without the requirement of posting a bond.
In addition to these equitable remedies, Licensee shall be liable to Licensor for any and all damage to Licensor caused by Licensee’s
breach of Article 13 or of Sections 12.2 or 12.3.

 

16.8.
No Waiver. No waiver shall be effective unless in writing. The failure of any party to enforce a right under this Agreement will
not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved.

 

16.9.
Limitation on Use. Nothing in this Agreement will be construed as conferring upon either party the right to include in any reference
to the other party, anywhere in the world, its trademarks, trade names, service marks, those trademarks and services marks used in connection
with the Licensed Products, or other trade identity without the other party’s prior express written consent.

 

16.10.
Interpretation. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not
apply to the interpretation and construction of this Agreement, and this Agreement shall be construed as having been jointly drafted
by the parties.

 

16.11.
Survival. The provisions of Articles 1, 8, 12, 13, 15, and 16, and Sections 3.5, 3.6, 3.7, 3.8, 4.2, 4.3, 4.4, 4.6, 5.1, 7.1,
7.2, 7.5, 9.4, and 14.6 and all other terms and provisions which by their nature survive the termination, expiration, or cancellation
of this Agreement, shall so survive.

 

[Remainder
of page intentionally left blank; signature page follows]

 

    	13

     

    

 

IN
WITNESS WHEREOF, the Licensor and Licensee have caused this Agreement to be executed by their respective duly authorized officers as
of the date first written above.

 

	 	Licensor:
	 	 
	 	MEDOVEX,
    CORP.,

    a
    Nevada corporation

	 	 
	 	By:	         
	 	Name:	 
	 	Title:	 

 

	 	Licensee:
	 	 
	 	MEDOVEX,
    LLC,

    a
    Delaware limited liability company

	 	 	 
	 	By:	         
	 	Name:	 
	 	Title:	 

 

Signature
Page to Intellectual Property License Agreement

 

    	 

     

    

 

EXHIBIT
“A”

 

	MB
    Ref.	 	STATUS	 	COUNTRY
    NAME	 	TITLE	 	INVENTORS	 	APPLICATION
    NUMBER	 	DATE
    FILED	 	LOCAL
    FILING DATE	 	PUBLICATION
    NO.	 	PUBLICATION
    DATE	 	PATENT
    NUMBER	 	GRANT
    DATE
	1179.10.CN	 	Published	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	2017100570314	 	1/26/17	 	 	 	107049473	 	Aug
    18, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.CNX	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	2017200981285	 	1/26/17	 	 	 	207220874	 	 	 	ZL2017200981285	 	4/13/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.EP	 	Published	 	European
    Patent Office	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	17702236.5	 	1/17/17	 	8/24/18	 	3407810	 	Dec
    5, 2018	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.WO	 	Completed	 	PCT	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	PCTUS17013744	 	1/17/17	 	 	 	WO17132004	 	Aug
    3, 2017	 	 	 	 

 

    	Exhibit A-1

     

    

 

	1179.10PR	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Scott M. W. Haufe, Jacob Blank, Adam L. Gullickson, Seth Iverson	 	62/288,638	 	1/29/16	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3	 	Issued	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	14/257,490	 	4/21/14	 	 	 	14
    0324044	 	Oct
    30, 2014	 	9883882	 	2/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.AU	 	Issued	 	Australia	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2014257302	 	4/21/14	 	9/22/15	 	 	 	 	 	2014257302	 	7/30/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.AU2	 	Pending	 	Australia	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2019205969	 	4/21/14	 	7/15/19	 	 	 	 	 	 	 	 

 

    	Exhibit A-2

     

    

 

	1179.3.BR	 	Published	 	Brazil	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	1120150259359	 	4/21/14	 	10/13/15	 	2429	 	Jul
    25, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CA	 	Published	 	Canada	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2938631	 	4/21/14	 	8/3/16	 	2938631	 	Oct
    30, 2014	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CN	 	Issued	 	China	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe	 	2014101674798	 	4/24/14	 	 	 	104116555	 	Oct
    29, 2014	 	104116555	 	1/22/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CNX	 	Issued	 	China	 	Minimally
    Invasive Surgical Tools for Spinal Facet Therapy To Alleviate Pain And Associated Kits And Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2014202029334	 	4/24/14	 	 	 	204394669	 	 	 	ZL2014202029334	 	6/17/15

 

    	Exhibit A-3

     

    

 

	1179.3.CNX2	 	Issued	 	China	 	Minimally
    Invasive Surgical Tools for Spinal Facet Therapy To Alleviate Pain And Associated Kits And Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2015202423693	 	4/21/15	 	4/21/15	 	 	 	 	 	ZL2015202423693	 	10/28/15
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.EP	 	Published	 	European
    Patent Office	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	14787585.0	 	4/21/14	 	9/22/15	 	2991564	 	Mar
    9, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.HK	 	Issued	 	Hong
    Kong	 	SURGICAL
    TOOLS AND KITS FOR PAIN ALLEVIATING SPINAL JOINT FACET THERAPY	 	Scott
    M. W. Haufe	 	151040272	 	7/19/19	 	 	 	1203342A	 	Oct
    30, 2015	 	1203342B	 	3/20/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.MX	 	Issued	 	Mexico	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2015014936	 	4/21/14	 	10/23/15	 	 	 	 	 	367291	 	8/13/19

 

    	Exhibit A-4

     

    

 

	1179.3.NZ	 	Issued	 	New
    Zealand	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	712599	 	4/21/14	 	9/22/15	 	 	 	 	 	712599	 	6/26/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.WO	 	Completed	 	PCT	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	PCTUS14034743	 	4/21/14	 	 	 	WO14176141	 	Oct
    30, 2014	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3CT	 	Published	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	15/850,630	 	12/21/17	 	 	 	20180132879	 	May
    17, 2018	 	 	 	 

 

    	Exhibit A-5

     

    

 

	1179.3DV	 	Published	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	15/850,662	 	12/21/17	 	 	 	20180132880	 	May
    17, 2018	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3PR	 	Expired	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET DEBRIDEMENT TO ALLEVIATE PAIN AND ASSOCIATED KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe	 	61/815,416	 	4/24/13	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3PR2	 	Expired	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	61/977,817	 	4/10/14	 	 	 	 	 	 	 	 	 	 

 

    	Exhibit A-6

     

    

 

	1179.4	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	14/810,683	 	7/28/15	 	 	 	16
    0030106	 	Feb
    4, 2016	 	9980771	 	5/29/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.AU	 	Issued	 	Australia	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2015298241	 	7/17/15	 	1/3/17	 	 	 	 	 	2015298241	 	1/9/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.BG	 	Lapsed	 	Bulgaria	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.BR	 	Closed	 	Brazil	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	1120170014696	 	7/17/15	 	1/24/17	 	2448	 	Dec
    5, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.CN	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2015104534515	 	7/29/15	 	 	 	105411666	 	Mar
    23, 2016	 	ZL2015104534515	 	11/5/19

 

    	Exhibit A-7

     

    

 

	1179.4.CNX	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	201520557413X	 	7/29/15	 	 	 	205181467	 	 	 	ZL201520557413X	 	4/27/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.DE	 	Issued	 	Germany	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.EP	 	Completed	 	European
    Patent Office	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.FR	 	Issued	 	France	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.GB	 	Issued	 	United
    Kingdom	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18

 

    	Exhibit A-8

     

    

 

	1179.4.HK	 	Issued	 	Hong
    Kong	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	161101801	 	7/29/15	 	8/26/16	 	1221888A	 	Jun
    16, 2017	 	HK1221888	 	7/31/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.IN	 	Published	 	India	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	201747002673	 	7/17/15	 	1/24/17	 	212017	 	May
    26, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.JP	 	Issued	 	Japan	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2016576012	 	7/17/15	 	12/26/16	 	 	 	 	 	6689761	 	4/10/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.JP2	 	Pending	 	Japan	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2020005550	 	7/17/15	 	1/17/20	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.NZ	 	Closed	 	New
    Zealand	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	728003	 	7/17/15	 	1/3/17	 	 	 	 	 	 	 	 

 

    	Exhibit A-9

     

    

 

	1179.4.WO	 	Completed	 	PCT	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	PCTUS15040867	 	7/17/15	 	 	 	WO16018643	 	Feb
    4, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4CT	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	15/964,422	 	4/27/18	 	 	 	20180243029	 	Aug
    30, 2018	 	10588688	 	3/17/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4IP	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	15/093,148	 	4/7/16	 	 	 	16
    0213415	 	Jul
    28, 2016	 	10398494	 	9/3/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4IPDV	 	Published	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	16/520,738	 	7/24/19	 	 	 	20190343575	 	Nov
    14, 2019	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4PR	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	62/031,037	 	7/30/14	 	 	 	 	 	 	 	 	 	 

 

    	Exhibit A-10

     

    

 

	1179.4PR2	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	62/043,537	 	8/29/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4PR3	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	62/135,791	 	3/20/15	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS WITH POSITIONAL COMPONENTS	 	Scott
    M. W. Haufe, Robert D. Carter	 	15/527,920	 	12/10/15	 	5/18/17	 	20180310975	 	Nov
    1, 2018	 	10595919	 	3/24/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.CN	 	Issued	 	China	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	201580067317X	 	12/10/15	 	6/9/17	 	106999210	 	Aug
    1, 2017	 	ZL201580067317X	 	10/30/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.DE	 	Issued	 	Germany	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.EP	 	Completed	 	European
    Patent Office	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.GB	 	Issued	 	United
    Kingdom	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.HK	 	Published	 	Hong
    Kong	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	181014903	 	1/31/18	 	 	 	1241681A	 	Jun
    15, 2018	 	 	 	 

 

    	Exhibit A-11

     

    

 

	1179.6.WO	 	Completed	 	PCT	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	PCTUS15064988	 	12/10/15	 	             	 	WO16094653	 	Jun
    16, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6PR	 	Expired	 	United
    States of America	 	Surgical
    Tools with Stabilizers	 	Scott
    M. W. Haufe, Robert D. Carter	 	62/091,226	 	12/12/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6PR2	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS WITH STABILIZERS	 	Scott
    M. W. Haufe, Robert D. Carter	 	62/093,589	 	12/18/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.8	 	Issued	 	United
    States of America	 	COMBINATION
    TISSUE REMOVAL AND CAUTERIZATION INSTRUMENT	 	Scott
    M. W. Haufe	 	12/361,184	 	1/28/09	 	 	 	10
    0191234	 	Jul
    29, 2010	 	8167879	 	5/1/12
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Scott M. W. Haufe, Jacob Blank	 	29/553,207	 	1/29/16	 	 	 	 	 	 	 	D810290	 	2/13/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.CN	 	Issued	 	China	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	201630355939X	 	7/29/16	 	 	 	 	 	 	 	ZL201630355939X	 	1/18/17
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0001	 	6/29/16	 	 	 	 	 	 	 	003254515-0001	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM2	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0002	 	6/29/16	 	 	 	 	 	 	 	003254515-0002	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM3	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0003	 	6/29/16	 	 	 	 	 	 	 	003254515-0003	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM4	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0004	 	6/29/16	 	 	 	 	 	 	 	003254515-0004	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM5	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0005	 	6/29/16	 	 	 	 	 	 	 	003254515-0005	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DSDV	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	29/631,173	 	12/28/17	 	 	 	 	 	 	 	D854150	 	7/16/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DSDV2	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	29/691,589	 	5/17/19	 	 	 	 	 	 	 	D870887	 	12/24/19

 

    	Exhibit A-12

     

    

 

EXHIBIT
“B”

 

Patent
Number (Granted Patents)

 

3148451

3190997

003254515-0001

003254515-0002

003254515-0003

003254515-0004

003254515-0005

 

Patent
Number (Pending)

 

3407810

2991564

 

    	Exhibit B-1Exhibit 10.3

 

Execution
Copy

 

AMENDED
AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT

 

OF

 

MEDOVEX,
LLC

 

a
Delaware limited liability company

 

Dated
as of April 2, 2021

 

    	 

    	 

    

 

AMENDED
AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT 

OF

MEDOVEX,
LLC

 

a
Delaware limited liability company

 

TABLE
OF CONTENTS

 

	ARTICLE
    1 - DEFINITIONS	1
	 	 
	ARTICLE
    2 - FORMATION; PURPOSE	2
	2.1	Formation;
    Continuation	1
	2.2	LLC
    Agreement	2
	2.3	Name	2
	2.4	Place
    of Business and Principal Office; Registered Agent and Registered Office	2
	2.5	Purpose
    and Powers	3
	2.6	Legal
    Title	3
	2.7	Term	3
	2.8	No
    State-Law Partnership	3
	 	 	 
	ARTICLE
    3 - UNITS; ADDITIONAL CAPITAL CONTRIBUTIONS; MEMBER LOANS	3
	3.1	Units
    Generally	3
	3.2	Additional
    Capital Contributions by the Members	4
	3.3	Issuance
    of Additional Equity	5
	3.4	Admission	5
	3.5	No
    Withdrawal of Capital	5
	3.6	Negative
    Capital Accounts	6
	3.7	Loans
    From Members	6
	3.8	Preemptive
    Rights	6
	3.9	Uniform
    Commercial Code	7
	 	 	 
	ARTICLE
    4 - CAPITAL ACCOUNTS; ALLOCATIONS AND DISTRIBUTIONS	7
	4.1	Capital
    Accounts	7
	4.2	Allocations
    of Net Income and Net Loss	8
	4.3	Regulatory
    and Special Allocations	8
	4.4	Tax
    Allocations	11
	4.5	Taxes
    of Taxing Jurisdictions	12
	4.6	Distributions	12
	4.7	Tax
    Distributions	12
	4.8	Priority
    and Distribution of Property	13
	4.9	No
    Creditor Status	13

 

    	ii

    	 

    

 

	ARTICLE
    5 - MANAGEMENT OF THE COMPANY	13
	5.1	Board
    of Managers	13
	5.2	Powers	13
	5.3	Composition
    of the Board of Managers	14
	5.4	Annual
    Budget	15
	5.5	Actions
    Requiring Board of Manager Consent	15
	5.6	Meetings
    of the Board of Managers	17
	5.7	Actions
    without a Meeting	18
	5.8	Committees
    of the Board of Managers	18
	5.9	No
    Compensation; Reimbursement	18
	5.10	Delegation
    of Authority	18
	5.11	Officers	19
	5.12	Purchase
    of Units	19
	5.13	Limitation
    of Liability	20
	 	 	 
	ARTICLE
    6 - RIGHTS AND OBLIGATIONS OF MEMBERS	21
	6.1	Limitation
    of Liability	21
	6.2	Management
    of the Company	21
	6.3	Effect
    of Bankruptcy, Death or Incompetency of Member	21
	6.4	Meetings
    of and Voting by Members	22
	6.5	Member
    Action Without a Meeting	23
	6.6	Investment
    Opportunities and Conflicts of Interest	24
	6.7	Action
    by Vote of the Members	25
	6.8	Major
    Decisions	25
	6.9	Financial
    Statements and Other Information	26
	6.10	Transactions
    with Related Parties	26
	 	 	 
	ARTICLE
    7 - TRANSFERS OF UNITS; SALE OF THE COMPANY	27
	7.1	Transfers
    in General	27
	7.2	Right
    of First Refusal	27
	7.3	Purchase
    Option	29
	7.4	Effect
    of Assignment	31
	7.5	Additional
    Restrictions on Transfer	32
	7.6	Assignees;
    Substituted Members	32
	7.7	Admission
    of New Members	33
	7.8	Amendment
    of Schedule	34
	7.9	Legend	34
	7.10	Transfer
    Fees and Expenses	35
	7.11	Void
    Transfers	35
	7.12	Resignation;
    Void Assignment	35
	7.13	Indirect
    Dispositions	35
	7.14	Deemed
    Offer	35
	 	 	 
	ARTICLE
    8 - ADMINISTRATION	37
	8.1	Bank
    Accounts	37
	8.2	Books
    and Records	38
	8.3	Notices	38

 

    	iii

    	 

    

 

	ARTICLE
    9 - FISCAL MATTERS	38
	9.1	Fiscal
    Year	38
	9.2	Tax
    Reports	39
	9.3	Tax
    Returns	39
	9.4	Partnership
    Representative	39
	9.5	Tax
    Elections	40
	 	 	 
	ARTICLE
    10 - TERMINATION	40
	10.1	Events
    of Dissolution	40
	10.2	Winding
    Up	41
	10.3	Distribution
    on Dissolution and Termination	41
	 	 	 
	ARTICLE
    11 - MISCELLANEOUS	42
	11.1	Governing
    Law; Venue; Expenses	42
	11.2	Successors
    and Assigns	43
	11.3	Grammatical
    Changes	43
	11.4	Captions
    and References	43
	11.5	Severability	43
	11.6	Counterparts;
    Electronic Transmission	43
	11.7	Waiver
    of Right to Partition	43
	11.8	Personal
    Property	43
	11.9	No
    Third Party Rights	44
	11.10	Amendments	44
	11.11	Waiver
    of Statutory Rights	44
	11.12	Certain
    Acknowledgments	44
	11.13	Confidentiality	45
	11.14	Power
    of Attorney	45
	11.15	Descriptive
    Headings; Interpretation	46
	11.16	Further
    Action	46
	11.17	WAIVER
    OF JURY TRIAL	46
	11.18	Entire
    Agreement	46
	11.19	Confirmation
    of Ownership	46
	11.20	Spousal
    Consent	46
	11.21	Tax
    Consequences	47
	11.22	Withholding	47
	11.23	Construction
    and Interpretation	47

 

    	iv

    	 

    

 

AMENDED
AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT

OF

Medovex,
LLC

 

This
AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT of Medovex, LLC (this
“Agreement”), is effective as of April 2, 2021 (the “Effective Date”), by and among Medovex,
LLC, a Delaware limited liability company (the “Company”), the Members and the Persons that in the future acquire
Equity Securities in the Company.

 

BACKGROUND

 

The
Company was formed as a limited liability company on December 8, 2020 (the “Formation Date”) under the Delaware
Law. On the Formation Date, the Company issued to each of Christopher Athavle (“Athavle”), Manfred Sablowski
(“Sablowski”) and Guy Beckerlegge (“Beckerlegge”), the number of Class A Units set forth
opposite their respective names on the Schedule of Members in exchange for aggregate cash capital contributions made by
the Investor Members of $140,000. The Company, Athavle, Sablowksi and Beckerlegge are parties to that certain Limited Liability
Company Agreement dated as of the Formation Date (the “Prior Agreement”).

 

On
or about the Effective Date, pursuant to a Contribution Agreement between the Company and Medovex Corp., a Nevada corporation
(the “H-Cyte Member”), the Company, among other things, is issuing to the H-Cyte Member (a) the Seller Note
and (b) a total of 400,000 Class B Units in the Company in exchange for the contribution of certain assets by the H-Cyte Member
to the Company (as described therein). On or about the Effective Date, Athavle also transferred his initial membership interest
in the Company to the Athavle Trust and Sablowski transferred his initial membership interest in the Company to ValMedX, LLC.

 

The
Company and the Members desire to enter into this Agreement to, among other things, amend and restate the Prior Agreement in its
entirety and to set forth the organization, management and operation of the Company, and the Members’ respective rights
and obligations with respect thereto from and after the Effective Date.

 

OPERATIVE
TERMS

 

The
parties agree as follows:

 

ARTICLE
1

DEFINITIONS

 

Unless
the context otherwise requires, capitalized terms used in this Agreement shall have the meanings specified in Appendix A.

 

    	 

    	 

    

 

ARTICLE
2

FORMATION;
purpose

 

2.1
Formation; Continuation. The Company was formed on the Formation Date upon the filing of the Certificate with the Secretary
of State of the State of Delaware. The Members hereby confirm the formation of the Company as a limited liability company pursuant
to the Delaware Law, authorize and ratify the filing of the Certificate of Formation by Ajay K. Malshe as their Authorized Person
and agree to continue the Company as a limited liability company pursuant to and in accordance with the Delaware Law for the purposes
and upon the terms and conditions set forth in this Agreement. Upon request of the Board of Managers, the Members shall take such
other actions as may from time to time be necessary or appropriate under the laws of the State of Delaware with respect to the
formation, continuation, operation and continued good standing of the Company as a limited liability company.

 

2.2
LLC Agreement. This Agreement amends and restates all prior limited liability company agreement(s) or operating agreement(s)
of the Company in their entirety, including without limitation, the Prior Agreement, and shall constitute the sole “limited
liability company agreement” of the Company as such term is used in the Delaware Law from and after the Effective Date.
The parties hereby agree that from the Effective Date and continuing during the term of the Company the rights, powers and obligations
of the Members with respect to the Company will be determined in accordance with the terms and conditions of this Agreement and
the Delaware Law, except where the Delaware Law provides that such rights, powers and obligations specified in the Delaware Law
apply “unless otherwise provided in the limited liability company agreement” or words of similar effect or where the
Delaware Law otherwise allows this Agreement to govern and control and, in such event, such rights, powers and obligations are
set forth in this Agreement.

 

2.3
Name. The name of the Company is “Medovex, LLC” or such other name as the Board of Managers may from time to
time determine. At the Company’s request, the Members agree to execute such certificates or documents and perform such filings
and recordings and all other acts, including the filing of the Certificate, in appropriate governmental offices as may be required
in order to comply with all Applicable Laws.

 

2.4
Place of Business and Principal Office; Registered Agent and Registered Office.

 

(a)
The mailing address of the Company’s principal place of business is 201 E. Kennedy Blvd, Suite 700, Tampa, Florida 33602,
or such other address as the Board of Managers may from time to time designate.

 

(b)
The Board of Managers may designate any Person as the registered agent and any location as the registered office, as the Board
of Managers deems appropriate subject to all Applicable Laws.

 

(c)
The Company will comply with all requirements necessary to qualify the Company as a foreign limited liability company in each
jurisdiction in which the Company’s business and operations require such qualification.

 

    	2

    	 

    

 

2.5
Purpose and Powers. The Company was formed to engage in any and all lawful activities. As of the date of this Agreement,
the purpose and business of the Company is to: (a) hold, directly or indirectly, the DenerveX Assets and to perform those obligations
and duties as are imposed upon the Company under this Agreement, the Delaware Law, the Certificate, the Contribution Agreement
or any other Equity Agreement, or any Subsidiary’s constituent documents and such other agreements, instruments or documents
to which the Company is a party, (b) manage and direct the business operations and affairs of the Company and its Subsidiaries
(including the development, adoption and implementation of strategies, business plans, and policies concerning the conduct of
the Company’s and Subsidiaries’ business), (c) engage in, conduct, carry on and direct all business affairs related
to the business and affairs of the Company, (d) license the intellectual property described in the IP License Agreement for use
in commercializing the DenerveX Device, and (e) engage in any and all lawful activities that are necessary, advisable or incidental
to the purposes set forth in this Section 2.5 or which the Board of Managers determines to be in the best interests of
the Company or any Subsidiary.

 

2.6
Legal Title. The legal title to all real or personal property or interests therein now or later acquired by the Company
shall be owned, held or operated in the name of the Company, and no Member, individually, shall have any ownership of such property.

 

2.7
Term. The existence of the Company commenced on filing the Certificate with the office of the Secretary of State of Delaware,
and shall continue in full force and effect until dissolution pursuant to the provisions of this Agreement or by operation of
Delaware Law.

 

2.8
No State-Law Partnership. The Members intend that the Company not be a partnership (including a limited partnership) or
joint venture, and that no Member be a partner or joint venturer of any other Member by virtue of this Agreement, for any purposes
other than as set forth in the last sentence of this Section 2.8, and neither this Agreement nor any other document entered
into by the Company or any Member relating to the subject matter hereof shall be construed to suggest otherwise. The Members intend
that the Company be treated as a partnership for federal and, if applicable, state and local income tax purposes, and that each
Member and the Company shall file all tax returns and shall otherwise take all tax and financial reporting positions in a manner
consistent with such treatment.

 

ARTICLE
3

UNITS;
additional capital CONTRIBUTIONS; MEMBER LOANS

 

3.1
Units Generally.

 

(a)
The Company has authority to issue three classes of Units: the Class A Units, the Class B Units and the Class C Units. The Class
C Units shall be further comprised of Class C-1 Units, Class C-2 Units and Class C-3 Units. The holders of Class C-3 Units shall
be entitled to all economic rights associated with such Units, but shall have no right to vote on any matter to be properly voted
on by the Members of the Company and shall not be deemed Voting Units. The Company has authority to issue 1,250,000 Class A Units
and 400,000 Class B Units.

 

    	3

    	 

    

 

(b)
From time to time from and after the Effective Date, and subject to the terms and conditions set forth in this Section 3.1,
the Board of Managers shall have the power and discretion to (i) approve and sell up to 1,500,000 Class C-1 Units to investors
for cash consideration to the Company, (ii) approve and sell up to 1,500,000 Class C-2 Units to investors for cash consideration
to the Company; and (iii) issue to up to 250,000 Class C-1 Units to the H-Cyte Member upon the conversion of all outstanding principal
and accrued interest under the Seller Note in accordance with its terms. Any purchaser acquiring Class C-2 Units will automatically
receive an equivalent number of Class C-3 Units and no Class C-3 Units may be issued to any Person except in connection with a
purchase of an equivalent number of Class C-2 Units pursuant to subclause (ii) above. Upon the issuance of Class C-2 Units to
any Person, the number of Class C-1 Units available for issuance pursuant to subclause (i) above shall be automatically reduced
by the number of Class C-2 Units issued. For example, if the Board of Managers authorizes the sale of 100,000 Class C-2 Units
to a purchaser in accordance with subclause (ii) above, such purchaser shall also receive 100,000 Class C-3 Units in connection
with such purchase and the number of Class C-1 Units available for issuance pursuant to subclause (i) above shall be reduced by
100,000 Class C-1 Units. At no point in time shall the aggregate number of Class C-1 Units and Class C-2 Units outstanding exceed
1,500,000 Units.

 

(c)
Subject to Section 3.1(b) above, the Board of Managers shall have the power and discretion to approve which Persons shall
be offered and sold Class C Units, the number and sub-class of Class C Units to be offered and issued and the purchase price and
other terms and conditions with respect thereto. The number of authorized Units shall be determined by the Board of Managers in
their discretion, provided that without the prior consent of the H-Cyte Member, (x) at no time shall the aggregate number of Class
B Units constitute less than ten percent (10%) of the total number of Units issued and outstanding on a fully-diluted basis, nor
shall the Company be permitted to issue and sell any Equity Securities that would cause the aggregate number of Class B Units
to constitute less than ten percent (10%) of the total number of Units on a fully-diluted basis and (y) at and no time shall the
aggregate number of Class A Units and Class B Units collectively constitute less than fifty one percent (51%) of the total number
of Units issued and outstanding on a fully-diluted basis, nor shall the Company be permitted to issue and sell any Equity Securities
that would cause the aggregate number of Class A Units and Class B Units to collectively, constitute less than fifty-one percent
(51%) of the total number of Units on a fully-diluted basis.

 

(d)
All Units issued shall be recorded on the Company’s books and records and reflected on the Schedule of Members. The
Company may (if elected by the Board of Managers) issue certificates representing the issued and outstanding Units (as applicable,
the “Certificated Units”). The Company’s authorized Units includes all Units held by the Members as reflected
on the Schedule of Members and all additional Equity Securities issued in accordance with Section 3.3. The Company may
issue fractional Units. The ownership by a Member of Units shall entitle such Member to allocations of Net Income, Net Losses
and other items and Distributions of cash and other property as set forth in this Agreement. Any reference in this Agreement to
the Schedule of Members shall be deemed a reference to the Schedule of Members, as amended and in effect from time
to time.

 

3.2
Additional Capital Contributions by the Members. No Member shall be required, at any time after the Effective Date, to
make an additional Capital Contribution to the Company with respect to its Units.

 

    	4

    	 

    

 

3.3
Issuance of Additional Equity. Subject to Sections 3.8, the Board of Managers may cause the Company to create and/or
issue additional Equity Securities (including in separate classes, groups or series of Units having such relative rights, powers
and obligations as may from time to time be established by the Board of Managers, including rights, powers, and/or obligations
different from, senior to or more favorable than existing classes, groups and series of Units). The Board of Managers may cause
the Company to issue additional Equity Securities to any Person (including a Person who is not then a current Member) on such
terms and conditions (including the amount of consideration to be received by the Company in exchange for the Unit, which may
be more than or less than the issue price of a Unit purchased before the date of such issuance) determined by the Board of Managers.
A Person who at the time it acquires a Unit is not a Member will be admitted as a Member if the conditions set forth in Section
7.7 are satisfied. The Board of Managers (without the consent of any of the Members) shall have the power to amend the Schedule
of Members to reflect the names of the Members, the number and class of Units held by the Members and the Percentage Interests
and Capital Proceeds Percentages of the Members after the Company issues additional Units and to make such other amendments to
this Agreement as are required to reflect such additional issuances made in accordance with the terms of this Agreement (including,
without limitation, amending this Agreement to increase the authorized number of Equity Securities of any class, group or series,
to create and authorize a new class, group or series of Equity Securities and to add the terms of such new class, group or series
of Equity Securities including economic, repurchase and governance rights which may be different from, senior to or more favorable
than the other existing Equity Securities), in each case without the approval or consent of any other Person. In connection with
any issuance of Units (whether on or after the date hereof), the Person who acquires such Units shall execute a counterpart to
this Agreement or an Adoption Agreement, accepting and agreeing to be bound by all terms and conditions hereof, and shall enter
into such other documents, instruments and agreements to effect such purchase as are required by the Board of Managers (including
such documents, instruments and agreements entered into on or prior to the date hereof by the Members, each, an “Equity
Agreement”). Each Person who acquires Units may be required in exchange for such Units to make a Capital Contribution
to the Company in an amount to be determined by the Board of Managers.

 

3.4
Admission. Each Investor Member and the H-Cyte Member is admitted to the Company as a member (within the meaning of the
Delaware Law) as of the Effective Date. A Person who acquires any Units after the Effective Date will only be admitted as a member
(within the meaning of the Delaware Law) after the requirements set forth in Section 7.7 have been satisfied.

 

3.5
No Withdrawal of Capital. No Member shall have any right to withdraw or make a demand for withdrawal of all or any portion
of such Member’s Capital Contributions (or the amount, if any, reflected in such Member’s Capital Account) or purchase
price paid to the Company for such Units. Except as otherwise provided in this Agreement, no interest or additional share of profits
shall be paid or credited to the Members on their respective Capital Accounts, or on any undistributed profits or funds left on
deposit with the Company; provided, however, that nothing in this Section 3.5 shall be construed to prevent
or prohibit the payment of interest on account of any loan made by any Person to the Company.

 

    	5

    	 

    

 

3.6
Negative Capital Accounts. No Member shall be required to pay to any other Member or the Company any deficit or negative
balance which may exist from time to time in the Member’s Capital Account (including upon and after dissolution of the Company).

 

3.7
Loans From Members. The Company may borrow money from any Member in such amounts as determined by the Board of Managers
and the lending Member. Each borrowing from any Member must be approved in advance by the Board of Managers. Loans by Members
will not be considered Capital Contributions, and shall not result in an increase in the amount of the Capital Account of such
Member. The amount of any such loans made by a Member (or an Affiliate thereof) shall be a debt of the Company to such Member
(or Affiliate) and shall be payable or collectible in accordance with the terms and conditions upon which such loans are made.

 

3.8
Preemptive Rights.

 

(a)
If the Company authorizes the issuance or sale of any New Securities (other than Exempted Securities) for cash, the Company shall
first offer to sell to each Eligible Member, a portion of such New Securities equal to the product of (i) the number of New Securities
to be issued and (ii) such Eligible Member’s Percentage Interest. Each such Eligible Member shall be entitled to purchase
such New Securities at the most favorable price as such New Securities are to be offered to any other Persons; provided
that if a Person purchasing New Securities is required to also purchase other securities of the Company, the Eligible Members
exercising their rights pursuant to this Section 3.8(a) shall also be required to purchase the same strip of securities
(on the same terms and conditions) that such other Person is required to purchase. If an Eligible Member does not elect to purchase
all of the New Securities that such Member is entitled to purchase under this Section 3.8, the Company shall promptly notify
the other Members that have elected to purchase their entire allotment of New Securities that they are entitled to purchase under
this Section 3.8 of their right to purchase such additional New Securities, on a proportional basis based on the number
of New Securities each such participating Eligible Member elected to purchase pursuant to this Section 3.8 (or in such
other proportion as to which they agree). The purchase price for all New Securities offered to the Eligible Members under this
Section 3.8(a) shall be payable in cash.

 

(b)
The Company shall deliver a written notice to the Eligible Members describing in reasonable detail the New Securities, the purchase
price thereof, the payment terms and such Eligible Member’s allotment of such New Securities. In order to exercise its purchase
rights hereunder, an Eligible Member must deliver a binding written notice to the Company describing its election hereunder within
thirty (30) days after receipt of such written notice provided for in the previous sentence stating that it elects to exercise
its rights to purchase its allotment of the New Securities described in the notice and the amount of the New Securities it wishes
to purchase (but not in excess of the amount it is entitled to purchase hereunder). Any elections made by Eligible Members shall
be deemed rescinded if the Company elects not to proceed with the issuance or sale.

 

(c)
Upon expiration of the 30-day period described in Section 3.8(b), the Company shall be entitled to sell such New Securities
that the Eligible Members have not elected to purchase during the ninety (90) days following such expiration on terms and conditions
not materially more favorable to the purchasers thereof than those offered to such Eligible Members. Any New Securities offered
or sold by the Company after such 90-day period or offered by the Company on terms or conditions more favorable than those offered
to the Eligible Members must be reoffered to the Eligible Members pursuant to the terms of this Section 3.8 prior to any
issuance or sale thereof.

 

    	6

    	 

    

 

(d)
The Company shall notify each Eligible Member electing to purchase New Securities within ten (10) days after the election notice
received under Section 3.8(b) of (to the extent known) (i) the aggregate consideration to be paid by the Eligible Member
for the additional securities; (ii) the proposed date of such issuance or sale of such securities; and (iii) wire instructions
for the account to which the Company wishes Eligible Members electing to participate in the sale transfer funds pursuant to Section
3.8(e).

 

(e)
Each Eligible Member electing to participate in an issuance or sale pursuant to this Section 3.8 shall deliver to the Company
by wire transfer in immediately available funds on the date of issuance of the securities the aggregate consideration to be paid
by that Eligible Member for the securities. The Company shall deliver to each Eligible Member electing to participate in a sale
pursuant to this Section 3.8, against such wire transfer, a certificate or certificates or other instrument representing
the New Securities purchased by such Eligible Member.

 

(f)
The provisions of this Section 3.8 shall terminate upon the Sale of the Company.

 

3.9
Uniform Commercial Code. The Units shall be a “certificated security” governed by Article 8 of the Uniform
Commercial Code as enacted in the State of Delaware, including for purposes of the definition of a “security” thereunder
and for purposes of the definition of a “certificated security” thereunder.

 

ARTICLE
4

CAPITAL ACCOUNTS; ALLOCATIONS AND DISTRIBUTIONS

 

4.1
Capital Accounts.

 

(a)
Generally. The Company shall establish and maintain, or cause the Company’s Accountants to maintain, a separate capital
account (a “Capital Account”) for each Member. Each Member’s Capital Account will be established and
maintained in a manner consistent with the rules set forth in Treasury Regulation Section 1.704-1. For this purpose, the Board
of Managers may, upon the occurrence of the events specified in Treasury Regulation Section 1.704-1(b)(2)(iv)(f), increase or
decrease the Capital Accounts in accordance with the rules of such regulation and Treasury Regulation Section 1.704-1(b)(2)(iv)(g)
to reflect a revaluation of the Company’s property.

 

(b)
Transfer of Capital Accounts. The original Capital Account established for each Substituted Member shall be in the same
amount as the Capital Account of the Member (or portion thereof) to which such Substituted Member succeeds, at the time such Substituted
Member is admitted as a Member of the Company. The Capital Account of any Member whose interest in the Company shall be increased
or decreased by means of the repurchase of Units as contemplated in any agreement to which the Company is a party shall be appropriately
adjusted to reflect such transfer or repurchase.

 

    	7

    	 

    

 

(c)
Modification. In the event the Board of Managers reasonably determines that it is prudent to modify the manner in which
the Capital Accounts, or any debits or credits thereto, are computed in order to comply with Treasury Regulation Section 1.704-1(b)(2)(iv),
the Managers may make such modification, provided that it will not have a material effect on the amounts distributable to any
Member or upon the dissolution of the Company.

 

4.2
Allocations of Net Income and Net Loss.

 

(a)
Allocations of Net Income and Net Loss. Except as otherwise provided in this Agreement, Net Income or Net Losses for any
Fiscal Year shall be allocated among the Members in such a manner that, as of the end of such Fiscal Year, the sum of (a) the
Capital Account of each Member, (b) such Member’s share of Minimum Gain (as determined according to Treasury Regulation
Section 1.704-2(g)) and (c) such Member’s partner nonrecourse debt minimum gain (as defined in Treasury Regulation Section
1.704-2(i)(3)) shall be equal to the respective net amounts, positive or negative, which would be distributed to them or for which
they would be liable to the Company under this Agreement, determined as if the Company were to (i) liquidate the assets of the
Company for an amount equal to their Gross Asset Value and (ii) distribute the proceeds of liquidation pursuant to Section
10.3.

 

(b)
Excess Loss. The Net Losses allocated under Section 4.2(a) to any Member shall not exceed the maximum amount of
Net Loss that can be so allocated without causing or increasing an Adjusted Capital Account Deficit. If some but not all of the
Members would have an Adjusted Capital Account Deficit as a consequence of an allocation of Net Loss pursuant to Section 4.2(a),
then the limitation set forth in this Section 4.2(b) shall be applied so as to allocate the maximum permissible Net Losses
to each Member under the preceding sentence and Treasury Regulation Section 1.704-1(b)(2)(ii)(d). In the event that the allocation
of Net Losses to any Member is prohibited under the first sentence of this Section 4.2(b), such Net Losses shall be allocated
to the remaining Members in proportion to their respective positive Capital Account balances. With respect to each Fiscal Year
or other Fiscal Period thereafter, Net Income (or, to the extent necessary, gross income) shall be allocated to the Members up
to the aggregate of, and in proportion to, any Net Losses previously allocated to each Member in accordance with this Section
4.2(b) in the reverse order in which such Net Losses were allocated.

 

4.3
Regulatory and Special Allocations.

 

(a)
Company Minimum Gain Chargeback. Notwithstanding any other provision of this Section 4.3, if there is a net decrease
in Company Minimum Gain during any Fiscal Year or Fiscal Period, each Member shall be specially allocated items of Company income
and gain (as specified in Treasury Regulation Section 1.704-2(f)(6)) for such Fiscal Year or Fiscal Period (and, if necessary,
for subsequent periods, as provided in Treasury Regulation Section 1.704-2(j)(2)(iii)) in an amount equal to the portion of such
Member’s share of the net decrease in such Company Minimum Gain, determined in accordance with Treasury Regulation Section
1.704-2(g)(2). The items of income and gain to be specially allocated pursuant to this Section 4.3(a) shall be determined
in accordance with Treasury Regulation Section 1.704-2(f). This Section 4.3(a) is intended to comply with the minimum gain
chargeback requirement of Treasury Regulation Section 1.704-2(f) and shall be interpreted consistently therewith.

 

    	8

    	 

    

 

(b)
Member Minimum Gain Chargeback. Notwithstanding any provision of this Section 4.3 to the contrary (except Section
4.3(a)), if there is a net decrease in Member Minimum Gain attributable to a “partner nonrecourse debt” (within
the meaning of Treasury Regulation Section 1.704-2(b)(4)) during any Fiscal Year or Fiscal Period, each Member who has a share
of the Member Minimum Gain attributable to such partner nonrecourse debt, determined in accordance with Treasury Regulation Section
1.704-2(i)(5), shall be specially allocated items of Company income and gain (as specified in Treasury Regulation Section 1.704-2(j)(2)(ii))
for such Fiscal Year or Fiscal Period (and, if necessary, subsequent periods, as provided in Treasury Regulation Section 1.704-2(j)(2)(iii))
in an amount equal to the portion of such Member’s share of the net decrease in Member Minimum Gain attributable to such
partner nonrecourse debt, determined in accordance with Treasury Regulation Section 1.704-2(i)(4). The items of income and gain
to be specially allocated pursuant to this Section 4.3(b) shall be determined in accordance with Treasury Regulation Section
1.704-2(i)(4). This Section 4.3(b) is intended to comply with the partner minimum gain chargeback requirement of Treasury
Regulation Section 1.704-2(i)(4) and shall be interpreted consistently therewith.

 

(c)
Qualified Income Offset. If any Member that unexpectedly receives an adjustment, allocation or distribution described in
Treasury Regulation Section 1.704-1(b)(2)(ii)(d)(4), (5) and (6) has an Adjusted Capital Account Deficit, computed after the application
of Sections 4.3(a) and 4.3(b) but before the application of any other provision of this ARTICLE 4, then items
of income and gain for such Fiscal Year or Fiscal Period shall be allocated to such Member in proportion to, and to the extent
of, such Adjusted Capital Account Deficit. This Section 4.3(c) is intended to be a qualified income offset provision as
described in Treasury Regulation Section 1.704-1(b)(2)(ii)(d) and shall be interpreted in a manner consistent therewith.

 

(d)
Nonrecourse Deductions. Nonrecourse deductions (within the meaning of Treasury Regulation Sections 1.704-2(b)(1) and 1.704-2(c))
for any Fiscal Year or Fiscal Period shall be specially allocated to the Members in proportion to their respective Percentage
Interests. “Partner nonrecourse deductions” (within the meaning of Treasury Regulation Section 1.704-2(i)) for any
Fiscal Year or Fiscal Period shall be specially allocated to the Member who bears the economic risk of loss with respect to the
partner nonrecourse debt (within the meaning of Treasury Regulation Section 1.704-2(b)(4)) to which such partner nonrecourse deductions
are attributable in accordance with Treasury Regulation Section 1.704-2(i).

 

(e)
Regulatory Allocations. The allocations set forth in Sections 4.3(a) through 4.3(d) (the “Regulatory
Allocations”) are intended to comply with certain requirements of Sections 1.704-1(b) and 1.704-2 of the Treasury Regulations.
The Regulatory Allocations may not be consistent with the manner in which the Members intend to allocate Net Income or Net Losses
of the Company or make Company distributions. Accordingly, notwithstanding the other provisions of this ARTICLE 4 (other
than allocations required to be made as a result of an adjustment to the tax basis of the Company’s assets pursuant to Section
743 of the Code or Section 734 of the Code) but subject to the Regulatory Allocations, income, gain, deduction, and loss shall
be reallocated among the Members so as to eliminate the effect of the Regulatory Allocations and thereby cause the respective
Capital Accounts of the Members to be in the amounts (or as close thereto as possible) they would have been if Net Income and
Net Losses (and such other items of income, gain, deduction and loss) had been allocated without reference to the Regulatory Allocations.
In general, the Members anticipate that this will be accomplished by specially allocating other Net Income and Net Losses (and
such other items of income, gain, deduction and loss) among the Members so that the net amount of the Regulatory Allocations and
such special allocations to each such Member is zero.

 

    	9

    	 

    

 

(f)
Change in Percentage Interest or Capital Proceeds Percentages. If during any Fiscal Year or Fiscal Period there is a change
in the Percentage Interests or Capital Proceeds Percentages of the Members, then items of income, gain, loss and deduction for
such Fiscal Year or Fiscal Period shall be allocated according to the varying interests of the Members pursuant to any reasonable
method selected by the Board of Managers and determined by it to be permitted under Section 706 of the Code.

 

(g)
Recharacterization; Section 754 Election.

 

(i)
Characterization of Payments. If a Taxing Jurisdiction disagrees with the Company’s characterization of any amounts
paid to a Member (or an Affiliate thereof) as salaries, management fees, commissions or other compensation for services (“Compensation”),
and refuses to treat such payments as either guaranteed payments within the meaning of Code Section 707(c) or payments made to
such Member other than in such Member’s capacity as a “partner” within the meaning of Code Section 707(a), and
such Taxing Jurisdiction ultimately treats such amounts paid to a Member (or an Affiliate thereto) as a distribution to such Member
for federal income tax purposes which reduces such Member’s Capital Account, then the Compensation shall be treated as an
allocation of an item of income or gain of the Company to the recipient Member so that, consistent with the intent of the Members,
the Compensation shall not be treated as a distribution which reduces the recipient Member’s Capital Account. Accordingly,
such Member shall be allocated the first available items of Company income and gain (including in a succeeding year) in an amount
equal to the Compensation.

 

(ii)
Section 754 Adjustments.

 

(A)
At the election of the Board of Managers, the Company will timely file an election pursuant to Section 754 of the Code in accordance
with the procedures set forth in the applicable Treasury Regulations. The Company shall pay all costs of preparing and filing
all instruments or documents necessary to effectuate such election and shall prepare and file all tax returns consistently with
this Section. Each Member agrees to furnish the Company with all information necessary to give effect to such election and otherwise
comply with any reasonable request from the Company relating to the Company’s Section 754 election.

 

(B)
Any adjustment to the tax basis of any Company asset pursuant to Section 734(b) or 743(b) of the Code that is required to be taken
into account in determining Capital Accounts pursuant to Treasury Regulation Section 1.704-1(b)(2)(iv)(m) shall be treated as
an item of gain (if the adjustment is an increase) or loss (if the adjustment is a decrease) and such gain or loss shall be allocated
to the Members in a manner consistent with the manner in which their Capital Accounts are required to be adjusted pursuant to
that Treasury Regulation.

 

    	10

    	 

    

 

(h)
Members are Independent Contractors: Withholding. The Members hereby acknowledge and agree that for purposes of federal,
state and local income taxes, excise taxes and employment taxes, and for purposes of any withholding obligations with respect
to such taxes, no Member shall be treated as an employee of the Company and that any compensation received by a Member from or
on behalf of the Company shall be treated as a guaranteed payment within the meaning of Section 707(c) of the Code. The Company
shall have no obligation to withhold any amount from compensation paid to a Member. Each Member shall be solely responsible for
payment of all federal, state and local taxes due on any compensation received from the Company. Each Member shall indemnify and
hold the Company harmless from and against any costs, damages, liabilities, interest, fines or penalties relating to such taxes
or withholdings.

 

(i)
Intent of Allocations. The parties intend that the allocation provisions of this ARTICLE 4 shall produce final Capital
Account balances of the Members to be equal to the amount each Member is entitled to receive pursuant to Section 10.3.
To the extent that the foregoing allocation provisions of this ARTICLE 4 would fail to produce such final Capital Account
balances, (1) such provisions may be amended by the Board of Managers, if and to the extent necessary to produce such result and
(2) taxable income and tax loss of the Company for prior open years (or items of gross income and deduction of the Company for
such years) may be reallocated by the Company (subject to the approval described in subpart (1)) among the Members to the extent
it is not possible to achieve such result with allocations of items of income (including gross income) and deduction for the year
in which the Company is liquidated.

 

4.4
Tax Allocations

 

(a)
Allocations Generally. Except as provided in Section 4.4(b), the income, gains, losses, deductions and credits of
the Company with respect to a Fiscal Year or Fiscal Period will be allocated for federal, state and local income tax purposes
among the Members in accordance with the allocation of such income, gains, losses, deductions and credits among the Members for
computing their Capital Accounts; except that if any such allocation is not permitted by the Code or other applicable law, the
Company’s subsequent income, gains, losses, deductions and credits will be allocated among the Members so as to reflect
as nearly as possible the allocation set forth herein in computing their Capital Accounts.

 

(b)
Section 704(c) Allocations. Items of the Company’s taxable income, gain, loss and deduction for federal income tax
purposes with respect to any property contributed to the capital of the Company shall be allocated among the Members to the extent
necessary to satisfy the requirements of Section 704(c) of the Code using the remedial method or any other permissible method
selected by the Board of Managers and approved by a Majority in Interest. In addition, if the Gross Asset Value of any Company
asset is adjusted pursuant to the requirements of Treasury Regulation Section 1.704-1(b)(2)(iv)(f), then subsequent allocations
of items of taxable income, gain, loss and deduction with respect to such asset shall take account of any variation between the
adjusted basis of such asset for federal income tax purposes and its Gross Asset Value in the same manner as under Code Section
704(c) (using the remedial method or any other permissible method selected by the Board of Managers and approved by a Majority
in Interest).

 

    	11

    	 

    

 

(c)
Allocation of Tax Credits, Tax Credit Recapture, Etc. Allocations of tax credits, tax credit recapture, and any items related
thereto shall be allocated to the Members according to their interests in such items as determined by the Board of Managers taking
into account the principles of Treasury Regulation Section 1.704-1(b)(4)(ii).

 

(d)
Effect of Allocations. Allocations pursuant to this Section 4.4 are solely for purposes of federal, state and local
taxes and shall not affect, or in any way be taken into account in computing, any Member’s Capital Account or share of Net
Income, Net Losses, or Distributions or other Company items pursuant to any provision of this Agreement.

 

4.5
Taxes of Taxing Jurisdictions. To the extent that the laws of any Taxing Jurisdiction permits or requires, each Member
requested to do so by the Board of Managers will submit an agreement in writing indicating that the Member will make timely income
tax payments to the Taxing Jurisdiction and that the Member accepts personal jurisdiction of the Taxing Jurisdiction with regard
to the collection of income taxes attributable to the Member’s income, interest and penalties assessed on such income. The
Company may withhold and pay over to any Taxing Jurisdiction the amount of tax, penalties and interest with respect to such income
determined under the laws of the Taxing Jurisdiction. The Board of Managers may, where permitted by the rules of any Taxing Jurisdiction,
file a composite, combined or aggregate tax return reflecting the income of the Company and pay the tax, interest and penalties
of some or all of the Members on such income to the Taxing Jurisdiction, in which case the Company shall inform the Members of
the amount of such tax, interest and penalties so paid. Any payments made on behalf of the Member(s) pursuant to this Section
4.5 shall be treated as a distribution to such Member(s) for purposes of this Agreement.

 

4.6
Distributions. Subject to Sections 4.7 and 10.3(a), (a) distributions of Available Cash shall be made to
the holders of Units, as a group, at such times and in such amounts as the Board of Managers may determine (ratably among such
holders in accordance with their respective Percentage Interests as of the time of such Distribution) and (b) distributions of
Capital Proceeds shall be made to the holders of Units, as a group, at such times and in such amounts as the Board of Managers
may determine (ratably among such holders in accordance with their respective Capital Proceeds Percentages as of the time of such
Distribution).

 

4.7
Tax Distributions. At least once each Fiscal Year (or more frequently at the election of the Board of Managers), unless
prohibited by Section 18-607 of the Delaware Act, the Board of Managers shall cause the Company to distribute to each Member an
amount of cash (a “Tax Distribution”) which equals the following: (a) (i) the Assumed Tax Rate, multiplied
by (ii) the cumulative taxable income of the Company allocated and estimated to be allocated to such Member in its capacity
as a holder of a Unit for tax purposes (net of any tax losses allocated to such Member and not previously taken into account under
this clause and including taxable income allocated to the Member under Section 704(c) of the Code with respect to assets contributed
to the Company by the Member) through the end of such Fiscal Year (or Fiscal Quarter, as applicable), as determined by the Board
of Managers, less (b) the aggregate amount of prior Distributions made to the Member during such period. A Tax Distribution
for a Fiscal Year shall be made not later than the fifth (5th) day prior to the date on which any Member’s estimated federal
income tax payments are due. For purposes of calculating the amounts payable under Section 4.6, Tax Distributions shall
be treated (without duplication) as advances of any amounts Members are entitled to receive pursuant to Section 4.6 in
accordance with the allocation of taxable income giving rise to such Tax Distributions; provided that no Member shall be
required to repay all or any portion of a Tax Distribution in excess of the amount it otherwise would have been entitled to receive
pursuant to Section 4.6. If legally available funds are insufficient to make all Tax Distributions with respect to a Fiscal
Year in full, Tax Distributions with respect to such Fiscal Year shall be made under this Section 4.7 in proportion to
the amounts that would otherwise be distributable to each Member pursuant to this Section 4.7. No Tax Distributions will
be paid during the dissolution and liquidation of the Company. In addition, if the Company’s payment of a Tax Distribution
would cause the Company to breach any contract to which it is a party, then Board of Managers may elect for the Company not to
make all or any portion of such Tax Distribution.

 

    	12

    	 

    

 

4.8
Priority and Distribution of Property. Except as expressly provided in this Agreement and except as may be provided by
the rights, preferences and privileges of any additional Equity Securities created by the Board of Managers pursuant to Section
3.3, (a) no Member shall have priority over any other Member as to the return of capital, income or losses, or Distributions
and (b) no Member shall have the right to demand or receive property other than cash for its Capital Contributions or purchase
price for Units paid to the Company or in payment of its share of Distributions (as determined in accordance with this Agreement).

 

4.9
No Creditor Status. A Member shall not have the status of, and is not entitled to the remedies available to, a creditor
of the Company with regard to distributions that such Member, in its capacity as such, becomes entitled to receive pursuant to
this Agreement and the Delaware Law.

 

ARTICLE
5

MANAGEMENT
OF THE COMPANY

 

5.1
Board of Managers. There is hereby established a committee (the “Board of Managers”) comprised of natural
persons (each a “Manager” and collectively, the “Managers”) having the authority and duties
set forth in this Agreement and the Delaware Law. Each Manager will be entitled to one (1) vote. Each Manager will be a “manager”
(as that term is defined in the Delaware Law) of the Company, but, notwithstanding such designation, no Manager will have any
rights or powers beyond the rights and powers granted to such Manager in this Agreement. Any decisions to be made by the Board
of Managers will require the approval of the Managers holding at least a majority of the votes of all Managers then serving on
the Board of Managers (i.e., excluding any vacancies on the Board of Managers). Except as provided in the immediately preceding
sentence, no Manager acting alone, or with any other Manager or Managers, will have the power to act for or on behalf of, or to
bind the Company in his or her capacity as a Manager. Managers need not be residents of the State of Delaware, a Member or a United
States citizen.

 

5.2
Powers. Except as otherwise required by non-waivable provisions of Applicable Law or expressly provided in this Agreement,
subject to Section 6.8 below, (a) all of the Company’s powers shall be exercised by or under the authority of the
Board of Managers, (b) the business and affairs of the Company will be managed by or under the direction of the Board of Managers,
and (c) the Board of Managers shall have the sole power (including the rights and powers to take certain actions, give or withhold
certain consents or approvals, or make certain determinations, opinions, judgments, or other decisions) granted to the Company
under this Agreement or any other agreement, instrument, or other document to which the Company is a party.

 

    	13

    	 

    

 

5.3
Composition of the Board of Managers.

 

(a)
Number; Initial Managers; Term. The Board of Managers shall initially consist of up to three (3) natural persons. Each
Manager shall serve until a successor is appointed in accordance with the terms of this Agreement or his or her earlier resignation,
death, or removal. A person shall become a Manager effective upon receipt by the Company of a written notice (or at such later
time or upon the happening of some other event specified in such notice) of such person’s designation in accordance with
Section 5.3(b) below; provided, however, that the Initial Managers are Managers effective upon the Effective
Date.

 

(b)
Voting Agreement. Each Member agrees to vote all of his, her or its voting Units, whether now owned or hereafter acquired
or which such Member may be empowered to, from time to time and at all times, in whatever manner shall be necessary to ensure
that at each annual or special meeting of the Members at which an election of Managers is held or pursuant to any written consent
of the Members, the following persons are elected to the Board of Managers:

 

(i)
Subject to Section 5.3(d) below, one (1) individual designated by the H-Cyte Member for so long as the H-Cyte Member owns
any Class B Units (the “H-Cyte Representative”), who shall initially be Schuyler Hansen;

 

(ii)
one (1) individual designated by the holders of a majority of Class C Units; and

 

(iii)
one (1) individual designated by the holders of a majority of Class A Units, who shall initially be Christopher Athavle.

 

(c)
Resignation. A Manager may resign at any time by delivering written notice to the Company. Such resignation shall be effective
upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.

 

(d)
Increase in Size of Board of Managers. Upon the occurrence of a Triggering Event, the size of the Board of Managers shall
automatically be increased by two (2) additional Manager positions and the H-Cyte Member shall have the right to fill such open
Manager positions with individual persons designated by the H-Cyte Member in its sole discretion to serve until each such Manager’s
resignation, death or removal by the H-Cyte Member.

 

(e)
Removal. Subject to Section 5.3(f), the removal from the Board of Managers or any of its committees (with or without
cause) of any Person shall be upon (and only upon) the written request of the Person or Persons entitled to appoint such Person.

 

(f)
Vacancies. A vacancy on the Board of Managers because of resignation, death or removal of a Manager, or an increase in
the number of natural persons constituting the Board of Managers will be filled by the Person or Persons entitled to appoint such
Manager pursuant to the terms of Section 5.3(b) or Section 5.3(d), as applicable. If any Person or Persons fail
to appoint a Manager pursuant to the terms of Section 5.3(b) or Section 5.3(d), as applicable or is no longer entitled
to appoint a Manager pursuant to the terms of Section 5.3(b) or Section 5.3(d), as applicable , such position on
the Board of Managers shall remain vacant until such Person or Persons (or Majority in Interest, in the case of a Person or Persons
no longer entitled to appoint a Manager) exercise their right to appoint a Manager as provided hereunder. Such vacancy shall not
affect the validity of any action taken by the Board of Managers.

 

    	14

    	 

    

 

5.4
Annual Budget. The Members have reviewed and approved the initial annual budget of capital expenditures and operating expenses
for the Company and its Subsidiaries for the period beginning on the Effective Date and ending on December 31, 2021 (the “Initial
Budget”), a copy of which attached hereto as Exhibit B. No later than November 30, 2021 (and no later than thirty
(30) days prior to the end of each Fiscal Year thereafter), the Company must prepare, approve and deliver to the Board of Managers,
an updated and detailed estimated annual budget of capital expenditures and operating expenses for the Company and its Subsidiaries
for the next Fiscal Year (the “Budget Update”), prepared on a line-item basis and setting forth the estimated
revenues and expenses of the Company and the Subsidiaries for the next Fiscal Year. If the Board of Managers is unable to approve
a Budget Update before the commencement of the next Fiscal Year, the then-effective Annual Budget shall continue to control with
respect to operating expenses (but not capital expenditures).

 

5.5
Actions Requiring Board of Manager Consent. Notwithstanding any other provision of this Agreement, no officer or other
appointed agent of the Company shall be authorized to cause the Company or any Subsidiary thereof to take any of the following
actions (in one or a series of related events) without the prior consent of the Board of Managers:

 

(a)
Enter into, amend or terminate any other contractual obligation in excess of $50,000;

 

(b)
Purchase, lease or otherwise acquire an interest in any asset for a total acquisition price in excess of $50,000 or any other
asset or property for a total acquisition price in excess of $50,000, or enter into or approve a contract, agreement or other
arrangement with respect to the same, in each case to the extent not contemplated by the Annual Budget;

 

(c)
Acquire any financing, including the approval of the amount of such financing, the security for such financing and all other terms
of such financing; approve the direct or indirect borrowing of money by the Company, whether secured or unsecured; approve the
refinancing, extension or modification of any loan in any material manner; or become a surety or guarantor of, or an accommodation
party to, any obligation of any other person or entity, regardless of the amount involved;

 

(d)
Loan to any Person any funds of the Company;

 

(e)
Enter into, amend or approve any contract, agreement or other arrangement with a Governmental Entity, except as otherwise expressly
provided in this Agreement;

 

(f)
The submission of any material application, plan, bid or request (including to any Governmental Entity) in connection with the
Business or the agreement to any terms, conditions or exactions related thereto;

 

    	15

    	 

    

 

(g)
Enter into, amend or approve any contract, agreement or other arrangement with a Member, Manager, or an Affiliate of any Member
or Manager, except as otherwise expressly provided in this Agreement;

 

(h)
Approve any expenditure, the incurrence of any obligation or the entering into of any contract by the Company in which the Company
will be obligated to pay or receive, over the term of the obligation or contract, an amount greater than $50,000;

 

(i)
Hire any employee or engage any independent contractor for the provision of services to the Company, or delegate to any Person
the power to exercise all or any material portion of the authority or duties of a Member or Manager;

 

(j)
Make a distribution to any Member;

 

(k)
Make any decision that materially alters the nature, character or scope of the Business;

 

(l)
Dissolve the Company; convert, merge or consolidate the Company with or into another entity; or transfer or otherwise dispose
of all or substantially all of the Company’s assets;

 

(m)
Confess a judgment against the Company; execute or deliver any general assignment for the benefit of the creditors of the Company;
initiate any insolvency or bankruptcy proceedings for the Company; secure any non-Company debts or obligations with any assets
of the Company; or cross-default any of the Company’s obligations with any non-Company obligations;

 

(n)
Assign, transfer, pledge, compromise, or release any debts due to the Company in excess of $10,000, except upon payment in full;

 

(o)
Except for any matter in which the amount at issue could result in the Company being obligated to pay or receive an amount not
greater than $10,000, select any legal counsel to represent the Company or make any decision relating to litigating, adjusting,
settling, compromising or submitting to arbitration any claim, obligation, demand, suit, or judgment involving the Company;

 

(p)
Issue additional Equity Securities in the Company or admitting a new member of the Company or repurchase, redeem or otherwise
acquire any equity interests or other securities of the Company;

 

(q)
Consent to any Transfer of any Units;

 

(r)
Make any material tax election or material change to an accounting method of the Company, except for such changes as may be required
by the Code;

 

(s)
Make any distribution in-kind to any Member;

 

    	16

    	 

    

 

(t)
Engage or terminate any professional services provider (legal, accounting, etc.);

 

(u)
Amend any organizational documents of the Company, including the Certificate or this Agreement;

 

(v)
Form or contribute any assets to any other entity that is not a wholly owned Subsidiary of the Company; or

 

(w)
Agree or commit to doing any of the foregoing.

 

5.6
Meetings of the Board of Managers.

 

(a)
Generally. The Board of Managers will meet at such time and at such place as the Board of Managers may designate. Additionally,
meetings of the Board of Managers may be called by or at the discretion of any three or more Managers. Meetings of the Board of
Managers will be called on at least forty-eight (48) hours (if the meeting is to be held in person) or twenty-four (24) hours
(if the meeting is to be held by telephone communications) prior oral, written or electronic notice to the Managers, if any, or
upon such shorter notice as all of the Managers may approve. Any Manager may waive (either in writing or by Electronic Transmission)
such notice as to such Manager either before or after the meeting. All notices for meetings of the Board of Managers shall designated
in Eastern Standard Time (i.e. the current time in Tampa, Florida).

 

(b)
Presence; Quorum. Any meeting of the Board of Managers may be held, and any Manager may attend and vote and be present
at a meeting, in person or telephonically. The presence (in person or telephonically) of a majority of the Managers then serving
on the Board of Managers (i.e., excluding any vacancies on the Board of Managers) will constitute a quorum of the Board
of Managers for purposes of conducting business. At all times when the Board of Managers is conducting business at a meeting,
a quorum of the Board of Managers must be present (in person or telephonically). If a quorum is not present, any act taken at
the meeting is not a valid act of the Board of Managers. Any decisions to be made by the Board of Managers will require the approval
of the Managers holding at least a majority of the votes of all Managers then serving on the Board of Managers (i.e., excluding
any vacancies on the Board of Managers). If a quorum is not present at any meeting of the Board of Managers, then Managers having
a majority of the votes of the Managers present at the meeting may adjourn the meeting from time to time, without notice other
than announcement at the meeting, until a quorum is present. The actions taken by the Board of Managers at any meeting (as opposed
to by written consent), however called and noticed, shall be as valid as though taken at a meeting duly held after proper notice
if (but not until), either before, at or after the meeting, the Managers as to whom it was improperly held submit a waiver to
the Company (either in writing or by Electronic Transmission) of notice or a consent to the holding of such meeting or an approval
of the minutes thereof or they are deemed to have waived notice pursuant to Section 5.6(c).

 

(c)
Attendance and Waiver of Notice. Attendance of a Manager at any meeting (in person or telephonically) will constitute a
waiver of notice of such meeting, except where a Manager attends a meeting for the express purpose of objecting to the transaction
of any business on the ground that the meeting is not properly called or convened and states the same at the beginning of the
meeting. Neither the business to be transacted at, nor the purpose of, any meeting of the Board of Managers need be specified
in the notice or waiver of notice of such meeting.

 

    	17

    	 

    

 

5.7
Actions without a Meeting. Notwithstanding any other provision of this Agreement, any action of the Board of Managers may
be taken without a meeting, without advance notice and without a vote, if a written consent to the action is signed and delivered
(either in writing or via Electronic Transmission) by all of the Managers then serving on the Board of Managers (excluding any
vacancies on the Board of Managers). If a consent is in writing, all the Managers need not sign the same written consent, but
may execute a written consent in any number of counterparts. A written consent of Managers will be effective as of the date stated
in it or, if an effective date is not stated in the written consent, on the date when the last Manager necessary to make the written
consent effective delivers it. A Manager’s delivery of a written consent is irrevocable after it has been delivered to another
Manager or the Company. Whenever the Board of Managers takes any action by written consent, the Board of Managers shall file the
written consent with the minutes of the proceedings of the Board of Managers. A written consent of Managers has the effect of
a vote at a meeting of the Board of Managers and can be described as a vote in any document.

 

5.8
Committees of the Board of Managers . The Board of Managers may, by resolution, designate from among the Managers one or
more committees, each of which will be comprised of one or more Managers and include the H-Cyte Representative. In addition, the
Board of Managers may designate one or more of the Managers as alternate committee members, who may, subject to any limitations
imposed by the Board of Managers, replace absent or disqualified Managers at any meeting of that committee. Any such committee
will have and may exercise all of the authority of the Board of Managers to the extent set forth in any resolution of the Board
of Managers, subject to the limitations set forth in the Delaware Law or in the establishment of the committee. A majority of
the Board of Managers may remove and/or replace any member or alternate member of any committee.

 

5.9
Compensation; Reimbursement. Except for reimbursement of reasonable out-of-pocket costs and expenses, the Managers shall
not be compensated for their services as Managers until such time as the Company has become profitable, following which such time,
the Company in its discretion may elect to pay compensation to the Managers in amounts approved under the applicable Budget Update,
which shall not exceed $30,000 per annum in the case of any Manager. Each Manager shall be entitled to reimbursement by the Company
of any reasonable out-of-pocket costs or expenses incurred by the Manager in the course of his or her service hereunder, including
in connection with attending regular and special meetings of the Board of Managers, any board of managers or board of directors
of each of the Company’s Subsidiaries and/or any of their respective committees, so long as such reimbursements are approved
in advance by the Board of Managers.

 

5.10
Delegation of Authority. The Board of Managers may, from time to time, delegate to one or more Persons (including any Member
or Officer and including through the creation and establishment of one or more other committees) such authority and duties as
the Board of Managers may deem advisable. Any delegation pursuant to this Section 5.10 may be revoked at any time by the
Board of Managers.

 

    	18

    	 

    

 

5.11
Officers.

 

(a)
Generally. Subject to Section 5.5, the Board of Managers may (but need not), from time to time, designate and appoint
one or more natural persons as an Officer of the Company. No Officer need be a resident of the State of Delaware, a Member or
a Manager. Any Officers so designated shall have such authority and perform such duties as the Board of Managers may, from time
to time, delegate to them. The Board of Managers may assign titles to particular Officers (including Chief Executive Officer,
President, or Chief Financial Officer), and, if the title is one commonly used for officers of a business corporation, the assignment
of such title shall constitute the delegation to such officer of the authority and duties that are normally associated with that
office, subject in all events to the Board of Managers’ right to limit, amend, modify or revoke the authority of the Officer.
Each Officer shall hold office until the earlier of the Officer’s death, resignation, or removal. Any number of offices
may be held by the same individual. The title and role of Chairman of the Board of Managers shall not denote or imply an Officer
of the Company.

 

(b)
Resignation; Removal; Vacancies. Any Officer (subject to any contract rights available to the Company, if any) may resign
as such at any time. Such resignation shall be made in writing and shall take effect at the time specified therein, or if no time
be specified, at the time of its receipt by the Board of Managers. The acceptance of a resignation shall not be necessary to make
it effective, unless expressly so provided in the resignation. Any Officer may be removed as such, either with or without cause,
by the Board of Managers at any time. Any vacancy occurring in any office of the Company may be filled by the Board of Managers
and shall remain vacant until filled by the Board of Managers.

 

(c)
Duties of Officers. Subject to Section 6.6, the Officers, in the performance of their duties as such, shall owe
to the Company and the Members duties of loyalty and due care of the type owed by the officers of a corporation to such corporation
and its shareholders under the laws of the State of Delaware. The Officers are expected to consult with each other in the conduct
of the affairs of the Company.

 

(d)
Initial Officers. As of the Effective Date, the initial Officers of the Company are listed on Exhibit A hereto.

 

5.12
Purchase of Units. Subject to the Company’s compliance with the other applicable provisions of this Agreement, the
Board of Managers may cause the Company to purchase or otherwise acquire Units; provided that this provision shall not
in and of itself obligate any Member to sell any Units to the Company. So long as any such Units are owned by the Company such
Units shall not be considered outstanding for any purpose.

 

    	19

    	 

    

 

5.13
Limitation of Liability.

 

(a)
Standards of Performance. No Member or any Manager appointed by a Member shall owe any duty (including fiduciary duties)
to the Company, its subsidiaries or any other Member, provided that the foregoing shall not in any way limit any Member or Manager’s
obligations of good faith and fair dealing with respect to the Company. Subject to the foregoing and except as otherwise provided
herein or in any agreement entered into by such Person and the Company and to the maximum extent permitted by the Delaware Law,
no Manager nor any such Manager’s Affiliates, employees, agents or representatives shall be liable to the Company or to
any Member for any act or omission performed or omitted by such Person in his capacity as Manager; provided that, except as otherwise
provided herein, such limitation of liability shall not apply (i) with respect to any act or omission by such Person in its capacity
as a Member, or (ii) to the extent the act or omission was attributable to such Person’s willful misconduct, gross negligence,
fraud or material breach of this Agreement, in each case as determined by a final judgment, order or decree of an arbitrator or
a court of competent jurisdiction (which is not appealable or with respect to which the time for appeal therefrom has expired
and no appeal has been perfected). Each Manager shall be entitled to rely upon the advice of legal counsel, independent public
accountants and other experts, including financial advisors, and any act or omission by such Manager in good faith reliance on
such advice shall in no event subject such Manager or any of such Manager’s Affiliates, employees, agents or representatives
to liability to the Company or to any Member or any other Person that is a party to or otherwise bound by this Agreement. No amendment,
alteration or termination of this Agreement or of any provision of this Section 5.13(a) after the date of this Agreement
shall expand the duties or liabilities of a present or former Manager of the Company with respect to acts or omissions prior to
the date of such amendment, alteration or termination.

 

(b)
Board Discretion. Whenever in this Agreement or any other agreement contemplated herein or to which the Company is a party
the Board of Managers is permitted or required to take any action or to make a decision or determination, the Board of Managers
may take such action or make such decision or determination in its sole discretion, unless another standard is expressly set forth
herein or therein. Whenever in this Agreement or any other agreement contemplated herein the Board of Managers is permitted or
required to take any action or to make a decision or determination in its “sole discretion” or “discretion,”
with “complete discretion” or under a grant of similar authority or latitude, each Manager shall be entitled to consider
such interests and factors as such Manager desires (including, without limitation, the interests of such Manager’s Affiliates
as Members).

 

(c)
Good Faith and Other Standards. Whenever in this Agreement or any other agreement contemplated herein or to which the Company
is a party the Board of Managers is expressly permitted or required to take any action or to make a decision or determination
in its “good faith” or under another express standard, each Manager shall act under such express standard and, to
the extent permitted by Applicable Law, shall not be subject to any other or different standards imposed by this Agreement or
any other agreement contemplated herein or to which the Company is a party, and, notwithstanding anything contained herein to
the contrary, so long as such Manager acts in good faith, the resolution, action or terms so made, taken or provided by the Board
of Managers shall not constitute a breach of this Agreement or any other agreement contemplated herein or impose liability upon
such Manager or any of such Manager’s Affiliates, employees, agents or representatives.

 

    	20

    	 

    

 

(d)
Indemnification. Subject to this Section 5.13(d), the Company shall indemnify and pay for the defense of, to the
fullest extent now or hereafter permitted by law, any Manager or former Manager who was or is a party or is threatened to be made
a party to, or is involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (hereafter, a “Proceeding”), by reason of the fact that he, she, or a Person of whom he or
she is the legal representative, is or was a Manager or serving as a manager, officer or director of any Subsidiary after the
Effective Date, whether the basis of such Proceeding is alleged action in an official capacity as a Manager, officer, director,
employee or agent or in any other capacity while serving as such, against all expense, liability and loss (including attorneys’
fees), judgments, fines, excise taxes or penalties and amounts paid or to be paid in settlement, reasonably incurred or suffered
by such individual in connection therewith; provided that the Company shall not indemnify for the defense of any Person
who is a party to any Proceeding, the basis of which is the fraud, gross negligence or willful misconduct of such Person (or an
Affiliate of such Person) or material breach of this Agreement or any other agreement between such Person (or an Affiliate of
such Person) and the Company or any Subsidiary.

 

ARTICLE
6

RIGHTS
AND OBLIGATIONS OF MEMBERS

 

6.1
Limitation of Liability. Except to the extent provided in the Delaware Law or in this Agreement, no Member shall be personally
liable for the debts, liabilities, contracts or any other obligations of the Company. No Member shall be obligated personally
for any such debt, liability, contract or other obligation of the Company solely by reason of being a Member or acting as a Member
or Manager.

 

6.2
Management of the Company. No Member in its capacity as such has the authority or power to act for or on behalf of the
Company in any manner or way, to bind the Company, or do any act that would be (or could be construed as) binding the Company,
in any manner or way, or to make any expenditures on behalf of the Company, unless such specific authority and power has been
expressly granted to such Member (and not revoked) by the Board of Managers. The Members hereby consent to the exercise by the
Board of Managers of the powers conferred on it by Applicable Law and this Agreement.

 

6.3
Effect of Bankruptcy, Death or Incompetency of Member.

 

(a)
Death. The death of any Member shall not in and of itself cause the termination or dissolution of the Company, and the
business of the Company shall continue. Upon any such occurrence the executor or administrator of the Member in question shall
be entitled to receive, with respect to such Member’s Units and on behalf of such Members or such Member’s estate,
the distributions and allocations of profits and losses to which such Member would be entitled as an assignee, and, subject to
the requirements of Section 7.6(b), upon execution of the Adoption Agreement shall have the right to act as a Substituted
Member. The successor in ownership interest shall not have the right to demand valuation or payment for the deceased Member’s
Units.

 

(b)
Bankruptcy or Incompetency. The bankruptcy, dissolution or adjudication of incompetency of any Member shall not in and
of itself cause the termination or dissolution of the Company, and the business of the Company shall continue. Upon any such occurrence,
subject to the provisions of ARTICLE 7, the trustee, receiver, administrator, committee, guardian or conservator of the
Member in question shall be deemed an assignee of such Member for the purpose of settling or managing the estate or property;
provided, however, that any pledgee of such Member who acquires such Member’s Membership Interest pursuant
to a Permitted Pledge shall automatically be admitted as a Substituted Member after satisfying the requirements set forth in Section
7.7. As an assignee, the successor to the ownership interest of such Member shall have only the rights of such Member in the
Company’s Net Income and Net Loss and in Distributions. The successor shall not be a Substituted Member except as provided
in Section 7.7, and neither such Member nor the successor in ownership interest shall have the right to demand immediate
valuation and payment for such Member’s Units.

 

    	21

    	 

    

 

6.4
Meetings of and Voting by Members. Every consent and approval of the Members that is required or permitted by Applicable
Law, the Certificate, or this Agreement will be valid only if it is signified by a resolution adopted by either the affirmative
vote of the requisite number of Members at a meeting of Members that was duly called and held in accordance with this Agreement,
or a written consent that is executed by the requisite number of Members in accordance with Section 6.5. Unless otherwise
provided in the resolution or written consent, a valid consent or approval of the Members will be effective when the resolution
is adopted by the Members, in the case of a vote, or signed by the last Member necessary to validate it, in the case of a written
consent.

 

(a)
Member Meetings. The Company will hold a meeting of Members for the purpose or purposes stated in the notice of the meeting.
The Board of Managers may call a meeting of the Members at any time for any purpose. Every meeting of Members of the Company will
be held at a time, date, and place as designated by the Board of Managers. The Members may conduct at a meeting only business
that is related to the purpose or purposes stated in the notice of the meeting unless the Board of Managers consents to the additional
matters as considered.

 

(b)
Notice of Member Meetings. The Board of Managers will give each Member not fewer than three (3) or more than sixty (60)
days advance notice, in writing or by Electronic Transmission, of every meeting of Members. Every written notice of a meeting
of Members will state the date, time, place, and each purpose of the meeting, and the action proposed for consideration at the
meeting and must be delivered to each Member. A notice of a meeting of Members will be adequate for both the meeting of Members
designated in the notice and any adjournment of that meeting, if the date, time, and place to which the meeting is adjourned are
announced at the meeting before the adjournment is taken, and if the Board of Managers does not establish after the adjournment
a new record date for the adjourned meeting of Members. If any Member transfers any Unit after the effective date of a notice
of a meeting of Members, the Board of Managers need not notify the transferee of the meeting of Members.

 

(c)
Waiver of Notice and Presumption of Assent. A Member may waive notice (either in writing or by Electronic Transmission)
of any meeting of Members or other action for which notice is required by Applicable Law, the Certificate, or this Agreement by
signing and delivering to the Board of Managers a waiver of the notice, in writing or by Electronic Transmission, either at, before,
or after the date and time of the meeting or other action for which notice is required. The Board of Managers will file a written
waiver of a notice of a meeting of Members with the minutes of that meeting and will file in the Company’s record book for
proceedings of its Members a written waiver of any other requisite notice. A Member’s attendance at a meeting of Members,
in person or by proxy, constitutes a waiver by the Member of the notice of the meeting or any defect in the notice of the meeting,
unless the Member (in person or by proxy) objects at the beginning of the meeting to the holding of the meeting or the conduct
of business at the meeting.

 

    	22

    	 

    

 

(d)
Quorum for Member Meetings. Unless otherwise required by Applicable Law, the presence in person or by proxy of Members
who own Units representing at least a Majority in Interest constitutes a quorum for the conduct of business at every meeting of
Members. Once a quorum is established at a meeting of Members, a subsequent withdrawal of a Member or Members that reduces the
Units entitled to vote and represented at the meeting (in person or by proxy) below the number required for a quorum will not
affect the validity of any action taken at the meeting or any adjournment of that meeting, unless a new record date is or must
be set for the adjourned meeting.

 

(e)
Member Voting. Except as otherwise provided in this Agreement, each Member shall have the right to one vote for each Unit
held by such Member on each matter submitted to a vote or approval by the Members. Only those Persons who are Members on the day
of a meeting will be entitled to vote at a meeting of Members. A Member may vote in person or by proxy. The matter will be approved
if a Majority in Interest vote in favor of the action either in person or by proxy, unless a greater number of affirmative votes
is required under other provisions of this Agreement.

 

(f)
Proxies. A Member entitled to vote at a meeting of Members or to express consent or dissent without a meeting, a Person
entitled to vote on behalf of a Member which is a corporation, limited partnership, or limited liability company, or a duly authorized
attorney-in-fact of a Member, may authorize one or more Persons to vote for such Member by proxy by signing a proxy appointment
form.

 

6.5
Member Action Without a Meeting.

 

(a)
Any action required or permitted by Applicable Law, the Certificate, or this Agreement to be taken at a meeting of Members of
the Company can be taken without a meeting, without advance notice, and without a vote, if a written consent to the action is
signed and dated, either in writing or by Electronic Transmission, by Members holding at least the percentage of Units that would
be required to approve such action if submitted to a vote at a meeting of Members entitled to vote at which all Members were in
attendance.

 

(b)
For the Member action to be effective, written consents representing the requisite vote must be delivered to the Company within
sixty (60) days after the earliest dated written consent. The Members need not sign the same written consent, but may execute
a written consent in any number of counterparts. The delivery to the Company within the 60-day period of a written consent via
Electronic Transmission that appears to have been signed, dated, and transmitted by a Member or the Member’s duly appointed
proxy or attorney-in-fact will be sufficient and effective so long as the manually signed copy of the written consent is delivered
to the Company (as provided above) promptly thereafter. A Member’s execution of a written consent is irrevocable, and a
Member cannot later reject or revoke a written consent that has been signed, dated, and delivered in the manner provided above.
Within ten (10) days after obtaining the authorization of its Members to undertake any Company action by written consent, the
Company shall notify those Members who did not consent in writing to the action, or who were not entitled to vote on the action
taken by written consent, of the action that was taken by written consent; provided that the Company’s failure to
timely provide notice will not affect the validity of the consent. The notice must fairly summarize the material features of the
authorized action.

 

    	23

    	 

    

 

6.6
Investment Opportunities and Conflicts of Interest. Unless the Board of Managers otherwise agrees in writing, no Member
or any Affiliate of a Member, in each case who is employed by the Company or any of its Subsidiaries, shall, or shall cause any
of its Affiliates to, accept or pursue, directly or indirectly on such Member’s (or Affiliate’s) own behalf, any investment
or business opportunities of which any of the foregoing become aware and which they believe are, or may be, within the scope of
the Business of the Company or any of its Subsidiaries which would or may be beneficial to the Company or any of its Subsidiaries.
For greater certainty, the H-Cyte Member is not employed by the Company or any of its Subsidiaries. It is the intent of the Members
that each of Athavle, Sablowski and Beckerlegge devote such time and attention to the Company and the Business as is reasonably
necessary to carry out their duties and responsibilities to the Company and its Subsidiaries, provided that the Members expressly
acknowledge and agree that Athavle, Sablowski and Beckerlegge are currently engaged in activities set forth on Exhibit E
to this Agreement that are unrelated to the Business and their continued engagement in such activities following the Effective
Date shall not be deemed a violation of this Section 6.6, provided further that the undertaking by any of Athavle, Sablowski
and Beckerlegge of additional activities not expressly identified on Exhibit E and unrelated to the business of the Company
will require the approval of the Board of Managers. The Members further expressly acknowledge and agree that (a) the managers,
directors, officers, shareholders, partners, members, employees, representatives, and agents of the H-Cyte Member and its Affiliates
(including any representative of the H-Cyte Member serving on the Board of Managers or on the board of directors or board of managers
of any of the Company’s Subsidiaries or as an officer of the Company or any of its Subsidiaries) (collectively, the “Specified
Persons”) are permitted (i) to have and develop, and may presently or in the future have and develop, investments, transactions,
business ventures, contractual, strategic or other business relationships, prospective economic advantages or other opportunities
(the “Business Opportunities”) in the Business (other than through the Company or any of its Subsidiaries)
or in businesses that are and may be competitive with the Company or any of its Subsidiaries (an “Other Business”),
for their own account or for the account of any Person other than the Company or any of its Subsidiaries or any other Member,
or (ii) to direct any such Business Opportunities to any other Person, in each case, regardless of whether such Business Opportunities
are presented to a Specified Person in his, her or its capacity as a Member, Manager, director or manager in the board of directors
or board of managers of the Company or any Subsidiaries or officer of the Company or any of its Subsidiaries or otherwise, (b)
none of the Specified Persons will be prohibited by virtue of their investments in the Company or any of its Subsidiaries or their
service as a Manager or service on the board of directors or board of managers of the Company or any of its Subsidiaries or as
an officer of the Company or any of its Subsidiaries or otherwise from pursuing and engaging in any such activities, (c) none
of the Specified Persons will be obligated to inform or present the Company or any of its Subsidiaries or the Board of Managers
or the board of directors or board of managers of any of the Company’s Subsidiaries or any other Member of or with any such
Business Opportunity, (d) neither the Company or any of its Subsidiaries nor the other Members will have or acquire or be entitled
to any interest or expectancy or participation (such right to any interest, expectancy or participation, if any, being hereby
renounced and waived) in any Business Opportunity as a result of the involvement therein of any of the Specified Persons, and
(e) the involvement, in and of itself, of any of the Specified Persons in any Business Opportunity will not constitute a conflict
of interest or breach of fiduciary duty by such Persons with respect to the Company or any of its Subsidiaries or the other Members.
This Section 6.6 shall not in any way affect, limit or modify any liabilities, obligations, duties or responsibilities
of any Person under any Equity Agreement. For the avoidance of doubt, none of the H-Cyte Member, H-Cyte, Inc. or their respective
Affiliates are Specified Persons for purposes of this Agreement.

 

    	24

    	 

    

 

6.7
Action by Vote of the Members. Unless prohibited by the Delaware Law or expressly otherwise provided in this Agreement,
whenever the Members are required or permitted to vote or otherwise act, the affirmative vote of Members holding not less than
a Majority in Interest shall be the act of the Members.

 

6.8
Major Decisions. The Company may not (and may not permit any Subsidiary to) take any of the following “Major Decisions”
without the prior written consent of the H-Cyte Member:

 

(a)
liquidate, dissolve or wind up the affairs of the Company or effect any merger or consolidation or any sale or other disposition
of all or substantially all of the assets of the Company;

 

(b)
making or revoking any tax election that would change the tax classification of any of the Company as a partnership for federal
income tax purposes, filing any material tax return or tax report on behalf of the Company that has not been first provided to
the Members for approval under this Section 6.8 and adopting significant accounting policies;

 

(c)
subject to Section 6.10 below, causing or permitting the Company or any Subsidiary to enter into any agreement, or amend
or materially modify or terminate any agreement, with any Member, Manager or any Affiliate thereof, or pay to any Member, Manager,
or any of their respective Affiliates any compensation, fees or reimbursement, except as otherwise expressly provided in this
Agreement or contemplated in the Annual Budget;

 

(d)
the filing on behalf of the Company (where the Company is the debtor) of any petition, or consent to the appointment of a trustee
or receiver or any judgment or order, under state or federal bankruptcy laws, seeking (for the Company or its subsidiaries) relief
under any laws relating to relief from debts or the protection of debtors generally, or taking any action solely in furtherance
thereof or otherwise instituting insolvency proceedings with respect to the Company;

 

(e)
increasing the number of authorized Units for any class of Units or issuing Class B Units to Persons other than the H-Cyte Member;

 

(f)
prior to such time as the DenerveX Device has been manufactured and approved for sale, any decision to provide any salary, commissions
or other compensation to Athavle;

 

(g)
amending this Agreement (other than amendments to the Schedule of Members from time to time in the ordinary course of business
to reflect the admission or withdrawal of Members or adjustment to their Units);

 

    	25

    	 

    

 

(h)
increasing or decreasing the size of the Board of Managers; or

 

(i)
any agreement or commitment to the foregoing.

 

6.9
Financial Statements and Other Information. Each Member and Manager shall have the right to receive all of the following
information from the Company, and the Company shall provide to each such Member and Manager:

 

(a)
no later than seven (7) days after the end of each monthly accounting period in each Fiscal Year, preliminary unaudited statements
of income and cash flows of the Company for such monthly period and for the period from the beginning of the Fiscal Year to the
end of such monthly period prepared on an accrual accounting basis, and a preliminary unaudited balance sheet of the Company as
of the end of such monthly period;

 

(b)
as soon as available but in any event within thirty (30) days after the end of each monthly accounting period in each Fiscal Year,
unaudited statements of income and cash flows of the Company for such monthly period and for the period from the beginning of
the Fiscal Year to the end of such monthly period prepared on an accrual accounting basis, and an unaudited balance sheet of the
Company as of the end of such monthly period, setting forth in each case comparisons to the Annual Budget and to the corresponding
period in the preceding Fiscal Year and all being certified as correct to the knowledge of the Company’s chief financial
officer, president, or chief executive officer;

 

(c)
as soon as available but in any event within forty-five (45) days after the end of each quarterly accounting period in each Fiscal
Year, unaudited statements of income and cash flows of the Company for such quarterly period and for the period from the beginning
of the Fiscal Year to the end of such quarterly period prepared on an accrual accounting basis, and an unaudited balance sheet
of the Company as of the end of such quarterly period, setting forth in each case comparisons to the Annual Budget and to the
corresponding period in the preceding Fiscal Year and all being certified as correct to the knowledge of the Company’s chief
financial officer, president, or chief executive officer;

 

(d)
within one hundred twenty (120) days after the end of each Fiscal Year, a statement of income and cash flows of the Company for
such Fiscal Year and a balance sheet of the Company as of the end of such Fiscal Year, setting forth in each case comparisons
to the Annual Budget and to the preceding Fiscal Year, all prepared in accordance with GAAP and if so requested by the Board of
Managers, audited by the Company Accountants;

 

(e)
within ninety (90) days following the end of the taxable year of the Company, copies of the Company’s federal partnership
return of income and other income tax returns, together with each such Member’s Schedule K-1 or analogous schedule, which
returns shall be signed by the partnership representative (as appointed pursuant to Section 9.4(a)) on behalf of the Company
and co-signed by the Company Accountant as preparer; and

 

(f)
with reasonable promptness, such other information and financial data concerning the Company as such Member may reasonably request.

 

    	26

    	 

    

 

6.10
Transactions with Related Parties.

 

(a)
No agreement or transaction between the Company or any Subsidiary, on the one hand, and any Member or Affiliate of a Member, on
the other hand (a “Related Party Agreement”), shall be void or voidable solely by reason of such relationship.
The execution of any such agreement or the entering into or consummation of such transaction by the Company shall require as a
condition precedent that (i) all of the material facts as to the agreement or transaction and the relationship between any such
Affiliate and the Member and the nature of any conflict of interest are disclosed or are known to the Board of Managers, (ii)
the Company shall have used commercially reasonable efforts to seek alternative contractual arrangements with third parties (including
soliciting third party bids), unless waived by the non-interested Managers serving on the Board of Managers and (iii) the Board
of Managers approves or ratifies such agreement or transaction.

 

(b)
Notwithstanding Section 6.10(a) above, the parties acknowledge that the Related Party Agreements identified on Exhibit
C to this Agreement are pre-approved for execution and delivery by the Company on the terms described on such exhibit and
shall require no further consent by any Person under this Agreement.

 

ARTICLE
7

TRANSFERS of UNITS; Sale of the company

 

7.1
Transfers in General. The sale, transfer, assignment, pledge or other disposition of any interest in any Unit (whether
with or without consideration and whether voluntarily or involuntarily or by operation of law), directly or indirectly, to another
Person is referred to herein as a “Transfer” and to take such action is referred to herein as to “Transfer.”
No Member shall Transfer any Units or Unit Equivalents (or any interest in any Units or Unit Equivalents), except (a) to the Company,
if approved by the Board of Managers; (b) pursuant to a Transfer approved by the Board of Managers; (c) to a Permitted Transferee
pursuant to a Permitted Transfer, subject to the terms of this ARTICLE 7; (d) pursuant to Section 7.3 in connection
with the exercise of a Purchase Option or (e) pursuant to Section 7.14 in connection with a Deemed Offer event. Any purported
Transfer of a Units or Unit Equivalents not in accordance with this ARTICLE 7 shall be null and void ab initio and
of no effect. Each Member shall hold the Company and each other Member harmless from all costs, liabilities or damages, including
the costs of enforcing this indemnity, incurred by the Company or any other Member as a result of the Member’s purported
Transfer of a Unit or Unit Equivalent other than in accordance with this Agreement.

 

7.2
Right of First Refusal.

 

(a)
Subject to the terms and conditions set forth in this ARTICLE 7, at least thirty (30) days prior to the Transfer of any
Units held by any Member, the transferring Member (the “Transferring Holder”) shall deliver a written notice
(the “Offer Notice”) to the Company and Eligible Members. The Offer Notice shall disclose in reasonable detail
the identity of the prospective transferee(s), the number of Units to be transferred, the price and the other terms and conditions
of the proposed Transfer together with a complete copy of the offer. The Transferring Holder shall not consummate such proposed
Transfer until at least thirty (30) days after the delivery of the Offer Notice, unless the parties to the Transfer have been
finally determined pursuant to this Section 7.2 prior to the expiration of such 30-day period (the date of the first to
occur of (x) the expiration of such 30-day period after delivery of the Offer Notice or (y) such final determination is referred
to herein as the “Authorization Date”). Each Offer Notice shall constitute an irrevocable offer by the Transferring
Holder to sell to the Company and Eligible Members the offered Units on the terms and conditions set forth in the Offer Notice
and this Section 7.2. Notwithstanding anything to the contrary contained in this Section 7.2, no offer in respect
of Units may include any form of consideration other than cash (which may be paid at closing, in installments or after any period
of time).

 

    	27

    	 

    

 

(b)
The Company may elect to purchase all or any portion of any Units to be transferred upon the same terms and conditions as those
set forth in the Offer Notice by delivering a written notice (the “Company Purchase Notice”) of such election
to the Transferring Holder within fifteen (15) days after the Offer Notice has been given to the Company. Within fifteen (15)
days following delivery of the Offer Notice, the Company shall deliver written notice (the “Available Unit Notice”)
to the Eligible Members setting forth the number and type of Units which it has elected to purchase and the aggregate number and
type of Units which are available for purchase by the Eligible Members (“Available Units”).

 

(c)
The Eligible Members shall then be entitled to purchase all or a portion of the Available Units by delivering written notice (the
“Available Unit Purchase Notice”) to the Company and the Transferring Holder within fifteen (15) days following
delivery of the Offer Notice setting forth the maximum number of Units of each class which it desires to purchase. The rights
of Eligible Members pursuant to this Section 7.2 shall be apportioned among them in accordance with their relative Percentage
Interests or in such other manner as they shall mutually agree (and any other Member or Person subject to this Section 7.2
shall be bound by any such mutual agreement).

 

(d)
If the Company and/or Eligible Members have elected to purchase all or any portion of the Units hereunder, the Transfer of such
Units shall be consummated as soon as practical after the delivery of the election notice(s) to the Transferring Holder, but in
any event within forty-five (45) days after the Authorization Date at the principal office of the Company. The Company and Eligible
Members, as applicable, shall give at least ten (10) days prior notice of the date of the closing. At such closing, (i) the Transferring
Holder shall deliver to electing Eligible Members and/or the Company, as applicable, the certificate or certificates (if any)
representing the Units to be sold at the closing, free and clear of any lien (except to the extent arising under this Agreement)
(and the Transferring Holder shall represent and warrant that such Units shall, immediately prior to such sale, be so free and
clear and that it will have good and valid title to such Units), (ii) the electing Eligible Members and/or the Company, as applicable,
shall deliver to the Transferring Holder the consideration to be paid for the purchased Units in accordance with the terms of
the Offer Notice, (iii) the Company shall duly record the Transfer on its books and records, and (iv) the electing Eligible Members
and/or the Company, as applicable, and the Transferring Holder shall execute such other documents and take such other action as
shall be necessary to consummate the purchase and sale of the applicable Units on the terms contemplated by the Offer Notice.

 

(e)
If the Company and the Eligible Members do not elect, in the aggregate, to purchase all of the Units offered in the Offer Notice
from the Transferring Holder, then, the Transferring Holder shall have the right, within the ninety (90) days following the Authorization
Date, to Transfer the portion of such Units which the Company and Eligible Members have not elected to purchase to the Transferee(s)
specified in the Offer Notice in the amounts specified in the Offer Notice at a price not less than the price per unit for such
Units specified in the Offer Notice and on other terms no more favorable to the Transferee(s) thereof than specified in the Offer
Notice. Any not so Transferred within such 90-day period shall be reoffered to the Company and Eligible Members pursuant to this
Section 7.2 prior to any subsequent Transfer.

 

    	28

    	 

    

 

(f)
The provisions of this Section 7.2 shall not apply to any proposed Transfer (i) to the Company or any of its Subsidiaries,
(ii) to a Permitted Transferee of any Member, (iii) pursuant to Section 7.3, or (iv) pursuant to the purchase of a Deemed
Offered Interest pursuant to Section 7.14.

 

7.3
Purchase Option.

 

(a)
No later than thirty (30) days following the fifth anniversary of the Effective Date, the Company will deliver to the H-Cyte Member
a report (the “Monthly Average Sales Report”) setting forth the average monthly number of sales of DenerveX
Devices made by the Company and its Subsidiaries as of the fifth anniversary of the Effective Date measured on a trailing twelve
(12) month basis (the “Average Sales Amount”), provided that if a Material Adverse Event has occurred with
respect to the Company and its Subsidiaries following the fourth anniversary of the Effective Date, the Average Sales Amount will
be calculated taking into account average monthly number of sales of DenerveX Devices in prior years. If the H-Cyte Member delivers
written notice (the “Disputed Items Notice”) to the Company within thirty (30) days after receipt by the H-Cyte
Member of the Monthly Average Sales Report, stating that the H-Cyte Member objects to any items in the Monthly Average Sales Report,
specifying in reasonable detail the basis for such objection and setting forth the H-Cyte Member’s proposed modification
to such report, the Company and the H-Cyte Member will attempt to resolve and finally determine and agree upon the Average Sales
Amount in good faith as promptly as practicable.

 

(b)
If the H-Cyte Member and the Company are unable to agree upon the Average Sales Amount within thirty (30) days after delivery
of the Disputed Items Notice, the H-Cyte Member and the Company will submit to an independent accounting firm with expertise in
financial analysis mutually satisfactory to the H-Cyte Member and the Company (the “Accounting Firm”) for review
and resolution of the items set forth in the Disputed Items Notice (the “Disputed Items”). The Accounting Firm
will (i) resolve the Disputed Items (and only the Disputed Items) based on written presentations from the H-Cyte Member and the
Company, (ii) not ascribe an Average Sales Amount higher or lower, as the case may be, than the highest or lowest Average Sales
Amount claimed by the Company or the H-Cyte Member in the Monthly Average Sales Report and Disputed Items Notice, respectively,
and (iii) make a determination of the Average Sales Amount based on its resolution of the Disputed Items. The fees, costs and
expenses of the Accounting Firm will be borne by the party whose positions generally did not prevail in such determination, as
determined by such accounting firm, or if the Accounting Firm determines that neither party could be fairly found to be the prevailing
party, then such fees, costs and expenses will be borne 50% by the H-Cyte Member and 50% by the Company.

 

    	29

    	 

    

 

(c)
Subject to terms and conditions of Section 7.5, and otherwise notwithstanding anything to the contrary contained in this
Agreement, if the Average Sales Amount (as finally determined under this Section 7.3) is a number less than 800 (a “Triggering
Event”), the H-Cyte Member shall have the right, exercisable upon written notice to the Company (which must be delivered
no later than ninety (90) days after the Average Sales Amount has been finally determined) to purchase up to the number of Class
A Units of the Company from the holders thereof calculated as follows (the “Purchase Option”):

 

(i)
if the Average Sales Amount is greater than 720 but less than or equal to 760, an amount equal to up to ten percent (10%) of all
outstanding Class A Units;

 

(ii)
if the Average Sales Amount is greater than 640 but less than or equal to 720, an amount equal to up to twenty percent (20%) of
all outstanding Class A Units;

 

(iii)
if the Average Sales Amount is greater than 560 but less than or equal to 640, an amount equal to up to thirty percent (30%) of
all outstanding Class A Units;

 

(iv)
if the Average Sales Amount is greater than 480 but less than or equal to 560, an amount equal to up to forty percent (40%) of
all outstanding Class A Units;

 

(v)
if the Average Sales Amount is greater than 400 but less than or equal to 480, an amount equal to up to fifty percent (50%) of
all outstanding Class A Units;

 

(vi)
if the Average Sales Amount is less than or equal to 400, an amount equal to up to one hundred percent (100%) of all outstanding
Class A Units;

 

If
the Purchase Option is exercised, each holder of Class A Units (or his, her or its legal representative or successor or assign,
as the case may be) (each a “Seller”) shall sell their applicable number of Class A Units to the H-Cyte Member
in accordance with this Section 7.3. For the avoidance of doubt, if a holder of Class A Units transfers Class A Units for
any reason, those Class A Units will remain subject to the Purchase Option upon the occurrence of a Triggering Event with respect
to that transferring holder thereof. Any Class A Units purchased pursuant to the exercise of a Purchase Option for less than one
hundred percent (100%) of all Class A Units in accordance with this Section 7.3 shall be acquired from the holders thereof
ratably in accordance with their relative Percentage Interests.

 

(d)
If the H-Cyte Member exercises the Purchase Option, in exchange for the Class A Units purchased, the H-Cyte Member shall pay an
aggregate purchase price for such Class A Units (the “Purchase Price”) equal to $1.00 (to be allocated to the
Sellers in accordance with their relative Percentage Interests). The purchase and sale of Class A Units under this Section
7.3 shall close at the offices of the Company (or by electronic exchange of documents) at a date and time reasonably determined
by the H-Cyte Member, but no later than thirty (30) days after the date the Purchase Option is exercised. At the closing the following
will occur:

 

(i)
The H-Cyte Member shall pay the aggregate Purchase Price to the Company (for further distribution to the Sellers) in full, by
any combination of cash or check.

 

    	30

    	 

    

 

(ii)
Each Seller shall assign and transfer to the Company all right, title and interest in and to his, her or its Class A Units being
sold, free and clear of all liens, charges, encumbrances, security interests, and adverse claims of every kind whatsoever. Each
Seller shall execute all conveyance and other documents reasonably requested by the Company to consummate the sale of the Class
A Units being sold under this Section 7.3. The H-Cyte Member shall be entitled to receive customary representations and
warranties from each Seller related to authority, ownership and ability to convey good title to the Class A Units purchased under
this Section 7.3, free and clear of any liens, charges, encumbrances, security interests, and adverse claims of every kind
whatsoever.

 

(e)
If any Seller fails to appear at the closing or otherwise defaults in its obligations under this Agreement, the Seller shall be
deemed to have sold its applicable number of Class A Units to the H-Cyte Member at the closing pursuant to the terms and conditions
of this Agreement, and the Seller shall have no further rights with respect to such Class A Units other than to receive such Seller’s
allocable portion of the Purchase Price. Each Seller irrevocably constitutes and appoints the H-Cyte Member, with full power of
substitution in the premises, as their due and lawful attorney in fact (i) to transfer any Class A Units purchased and sold pursuant
to the terms of this Section 7.3 on the books of the Company, and (ii) take such other actions and execute such assignments,
conveyances, transfers and other documents in the Seller’s name and on the Seller’s behalf as may be necessary or
appropriate to effect such purchase and sale. This power of attorney is coupled with an interest, and is irrevocable.

 

(f)
The H-Cyte Member may assign its right to purchase any Class A Units under this Section 7.3 to any Affiliate thereof.

 

7.4
Effect of Assignment.

 

(a)
Termination of Rights. Any Member who assigns any Units or other interest in the Company shall cease to be a Member with
respect to such Units or other interest and shall no longer have any rights or privileges of a Member with respect to such Units
or other interest. For greater certainty, a Member will not cease to be a Member merely as a result of pledging its Units pursuant
to a Permitted Pledge. A Transfer shall not otherwise eliminate the Member’s entitlement to any rights associated with the
Member’s remaining interest and shall not cause the Member to be released from any liability to the Company or any other
Person solely as a result of the Transfer.

 

(b)
Deemed Agreement. Any Person who acquires in any manner whatsoever any Units or other interest in the Company, irrespective
of whether such Person has accepted and adopted in writing the terms and provisions of this Agreement, shall be deemed by the
acceptance of the benefits of the acquisition thereof and to have agreed to be subject to and bound by all of the terms and conditions
of this Agreement.

 

(c)
Assignee’s Rights. A Transfer of Units permitted hereunder shall be effective as of the date of assignment and compliance
with the conditions to such Transfer and such Transfer shall be shown on the books and records of the Company. Unless and until
an Assignee becomes a Substituted Member pursuant to Section 7.6, the Assignee shall not be entitled to any of the rights
or privileges granted to a Member hereunder or under Applicable Law, other than the rights and privileges specifically granted
to Assignees pursuant to this Agreement.

 

    	31

    	 

    

 

7.5
Additional Restrictions on Transfer.

 

(a)
Restrictions. Units are transferable only pursuant to (i) public offerings registered under the Securities Act or any transfer
exempt from registration under the Securities Act, (ii) Rule 144 or Rule 144A of the U.S. Securities and Exchange Commission (or
any similar rules then in force) if such rule is available and (iii) other legally available means of transfer permitted by this
Agreement.

 

(b)
Execution of Counterpart. Each Transferee of Units or other interests in the Company shall, as a condition prior to such
Transfer, execute and deliver to the Company an Adoption Agreement pursuant to which such Transferee shall agree to be bound by
the provisions of this Agreement.

 

(c)
Notice. In connection with the Transfer of any Units, the holder of such Units will deliver written notice to the Company
describing in reasonable detail the Transfer or proposed Transfer.

 

(d)
Legal Opinion. No Transfer of Units or any other interest in the Company may be made unless in the opinion of counsel,
satisfactory in form and substance to the Board of Managers (which opinion may be waived by the Board of Managers), such Transfer
would not violate any federal securities laws or any state or provincial securities or “blue sky” laws (including
any investor suitability standards) applicable to the Company or the interest to be Transferred, or cause the Company to be required
to register as an “Investment Company” under the U.S. Investment Company Act of 1940, as amended. Such opinion of
counsel shall be delivered in writing to the Company prior to the date of the Transfer.

 

(e)
Regulatory. No Transfer of Units or any other interest in the Company may be made if the Transfer will result in the Company
violating or losing any license, right, permit or authorization required by law or any regulatory authority to operate the Company
and its Subsidiaries respective businesses.

 

7.6
Assignees; Substituted Members.

 

(a)
Unless the assignee of any Unit is admitted as a Substituted Member as provided in Section 7.6(b) (or is the Company or
another Member), (i) the assignee shall only have the rights of the transferring Member in the Company’s income, gain, loss,
deductions and distributions, (ii) the assignee shall have no right to vote on Company matters, inspect Company books and records
or otherwise participate in Company affairs, and (iii) the interest of the assignee shall be disregarded for purposes of determining
whether Members owning the required Units have voted on any matter requiring a vote of the Members.

 

    	32

    	 

    

 

(b)
An assignee of the whole or any portion of the transferring Member’s Units, validly assigned pursuant to this ARTICLE
7, may become a member (within the meaning of the Delaware Law) of the Company (a “Substituted Member”)
in the place of the transferring Member, to the extent of the Units validly transferred, if all of the following conditions are
satisfied; provided, however, that any Person who acquires a Member’s Units pursuant to a Permitted Pledge
shall automatically be admitted as a Substituted Member after delivering a fully executed Adoption Agreement to the Board of Managers:

 

(i)
A fully executed and acknowledged written instrument of assignment has been filed with the Company which sets forth the intention
of the transferring Member that the assignee become a Substituted Member in its place, to the extent of the Units assigned;

 

(ii)
The assignee executes and acknowledges an Adoption Agreement and such other instruments, in form and substance reasonably satisfactory
to the Board of Managers, as are reasonably necessary or desirable to effectuate the admission and to confirm the agreement of
the assignee to be bound by all the terms and provisions of this Agreement with respect to the Units acquired; and

 

(iii)
The Board of Managers approves the admission of the assignee as a Substituted Member, provided that no such approval shall
be required to admit any assignee or transferee that acquired Units pursuant to a transfer expressly permitted by ARTICLE 7.

 

(c)
Notwithstanding anything to the contrary in this Agreement, both the Company and the Board of Managers will be entitled to treat
the transferring Member as its absolute owner in all respects, and will incur no liability for distributions made in good faith
to that Member, until a written assignment that conforms to the requirements of this ARTICLE 7 has been received by the
Company and accepted by the Board of Managers.

 

(d)
No party hereto shall avoid the provisions of this Agreement by making one or more Transfers to one or more Permitted Transferees
and then disposing of all or any portion of such party’s interest in any such Permitted Transferee.

 

7.7
Admission of New Members. A Person who acquires a Unit pursuant to an issuance of additional Units under Section 3.3
shall be admitted as a Member if all of the following conditions are satisfied:

 

(a)
In the case of a Person which is not a natural person, the Person provides evidence satisfactory to the Board of Managers of the
Person’s authority to become a Member of the Company;

 

(b)
The Company receives the consideration that the Board of Managers has set as the subscription price for the new Units being issued;

 

(c)
The Person executes and acknowledges an Adoption Agreement and such other instruments, in form and substance satisfactory to the
Board of Managers, as the Board of Managers deems reasonably necessary or desirable to effectuate the admission and to confirm
the agreement of the Person to be bound by all the terms and provisions of this Agreement with respect to the Units acquired;

 

    	33

    	 

    

 

(d)
The Board of Managers approves the admission of the Person as a Member; and

 

(e)
The Person satisfies all other terms and conditions for admission as a Member as set forth by the Board of Managers.

 

7.8
Amendment of Schedule. As soon as reasonably practicable following a transaction described in this ARTICLE 7, the
Board of Managers will, without the need for the consent of the Members, amend the Schedule of Members to reflect the names
of the Members, the number of Units held and the Percentage Interests and Capital Proceeds Percentages of the Members immediately
after the transaction. Such revised Schedule of Members shall replace in its entirety the Schedule of Members in
effect immediately prior to the transaction.

 

7.9
Legend.

 

In
the event that Certificated Units are issued, such Certificated Units will bear the following legend:

 

“THE
UNITS REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR APPLICABLE STATE SECURITIES LAWS (“STATE ACTS”) AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE
DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR STATE ACTS OR AN EXEMPTION FROM REGISTRATION
THEREUNDER. THE TRANSFER OF THE UNITS REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE CONDITIONS SPECIFIED IN THE LIMITED LIABILITY
COMPANY AGREEMENT, AS AMENDED AND MODIFIED FROM TIME TO TIME, GOVERNING THE ISSUER (THE “COMPANY”), BY AND
AMONG ITS MEMBERS, A COPY OF WHICH SHALL BE FURNISHED UPON REQUEST.”

 

To
the extent applicable, Certificated Units may also bear a legend in substantially the following form:

 

“THE
UNITS REPRESENTED BY THIS CERTIFICATE MAY ALSO BE SUBJECT TO CERTAIN PURCHASE OPTIONS SET FORTH IN THE LIMITED LIABILITY COMPANY
AGREEMENT AND/OR A SEPARATE AGREEMENT WITH THE INITIAL HOLDER, A COPY OF WHICH SHALL BE FURNISHED BY THE COMPANY UPON WRITTEN
REQUEST AND WITHOUT CHARGE.”

 

If
a Member holding Certificated Units delivers to the Company an opinion of counsel, satisfactory in form and substance to the Board
of Managers (which opinion may be waived by the Board of Managers), that no subsequent Transfer of such Units will require registration
under the Securities Act, the Company will promptly upon such contemplated Transfer deliver new Certificated Units which do not
bear the portion of the restrictive legend relating to the Securities Act set forth in this Section 7.9.

 

    	34

    	 

    

 

7.10
Transfer Fees and Expenses. The Transferor and Transferee of any Units or other interest in the Company shall be jointly
and severally obligated to reimburse the Company for all reasonable expenses (including attorneys’ fees and expenses) of
any Transfer or proposed Transfer, whether or not consummated.

 

7.11
Void Transfers. Any Transfer by any Member of any Units or other interest in the Company in contravention of this Agreement
or which would cause the Company to not be treated as a partnership for U.S. federal income tax purposes shall be void and ineffectual
and shall not bind or be recognized by the Company or any other party.

 

7.12
Resignation; Void Assignment. No Members shall have the right to resign or withdraw as a Member. Any Transfer by any holder
of Units in contravention of this Agreement shall be void and ineffectual and shall not bind or be recognized by the Company or
any other party. In the event of any Transfer in contravention of this Agreement, the purported transferee shall have no right
to any profits, losses or Distributions of the Company or any other rights of a holder of Units.

 

7.13
Indirect Dispositions. The transfer, sale, assignment or other disposition of any equity interest in any Member (other
than the H-Cyte Member), shall be deemed a Transfer of the Units owned by such Member and subject to the provisions of this ARTICLE
7. The sale, assignment or transfer by a Member of all or any part of the economic interest associated with such Member’s
Units (including the interest in the profits or capital appreciation of the Company and the right to receive distributions from
the Company), other than pursuant to a Permitted Transfer, shall be deemed a Transfer of the Units owned by such Member. For the
sake of clarity, if an indirect transfer would be a Permitted Transfer if the transfer had been a Transfer of a Unit, then this
Section 7.13 will not apply to such indirect transfer. The intent of this Section 7.13 is to prevent a Member from
circumventing the provisions of this ARTICLE 7 by transferring, selling, assigning or otherwise disposing of an equity
interest in an entity that directly or indirectly through other entities owns one or more Units.

 

7.14
Deemed Offer.

 

(a)
Any of the events set forth in Section 7.14(b) with respect to any Key Person shall constitute a deemed offer (a “Deemed
Offer”) by such Key Person (or the Member in which such Key Person holds a direct or indirect equity interest) (the
“Deemed Offeror”) to sell all or a portion of such Member’s Class A Units as determined pursuant to Section
7.14(c) below (the “Deemed Offered Interest”), and the Company shall have the right to purchase such Deemed
Offered Interest pursuant to the ordering and timing provisions set forth below.

 

    	35

    	 

    

 

(b)
For purposes of this Section 7.14, with respect to any Key Person, the Deemed Offer events are each of the following:

 

(i)
The resignation from employment by or engagement with the Company or Subsidiary by such Key Person (or the entity through which
such Key Person provides such services to the Company and its Subsidiaries), voluntary cessation of services by such Key Person
(or the entity through which such Key Person provides such services to the Company and its Subsidiaries) with respect to the Company
or any Subsidiary or the abandonment by such Key Person (or the entity through which such Key Person provides such services to
the Company and its Subsidiaries) of their duties and responsibilities to the Company or any Subsidiary, provided that a termination
of Athavle’s employment with or engagement by the Company and its Subsidiaries in connection with his elevation to the Board
of Managers following the Effective Date shall not be deemed to be a Deemed Offer event with respect to Athavle;

 

(ii)
The Key Person’s Bankruptcy;

 

(iii)
Such Key Person’s material breach of, or failure or discharge their duties and responsibilities with respect, the terms
of their employment or engagement by the Company or any Subsidiary thereof, including but not limited to, any engagement in any
willful or serious misconduct, failure to observe policies and reasonable requests of the Company and its Subsidiaries, and failure
to professional carry out such Key Person’s responsibilities in accordance with the terms of such Key Person’s employment
or engagement;

 

(iv)
A transfer, sale, assignment or other disposition of equity of the Key Person (or the Member in which such Key Person holds a
direct or indirect equity interest) that violates this ARTICLE 7, including any purported voluntary or involuntary Transfer
of Units not otherwise permitted by this Agreement; provided that a Transfer of Units by a Key Person (or the Member in which
such Key Person holds a direct or indirect equity interest) to any other entity that is controlled by such Key Person shall not
be deemed a Deemed Offer Event; or

 

(v)
If, in the reasonable judgment of the Board of Managers, such Key Person has engaged or is engaging in any action or omission
which is reasonably likely to jeopardize the reputation or goodwill of the Company, its Subsidiaries or the Business.

 

A
Key Person may be subject to more than one Deemed Offer event and each Deemed Offer event will be treated separate and distinct
from each other Deemed Offer event, the rights and obligations of the Deemed Offeror and the Company will apply to each Deemed
Offer event and the Company will be entitled to exercise its rights regardless of whether or not the Company elects to purchase
any portion of the Deemed Offered Interest in connection with any other Deemed Offer event. If more than one Deemed Offer event
exists at the time when the Deemed Offered Interest is purchased, the Deemed Offer event that results in the lowest purchase price
paid to the Deemed Offeror shall be the Deemed Offer event applicable to such purchase

 

(c)
In the event of a Deemed Offer event, the Deemed Offeror shall be deemed to have offered to sell all or a portion of the Deemed
Offered Interest to the Company as follows:

 

(i)
If the Deemed Offer event occurs on or prior to the first anniversary of the Effective Date, the Deemed Offeror shall be deemed
to have offered to sell up to eighty percent (80%) of the Deemed Offered Interest to the Company;

 

    	36

    	 

    

 

(ii)
If the Deemed Offer event occurs after the first anniversary of the Effective Date but on or prior to the second anniversary of
the Effective Date, the Deemed Offeror shall be deemed to have offered to sell up to seventy percent (70%) of the Deemed Offered
Interest to the Company;

 

(iii)
If the Deemed Offer event occurs after the second anniversary of the Effective Date but on or prior to the third anniversary of
the Effective Date, the Deemed Offeror shall be deemed to have offered to sell up to fifty percent (50%) of the Deemed Offered
Interest to the Company; and

 

(iv)
If the Deemed Offer event occurs after the third anniversary of the Effective Date, the Deemed Offeror shall be deemed to have
offered to sell up to thirty percent (30%) of the Deemed Offered Interest to the Company.

 

(d)
The Company shall have the right and option to accept the Deemed Offer and acquire the Deemed Offered Interest for the purchase
price and on the terms set forth in Section 7.14(f) below. This Section 7.14 shall apply following the occurrence
of each Deemed Offer event.

 

(e)
If the Company accepts such offer to purchase, it shall so advise the Deemed Offeror in writing no later than one hundred eighty
(180) days after the Board of Managers is notified in writing of the Deemed Offer and shall designate the date and the aggregate
consideration to be paid for the Deemed Offered Interest not more than thirty (30) days following the date of such notice (which
time period shall be tolled for any time when the Company is prohibited from purchasing the Deemed Offered Interest pursuant to
any loan agreement to which the Company is a party), and the time and place, where such sale shall be completed. If the Deemed
Offered Interest is not purchased in full by the Company, the balance of the Deemed Offered Interest will remain with the Deemed
Offeror or be transferred to the Deemed Offeror’s permitted successor, as the case may be, but shall remain fully subject
to and bound by the terms of this Agreement.

 

(f)
The purchase price for any Deemed Offered Interest purchased pursuant to this Section 7.14 will be equal to $1.00. The
purchase of the Deemed Offered Interest will take place at the principal office of the Company, or at such other place as may
be mutually agreed upon by the Company and Deemed Offeror. Upon the closing of the purchase and sale pursuant to this Section
7.14, the Deemed Offeror will deliver to the purchasing party in exchange for payment of the purchase price, the certificate(s),
if any, representing the portion of the Deemed Offered Interest being purchased, duly endorsed for transfer and free and clear
of all liens, claims, or encumbrances, with evidence of payment of any applicable transfer taxes and fees, and the Company will
pay the purchase price for the Deemed Offered Interest by cash, bank cashier’s or certified check.

 

ARTICLE
8

ADMINISTRATION

 

8.1
Bank Accounts. All funds of the Company shall be deposited in a separate bank account or money market account, as the Board
of Managers shall determine, and withdrawals shall be made only on the signature of a Manager, the Company’s Chief Financial
Officer, Chief Executive Officer or President or such other Persons authorized by the Board of Managers.

 

    	37

    	 

    

 

8.2
Books and Records. The Company will maintain separate books and records of the Company that show a true record of its costs
and expenses incurred, sources and applications of funds, charges made, credits made and received, and income derived in connection
with the operation of the Company’s business. These books of account, together with a copy of this Agreement and the Certificate
will at all times be maintained at the principal place of business of the Company. All such books of account and records may be
inspected, copied and audited by any Member, its designees or representatives from time to time and upon five (5) Business Days’
notice at the office of the Company or other Person maintaining the same.

 

8.3 Notices.
The address of each of the Members shall for all purposes be as set forth in the Company’s books and records, and the
address of the Company shall for all purposes be as set forth in Section 2.4(a), unless otherwise changed by the
applicable party by notice to the other parties as provided herein. Except as otherwise provided in Sections 5.6 and 5.7
and this Section 8.3, all notices or other communications required or permitted to be given pursuant to the provisions
of this Agreement shall be in writing and shall be deemed to have been given, delivered or made, as the case may be
(notwithstanding lack of actual receipt by the addressee): (a) upon hand delivery, (b) three (3) business days after having
been deposited in the United States mail, certified or registered, return receipt requested, sufficient postage affixed and
prepaid, (c) one (1) business day after having been timely deposited with an expedited, overnight courier service (including
U.S. Express Mail, Federal Express or Airborne), or (d) upon delivery of an electronic mail or a facsimile transmission which
is confirmed on the sender’s facsimile machine or electronic mail account as having been sent to the recipient at the
proper facsimile number or electronic mail address, addressed to the party to whom notice is intended to be given at the
address or facsimile number for the party. Without limiting the manner in which a notice, consent or waiver may otherwise be
effectively given, any notices, consents or waivers permitted or required by Section 5.6 or Section 5.7 may
also be given effectively to Managers and the Company by Electronic Transmission. Notice given by Electronic Transmission
pursuant to the immediately preceding sentence shall be deemed given: (x) if by facsimile, upon delivery of such facsimile
confirmed on the sender’s facsimile machine as having been sent to the recipient at the facsimile number for the
Manager or the Company; (y) by electronic mail, with respect to a Manager, when directed to such Manager’s electronic
mail address, and, with respect to the Company, when directed to the corporate e-mail address of the Company’s Chief
Executive Officer, President or Secretary, or if there be none, any other similar officer or of the Company; or (z) if by any
other form of Electronic Transmission, with respect to a Manager, when directed to such Manager, and, with respect to the
Company, when directed to the Company’s Chief Executive Officer, President or Secretary, or if there be none, any other
similar officer or of the Company.

 

ARTICLE
9

FISCAL
MATTERS

 

9.1
Fiscal Year. The fiscal year of the Company (the “Fiscal Year”) shall be the year selected by the Board
of Managers.

 

    	38

    	 

    

 

9.2
Tax Reports. As soon as reasonably practicable after the end of each tax year of the Company, the Company will deliver
or cause to be delivered to each Member such information as is necessary (including a statement for that year of each Member’s
share of net income, net losses or other items of the Company) for such Member’s preparation of its federal and state or
other income tax returns.

 

9.3
Tax Returns. The Company shall prepare, or cause the Company’s Accountants to prepare at the expense of the Company,
and file a federal information tax return in compliance with the provisions of the Code and any required state or local tax returns.

 

9.4
Partnership Representative.

 

(a)
The Board of Managers will appoint the Company’s “partnership representative” (as such term is defined in Code
Section 6223(a)) (and in any other similar capacity under applicable state or local tax law). The partnership representative may
cause the Company to make any election provided by Title XI of the Bipartisan Budget Act of 2015 (H.R. 1315) (such provisions,
the “New Audit Rules”), including the election out of the New Audit Rules pursuant to Section 6221(b) or under
Section 6226(a) of the Code to have any underpayment taken into account at the Member level. The partnership representative may
be replaced by the Board of Managers.

 

(b)
Each Member shall provide to the partnership representative such information (or, if applicable, certify as to the filing of initial
or amended tax returns) as is reasonably requested by the partnership representative to enable the partnership representative
(i) to reduce any Company level assessment under Code Section 6225 as set forth in the New Audit Rules, (ii) to determine the
allocation of any item of income, gain, loss, deduction, or credit of any such Company level assessment among the Members (such
allocation, the “Apportionment”), in good faith consultation with the Company’s tax accountants and tax
counsel, (iii) to elect out of the New Audit Rules or (iv) to comply with or be eligible to invoke any aspect of the New Audit
Rules in any other respect.

 

(c)
Any payment by the Company of a liability arising as a result of the New Audit Rules shall be treated (i) as a deemed distribution
to the Members in the same ratios as the Apportionment of such liability is made among the Members, and (ii) as a reduction to
the applicable Members’ Capital Account balances. Alternatively, and notwithstanding anything herein to the contrary, the
partnership representative shall have authority to call additional capital from each of the Members and/or former Members to pay
any liability imposed on the Company by the New Audit Rules, in an amount not to exceed each such Member’s or former Member’s
respective shares (if any) of such Company liability, and any such contribution shall not be treated as a Capital Contribution
or increase a Member’s Capital Account balance except to the extent such Member is repaying or funding an amount treated
as a distribution to such Member under preceding clause (i).

 

(d)
The Company shall indemnify, defend and hold the partnership representative harmless from and against any loss, liability, damage,
cost or expenses (including reasonable attorneys’ fees) sustained or incurred as a result of any act or decision concerning
Company tax matters and within the scope of its responsibilities as partnership representative.

 

    	39

    	 

    

 

(e)
The Board of Managers may unilaterally amend this Agreement to make any changes in good faith consultation with the Company’s
Accountants and tax counsel that are necessary, desirable or appropriate (i) to reduce any Company level assessment under Code
Section 6225 as set forth in the New Audit Rules, (ii) to determine any Apportionment or (iii) in connection with the New Audit
Rules and administrative, judicial or legislative interpretations thereof or changes thereto.

 

(f)
Notwithstanding the foregoing, the partnership representative shall not take any of the following actions without first receiving
the prior written consent of the H-Cyte Member (which consent shall not be unreasonably withheld, conditioned, delayed or denied):
(i) extend the statute of limitations for assessing or computing any tax liability against the Company; (ii) settle any audit
with the Internal Revenue Service concerning the adjustment or readjustment of any partnership (Company) tax items; (iii) file
a request for an administrative adjustment with the Internal Revenue Service at any time or file a petition for judicial review
with respect to any such request; (iv) initiate or settle any judicial review or action concerning the amount or character of
any partnership (Company) tax items; and (v) take any other action which is contrary to any provision of this Agreement on behalf
of the Members of the Company in connection with any administrative or judicial tax proceeding.

 

(g)
The obligations of each Member (or former Member) under this Section 9.4 shall survive the Transfer by such Member of its
Company Interest or the dissolution of the Company. In the event a Member Transfers a Company Interest, the transferee and transferor
shall be jointly and severally liable for any liability with respect to the obligations of the transferor Member under this Section
9.4.

 

9.5
Tax Elections. Except as otherwise provided in this Agreement, the Board of Managers shall determine whether to make or
revoke any election pursuant to the Code.

 

ARTICLE
10

TERMINATION

 

10.1
Events of Dissolution. The Company shall be dissolved on the earliest to occur of:

 

(a)
A reasonable period of time (taking into account, among other matters, the need to determine, pay or discharge, or make adequate
provision for the payment or discharge of, contingent liabilities) after (i) the consummation of a transaction or series of related
transactions that constitute a Sale of the Company under clause (a) of the definition thereof, and (ii) the liquidation, dissolution
or winding up of all of the Subsidiaries;

 

(b)
Subject to Section 6.4, the approval of a Majority in Interest and the Board of Managers; or

 

(c)
any other event requiring the dissolution of the Company under the Delaware Law.

 

    	40

    	 

    

 

10.2
Winding Up.

 

(a)
Upon the dissolution of the Company pursuant to Section 10.1, the Company business shall be wound up and its assets liquidated
by the Board of Managers (or one or more representatives appointed by the Board of Managers) in accordance with this Section
10.2, and the net proceeds of such liquidation shall be distributed in accordance with Section 10.3. The Board of Managers
shall be responsible for taking all action necessary or appropriate to wind up the affairs and distribute the assets of the Company
upon its dissolution. The costs of liquidation shall be borne as a Company expense.

 

(b)
On completion of the distribution of Company assets as provided herein, the Company is terminated (and the Company shall not be
terminated prior to such time), and the Board of Managers shall file (or cause to be filed) all certificates and notices of the
dissolution of the Company required by law. The Board of Managers shall proceed without any unnecessary delay to sell and otherwise
liquidate the Company’s assets; provided, however, that (i) if the Board of Managers shall determine that
an immediate sale of part or all of the Company assets would cause undue loss to the Members, then in order to avoid such loss,
the Board of Managers may defer the liquidation, to the extent permitted by Applicable Law, and (ii) with the consent of a Majority
in Interest, the Board of Managers may distribute the Company’s assets in-kind. In the event that the Board of Managers
distributes the Company’s assets in-kind, the Board of Managers shall ascertain the fair market value by appraisal of such
assets, and each Member’s Capital Account shall be charged or credited, as the case may be, as if such asset had been sold
for cash at such fair market value and the gain or loss recognized thereby had been allocated to and among the Members in accordance
with ARTICLE 4 above.

 

10.3
Distribution on Dissolution and Termination.

 

(a)
Upon dissolution of the Company, the net proceeds of such liquidation shall be applied and distributed in the following order
of priority (provided that the higher level(s) of priority have been fully satisfied):

 

(i)
First, to pay to all creditors of the Company (including, but not limited to, any Members, Managers or Affiliates of a Member
or Manager that are creditors of the Company) and the expenses of liquidation;

 

(ii)
Second, to the setting up of any reserves that may be deemed reasonably necessary by the Board of Managers for any contingent
or unforeseen liabilities or obligations of the Company, which reserves may be paid over to an escrowee designated by the Board
of Managers to be held for the purpose of disbursing such reserves in payment of any of the aforementioned contingencies and,
at the expiration of such period as shall be deemed advisable, to distribute the balance thereafter remaining in the manner provided
in this Section 10.3; and

 

(iii)
Thereafter, to the Members in accordance with Section 4.6.

 

(b)
No Member shall have any right to demand or receive property other than cash upon dissolution and liquidation of the Company.

 

(c)
Each Member shall look solely to the assets of the Company for all distributions with respect to the Company and its Capital Contributions
thereto and share of profits and losses thereof, and shall have no recourse therefore (upon dissolution or otherwise) against
the Board of Managers or any other Member.

 

    	41

    	 

    

 

ARTICLE
11

MISCELLANEOUS

 

11.1
Governing Law; Venue; Expenses.

 

(a)
This Agreement and the rights of the parties hereunder shall be governed by and interpreted in accordance with the laws of the
State of Delaware, without regard to conflict of laws principles. ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST THE PARTIES ARISING
OUT OF OR RELATING TO THIS AGREEMENT, ANY OBLIGATIONS HEREUNDER, OR THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE BROUGHT IN
ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN HILLSBOROUGH COUNTY, FLORIDA. BY EXECUTING AND DELIVERING THIS AGREEMENT,
THE PARTIES, IRREVOCABLY (A) ACCEPT GENERALLY AND UNCONDITIONALLY THE EXCLUSIVE JURISDICTION AND VENUE OF SUCH COURTS, (B) WAIVE
ANY OBJECTIONS WHICH SUCH PARTY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE AFORESAID ACTIONS OR PROCEEDINGS
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, ANY OBLIGATIONS HEREUNDER OR THE TRANSACTIONS CONTEMPLATED HEREBY BROUGHT
IN THE COURTS REFERRED TO IN CLAUSE (A) ABOVE AND HEREBY FURTHER IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH
COURT THAT SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM, (C) AGREE THAT SERVICE
OF ALL PROCESS IN ANY SUCH PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED,
TO SUCH PARTY AT THEIR RESPECTIVE ADDRESSES PROVIDED IN ACCORDANCE WITH SECTION 8.3, AND (D) AGREE THAT SERVICE AS PROVIDED IN
CLAUSE (C) ABOVE IS SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER SUCH PARTY IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE
CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT. EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH
MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT
OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY
OR THEREBY.

 

(b)
In any arbitration or legal proceeding arising out of this Agreement, the losing party shall reimburse the prevailing party, on
demand, for all costs incurred by that prevailing party in enforcing, defending, or prosecuting the terms of this Agreement, including
all fees, costs, and expenses of experts, mediators, attorneys, witnesses, arbitrators, and supersede as bonds, whether incurred
before or after demand or commencement of legal proceedings and whether incurred pursuant to trial, appellate, mediation, arbitration,
bankruptcy, administrative, or judgment-execution proceedings.

 

    	42

    	 

    

 

11.2
Successors and Assigns. Any Person acquiring or claiming an interest in the Company, in any manner whatsoever, shall be
subject to and bound by all terms, conditions and obligations of this Agreement to which its predecessor in interest was subject
or bound, without regard to whether such a Person has executed a counterpart hereof or any other document contemplated hereby.
No Person, including the legal representative, heir or legatee of a deceased Member, shall have any rights or obligations greater
than those set forth in this Agreement, and no Person shall acquire an interest in the Company or become a Member hereof except
as permitted by the terms of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto
and their permitted successors, assigns, heirs, legal representatives, executors and administrators.

 

11.3
Grammatical Changes. Whenever from the context it appears appropriate, each term stated in either the singular or the plural
shall include the singular and the plural, and pronouns stated in the masculine, the feminine or the neuter gender shall include
the masculine, feminine and neuter gender as the circumstances require.

 

11.4
Captions and References. Captions contained in this Agreement are inserted only as a matter of convenience and in no way
define, limit or extend the scope or intent of this Agreement or any provision hereof. Unless otherwise expressly provided to
the contrary, references in this Agreement to articles, sections, paragraphs and the like constitute references to the articles,
sections and paragraphs of this Agreement.

 

11.5
Severability. If any provision of this Agreement, or the application of such provision to any Person or circumstance, shall
be held invalid, the remainder of this Agreement, or the application of such provision to Persons or circumstances other than
those to which it is held invalid, shall not be affected thereby; provided that the parties shall attempt to reformulate
such invalid provision to give effect to such portions thereof as may be valid without defeating the intent of such provision;
and provided further that this Section 11.5 shall not apply to change the status of any Member to that of a Manager
or Officer, or to alter the classification of the Company as a partnership under the Code.

 

11.6
Counterparts; Electronic Transmission. This Agreement and any amendment hereto may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which shall constitute one and the same instrument, notwithstanding that
all of the Members are not signatories to the original or the same counterpart. A party’s receipt of a signature page to
this Agreement via Electronic Transmission shall be treated as the party’s receipt of an original signature page.

 

11.7
Waiver of Right to Partition. Each of the Members hereby irrevocably waives any and all rights that it may have to maintain
an action for partition of the Company’s assets.

 

11.8
Personal Property. This Agreement shall not be deemed to create in any Member any right, title, interest or lien in, to
or on all or any portion of the Company’s assets, it being understood that any right or interest of any Member created by
this Agreement shall solely be an interest in the Company and shall be personal property.

 

    	43

    	 

    

 

11.9
No Third Party Rights. This Agreement is for the sole and exclusive benefit of the Members, the Managers and the Company
and no other Person or entity (including any creditors of the Company or the Members other than any pledgee of a Member who acquires
such Member’s Units pursuant to a Permitted Pledge) shall under any circumstances be deemed to be a beneficiary of any of
the rights, remedies, terms and provisions of this Agreement.

 

11.10
Amendments. Except as otherwise expressly provided elsewhere in this Agreement, this Agreement and the Certificate may
be altered, modified or changed, and one or more of the provisions of this Agreement waived, with the written approval of, at
the time of such alteration, modification, change or waiver, (a) the Board of Managers and (b) a Majority in Interest, and all
parties to this Agreement shall be bound by any amendment, modification, alteration, change or waiver of this Agreement effected
in accordance with this Section 11.10, whether or not such party consent to such amendment, alteration, modification, change
or waiver; provided, however, that if any amendment, modification, alteration, change or waiver adversely affects
one or more Members in a manner different from the Members approving the amendment, modification, alteration, change or waiver,
the consent of the majority in interest (measured by their respective Percentage Interests) of such Members shall also be required
for such amendment, modification, alteration, change or waiver of this Agreement.

 

11.11
Waiver of Statutory Rights. Matters not covered in this Agreement relating to limited liability companies shall be governed
and controlled by the Delaware Law; Section 18-210 of the Delaware Law (entitled “Contractual Appraisal Rights”),
Section 18-217 of the Act (entitled “Division of a limited liability company”) and Section 18-305(a) of the Delaware
Law (entitled “Access to and Confidentiality of Information; Records”) shall not apply to or be incorporated into
this Agreement and each Member hereby expressly waives any and all rights under such Sections of the Delaware Law.

 

11.12
Certain Acknowledgments. Upon execution and delivery of a counterpart to this Agreement, an Adoption Agreement or similar
document or agreement, each Member (including each Substituted Member, but not including the H-Cyte Member) shall be deemed to
acknowledge to the H-Cyte Member as follows (and with respect to clauses (a) and (b), to each other Member and the Company): (a)
the determination of such Member to enter into this Agreement has been made by such Member independent of any other Member and
independent of any statements or opinions as to the advisability of such purchase or as to the properties, business, prospects
or condition (financial or otherwise) of the Company and its Subsidiaries which may have been made or given by any other Member
or by any agent or employee of any other Member, (b) no other Member has acted as an agent of such Member in connection with making
its investment hereunder and that no other Member shall be acting as an agent of such Member in connection with monitoring its
investment hereunder, (c) the H-Cyte Member on the Effective Date retained Hill, Ward & Henderson, P.A. (the “Law
Firm”) in connection with the transactions contemplated by the Transaction Documents, (d) the Law Firm is not representing
and will not represent any Member (other than the H-Cyte Member) in connection with the Transaction Documents or any dispute which
may arise between the H-Cyte Member, on the one hand, and the Company, any of its Subsidiaries or any other Member, on the other
hand, in connection with the Transaction Documents, (e) such Member will, if it wishes counsel on the transactions contemplated
by the Transaction Documents, retain its own independent counsel, (f) the Law Firm may represent the H-Cyte Member in connection
with any and all matters contemplated by the Transaction Documents (including any dispute between the H-Cyte Member, on the one
hand, and the Company, any of its Subsidiaries or any other Member, on the other hand) and such Member waives any conflict of
interest in connection with such representation by the Law Firm and (g) the Company and its Subsidiaries may engage the Law Firm
to represent the Company and its Subsidiaries on any matter other than the transactions contemplated by the Transaction Documents,
or any dispute arising out of the Transaction Documents that involves the H-Cyte Member.

 

    	44

    	 

    

 

11.13
Confidentiality. It is anticipated that the Company and Members will exchange certain Confidential Information relating
to the Company’s and its Subsidiaries’ businesses, including analyses, compilations, studies or other material containing,
or based in whole or in part upon, Confidential Information. Each Member agrees that such Confidential Information of the Company
and its Subsidiaries shall (a) be kept confidential, (b) not, except as provided below, be disclosed by a receiving party to any
Person in any manner without the prior written consent of the Company and (c) except as expressly provided in this Agreement,
not be used by a receiving party other than for the Company’s business. Notwithstanding the foregoing, (x) each Member may
disclose such Confidential Information to its partners or members (existing or potential, provided that the party receiving such
Confidential Information is required to keep such information strictly confidential), financing sources, managers, directors or
officers, and also to its auditors, attorneys, employees and agents on a “need to know” basis, and (y) no Person shall
have an obligation to keep confidential any Confidential Information if and to the extent disclosure of any Confidential Information
is specifically required by law or by any regulatory authority having jurisdiction over the Company, its Subsidiaries or any of
the Members (a “Regulatory Authority”); provided, however, that in the event disclosure by any
Person is required by any Regulatory Authority, the Person shall provide the Company with prompt notice of such requirement, prior
to making any disclosure, so that the Company may seek an appropriate protective order.

 

11.14
Power of Attorney. Each Member hereby constitutes and appoints the Board of Managers and the liquidators, as applicable,
and their respective designees, with full power of substitution, as its true and lawful agent and attorney-in-fact, with full
power and authority in its name, place and stead, to execute, swear to, acknowledge, deliver, file and record in the appropriate
public offices (a) this Agreement, all certificates and other instruments and all amendments hereof or thereof in accordance with
the terms hereof which the Board of Managers deems appropriate or necessary to form, qualify, or continue the qualification of,
the Company as a limited liability company in the State of Delaware and in all other jurisdictions in which the Company may conduct
business or own property or as otherwise permitted herein; (b) all instruments, agreements or other documents which the Board
of Managers deems appropriate or necessary to reflect any amendment, change, modification or restatement of this Agreement in
accordance with its terms; (c) all conveyances and other instruments or documents which the Board of Managers and/or the liquidators
deems appropriate or necessary to reflect the dissolution and liquidation of the Company pursuant to the terms of this Agreement;
and (d) all instruments relating to the admission, withdrawal or substitution of any Member pursuant to this Agreement. The foregoing
power of attorney is irrevocable and coupled with an interest, and shall survive the death, disability, incapacity, dissolution,
bankruptcy, insolvency or termination of any Member that is subject to this Section 11.14 and the Transfer of all or any
portion of its Units and shall extend to such Member’s heirs, successors, assigns and personal representatives.

 

    	45

    	 

    

 

11.15
Descriptive Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and
do not constitute a substantive part of this Agreement. Whenever required by the context, any pronoun used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include
the plural and vice versa. The use of the word “including” in this Agreement shall be by way of example rather than
by limitation. Reference to any agreement, document or instrument means such agreement, document or instrument as amended or otherwise
modified from time to time in accordance with the terms thereof, and if applicable hereof. Whenever required by the context, references
to a Fiscal Year shall refer to a portion thereof. The use of the words “or,” “either” and “any”
shall not be exclusive. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party
by virtue of the authorship of any of the provisions of this Agreement. Wherever a conflict exists between this Agreement and
any other agreement, this Agreement shall control but solely to the extent of such conflict.

 

11.16
Further Action. The parties agree to execute and deliver all documents, provide all information and take or refrain from
taking such actions as may be necessary or appropriate to achieve the purposes of this Agreement.

 

11.17
WAIVER OF JURY TRIAL. EACH PARTY HERETO EXPRESSLY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY LAWSUIT OR PROCEEDING RELATING
TO OR ARISING IN ANY WAY FROM THIS AGREEMENT OR THE MATTERS CONTEMPLATED HEREBY.

 

11.18
Entire Agreement. This Agreement, those documents expressly referred to herein and other documents dated as of even date
herewith embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings,
agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in
any way.

 

11.19
Confirmation of Ownership. Each Member on the Effective Date acknowledges and confirms (a) its ownership of Units of the
Company as shown on the Schedule of Members and (b) that it does not own, or have the right to acquire, any other Units,
membership interests or other equity interests in the Company.

 

11.20
Spousal Consent. If requested by the Board of Managers, each married Member, and each such Member who, subsequent to the
date hereof, marries or remarries, shall concurrently with his or her execution hereof deliver to the Board of Managers the written
consent of his or her spouse; provided, however, that the failure of any such Member to do so shall not affect the
validity or enforcement of this Agreement.

 

    	46

    	 

    

 

11.21
Tax Consequences. Each Member understands that it (and not the Company) shall be responsible for its own liability that
may arise out of its acquisition, ownership and sale of such Member’s Units.

 

11.22
Withholding. Each Member represents, severally and not jointly, to the Company that it is not, and at all times while it
is a Member will not be, a foreign person subject to withholding under the Code.

 

11.23
Construction and Interpretation. The language in all parts of this Agreement shall be construed, in all cases, according
to its fair meaning, and not for or against either party hereto. The parties acknowledge that each party and its counsel have
reviewed revised or otherwise had input into this Agreement and that the normal rule of construction to the effect that any ambiguities
are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.

 

[Signature
Pages Follow]

 

    	47

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Limited Liability Company Agreement on the day
and year first above written.

 

	 	Company:
	 	 
	 	MEDOVEX,
    LLC,
	 	a
    Delaware limited liability company
	 	 	 
	 	By:	 
	 	Name:	Christopher
    Athavle
	 	Title:	Chief
    Executive Officer

 

[Signatures
continue on following page.]

 

Signature
Page to Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 
	 	MEDOVEX
    CORP.,
	 	a
    Nevada corporation
	 	 	        
	 	By:	 
	 	Name:	 
	 	Title:	 

 

[Signatures
continue on following page]

 

Signature Page to Amended and Restated Limited
Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 	 
	 	THE
    MAGNOLIA TRUST
	 	 	 
	 	By:	 
	 	Name:
    	Shajanamon
    Enterprises Pty Ltd.
	 	Title:
    	Trustee

 

[Signatures
continue on following page]

 

Signature
Page to Amended and Restated Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 	 
	 	THE
    FUTURE IDEA OF INVESTMENT
	 	 	 
	 	By:	 
	 	Name:
    	Trinity
    Services Pty Ltd.
	 	Title:
    	Trustee

 

[Signatures
continue on following page]

 

Signature
Page to Amended and Restated Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 
	 	 
	 	DAVID
    STRANG

 

[Signatures
continue on following page]

 

Signature
Page to Amended and Restated Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 	 
	 	VALMEDX,
    LLC
	 	 	         
	 	By:	 
	 	Name:	 
	 	Title:	 

 

[Signatures
continue on following page]

 

Signature
Page to Amended and Restated Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

	 	Member:
	 	 
	 	 
	 	GUY
    BECKERLEGGE

 

Signature
Page to Amended and Restated Limited Liability Company Agreement of Medovex, LLC

 

    	 

    	 

    

 

APPENDIX
A

 

DEFINITIONS

 

1.
Accounting Firm has the meaning set forth in Section 7.3(b).

 

2.
Adjusted Capital Account Deficit means with respect to any Capital Account as of the end of any relevant Fiscal Year or
Fiscal Period, the amount by which the balance in such Capital Account is less than zero. For this purpose, such Person’s
Capital Account balance shall be (a) reduced for any items described in Treasury Regulation Section 1.704-1(b)(2)(ii)(d)(4), (5),
and (6), and (b) increased for any amount such Person is obligated to contribute or is treated as being obligated to contribute
to the Company pursuant to Treasury Regulation Sections 1.704-1(b)(2)(ii)(c) (relating to partner liabilities to a partnership)
1.704-2(g)(1) or 1.704-2(i) (relating to Minimum Gain).

 

The
above definition is intended to comply with the provisions of Treasury Regulation Section 1.704-1(b)(2)(ii)(d) and shall be interpreted
consistently therewith.

 

3.
Adoption Agreement means an agreement substantially in the form of the Adoption Agreement attached as Exhibit D
to this Agreement.

 

4.
Affiliate means, when used with reference to a specified Person, (a) any officer, manager, partner, member, relative or
spouse, or trustee thereof, of the specified Person, or (b) any Person that directly or indirectly through one or more intermediaries
controls or is controlled by or is under common control with the specified Person. “Affiliate” when used in reference
to any Member shall also include any Person that directly or indirectly through one or more intermediaries controls or is controlled
by or is under common control with any one or more of the beneficial owners of such Member.

 

5.
Agreement means this Amended and Restated Limited Liability Company Agreement of the Company, as it may be further amended,
restated, modified and/or waived from time to time.

 

6.
Annual Budget means the Initial Budget, together with any Budget Update approved in accordance with Section 5.4.

 

7.
Applicable Laws means any treaty, law, statute, regulation, ordinance, rule, Order, principal of common law or other requirement
enacted, promulgated or imposed by any Governmental Entity, including any federal, state or foreign constitution.

 

8.
Apportionment has the meaning set forth in Section 9.4(b).

 

9.
Assignee means a Person to whom Units have been Transferred in accordance with the terms of this Agreement and the other
agreements contemplated hereby, but who has not become a member (as defined in Delaware Law) of the Company in accordance with
Section 7.6(b).

 

    	A-1

    	 

    

 

10.
Assumed Tax Rate means, for each Fiscal Year or Fiscal Quarter, as applicable, the maximum federal income tax rate to be
applied with respect to the Company’s taxable income in respect of the Fiscal Year or Fiscal Quarter, as applicable, calculated
by the Board of Managers based on their determination of the highest maximum marginal federal income tax rates to which any Member
(or, if any Member is a pass-through entity for federal income tax purposes, any Person owning an equity interest in such Member)
may be subject with respect to such taxable income taking into account the character of such taxable income.

 

11.
Athavle has the meaning set forth in the Background.

 

12.
Athavle Trust means The Magnolia Trust.

 

13.
Authorization Date has the meaning set forth in Section 7.2(a).

 

14.
Available Cash means, for any period: (i) the sum of the Gross Receipts of the Company (inclusive of the Subsidiaries)
during such period of any kind and description, but specifically excluding Capital Contributions and Capital Proceeds, plus any
cash that is released from reserves established by the Board of Managers, minus (ii) without duplication, the sum of all Debt
Service Payments made during such period by the Company, all cash expenditures made during such period by the Company to cover
operating expenses and all amounts deposited into reserves during such period.

 

15.
Available Unit Notice has the meaning set forth in Section 7.2(b).

 

16.
Available Unit Purchase Notice has the meaning set forth in Section 7.2(c).

 

17.
Available Units has the meaning set forth in Section 7.2(b).

 

18.
Average Sales Amount has the meaning set forth in Section 7.3(a).

 

19.
Bankruptcy of a Person shall be deemed to have occurred upon the happening of any of the following: (a) the filing by such
Person of an application for, or a consent to, the appointment of a trustee for such Person’s assets; (b) the filing by
such Person of a voluntary petition in bankruptcy or the filing of a pleading in any court of record admitting in writing its
inability to pay its debts as they come due; (c) the making by the Person of a general assignment for the benefit of creditors;
(d) the filing by the Person of an answer admitting the material allegations of, or its consenting to or defaulting in answering,
a bankruptcy petition filed against it in any bankruptcy proceeding; or (e) the entry of an order, judgment or decree by any court
of competent jurisdiction adjudicating the Person a bankrupt or appointing a trustee of its assets, and such order, judgment or
decree continues unstayed and in effect for a period of ninety (90) days.

 

20.
Beckerlegge has the meaning set forth in the Background.

 

21.
Board of Managers has the meaning set forth in Section 5.1.

 

22.
Budget Update has the meaning set forth in Section 5.4.

 

    	A-2

    	 

    

 

23.
Business means (a) the business of developing, manufacturing, marketing and selling DenerveX Devices and (b) any other
business engaged in by the Company and its Subsidiaries.

 

24.
Business Opportunities has the meaning set forth in Section 6.6.

 

25.
Capital Account has the meaning set forth in Section 4.1(a).

 

26.
Capital Contribution means the total amount of money and the Gross Asset Value (as determined by the Board of Managers)
of any property (determined net of any liabilities secured by such property that the Company is considered to assume or take subject
to and determined consistently with Section 752(c) of the Code and without regard to Section 7701(g) of the Code) contributed
to or deemed contributed to the Company by a Member.

 

27.
Capital Proceeds means the gross proceeds of the Company (inclusive of the Subsidiaries) in connection with or resulting
from a Sale of the Company (and, if in connection with the liquidation of the Company and/or any Subsidiaries, any other property
available for distribution), including, without limitation, any and all condemnation awards, title insurance proceeds, and casualty
loss insurance proceeds (other than business interruption or rental loss insurance proceeds) to the extent that such awards and
proceeds are not applied to mortgage indebtedness for the Company and/or any Subsidiaries or are not used to repair damage caused
by a casualty or taking or in alleviation of a title defect, after deduction of the following, to the extent paid out of such
proceeds: (a) all expenses incurred in connection with the Sale of the Company, including without limitation all applicable sales
or other commissions, (b) all debts and obligations of the Company and/or any Subsidiary then due relating to the Sale of the
Company, or required by any agreement to which the Company or any Subsidiary is a party, (c) payment of all other debts and obligations
of the Company and/or any Subsidiary then due, other than to any Member, and (d) any amounts set aside for the establishment or
replenishment of reserves established by the Board of Managers.

 

28.
Capital Proceeds Percentage means, with respect to each Member, the product of (a) a fraction, the numerator of which is
the number of holders of Class A Units, Class B Units, Class C-1 Units and Class C-3 Units held by such Member and the denominator
of which is the total number of holders of Class A Units, Class B Units, Class C-1 Units and Class C-3 Units outstanding multiplied
by (b) 100. For the avoidance of doubt, Class C-2 Units shall be disregarded for purposes of calculating the Capital Proceeds
Percentage for any Member. The Capital Proceeds Percentage so determined shall be rounded to the nearest one-thousandth of a percent.
The Capital Proceeds Percentages of the Members are set forth on the Schedule of Members, and are subject to adjustment
from time to time in accordance with this Agreement.

 

29.
Certificate means the Certificate of Formation of the Company filed with the Department of State of the State of Delaware
pursuant to the Delaware Law on December 8, 2020.

 

30.
Certificated Units means Units evidenced by a membership unit certificate and has the meaning set forth in Section 3.1(d).

 

    	A-3

    	 

    

 

31.
Class A Unit means a Unit having the rights and obligations specified in this Agreement with respect to Class A Units.

 

32.
Class B Unit means a Unit having the rights and obligations specified in this Agreement with respect to Class B Units.

 

33.
Class C-1 Unit means a Unit having the rights and obligations specified in this Agreement with respect to Class C-1 Units.

 

34.
Class C-2 Unit means a Unit having the rights and obligations specified in this Agreement with respect to Class C-2 Units.

 

35.
Class C-3 Unit means a Unit having the rights and obligations specified in this Agreement with respect to Class C-3 Units.

 

36.
Class C Units means, collectively, the Class C-1 Units, Class C-2 Units and Class C-3 Units.

 

37.
Code means the Internal Revenue Code of 1986, as amended.

 

38.
Company has the meaning provided in the first paragraph of this Agreement.

 

39.
Company Purchase Notice has the meaning set forth in Section 7.2(b).

 

40.
Company’s Accountants means a firm of independent certified public accountants or chartered accountants selected
by the Board of Managers.

 

41.
Company Interest means, with respect to each Member, (a) all of the interest of such Member in the Company including, without
limitation, such Member’s (i) right to a distributive share of the profits and losses and cash flow of the Company, (ii)
right to a distributive share of Company assets and (iii) right to participate in the management of the business and affairs of
the Company in accordance with the terms hereof; and (b) the aggregate outstanding amount (including accrued and unpaid interest
thereon) of any loans made by such Member to the Company pursuant to Section 3.7.

 

42.
Company Minimum Gain has the same meaning as the term “partnership minimum gain” under Treasury Regulation
Sections 1.704-2(b) and 1.704-2(d).

 

43.
Compensation has the meaning set forth in Section 4.3(g)(i).

 

    	A-4

    	 

    

 

44.
Confidential Information means, with respect to the Company or any of its Affiliates, any financial statements, budgets
and other financial information, trade secret, confidential study, data, calculations, software storage media or other compilation
of confidential information, patent application, customer lists, details of client or consultant contracts, confidential pricing
policies, sales techniques, information relating to suppliers, information relating to special and particular needs of the operational
methods, marketing plans or strategies, product development techniques or plans, business acquisition plans or any portion or
phase of any scientific or technical information, confidential designs, computer programs (including source or object codes),
confidential processes or procedures, unpublished research or technical data or improvements, or other confidential proprietary
or intellectual property of the Company or any of its Affiliates, whether or not in written or tangible form, and whether or not
registered, which, in each case, are known only to the Company and/or its Affiliates and others, such as lenders and advisors,
having a confidential relationship to the Company and/or its Affiliates with respect thereto, and including all files, records,
manuals, books, catalogues, memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof. With respect
to each Member or other Person holding any Units, the term “Confidential Information” does not include information
that becomes available to the Member or such other Person on a non-confidential basis from a source other than the Company or
any of its Affiliates or their respective representatives, provided that the source is not reasonably known by the Member
or other Person to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality
to the Company or any other party with respect to such information.

 

45.
Control of any Person means the possession, directly or indirectly, of the power to direct or cause the management and
policies of such Person, whether through the ownership of voting interest, by contract or otherwise. The terms “Controlled”
and “Controlling” shall have the correlative meanings.

 

46.
Debt Service Payments means all required principal and interest payments under any indebtedness, financing or refinancing
by debt, bonds, sale and leaseback or other form of financing relating to any Company asset or any debt or other similar monetary
obligation of the Company or any Subsidiary (but excluding trade payables and vehicle and equipment leases incurred or entered
into in the ordinary course of business).

 

47.
Deemed Offer has the meaning set forth in Section 7.14(a).

 

48.
Deemed Offered Interest has the meaning set forth in Section 7.14(a).

 

49.
Deemed Offeror has the meaning set forth in Section 7.14(a).

 

50.
Delaware Law means the Delaware Limited Liability Company Act, as it may be amended from time to time, and any successor
to the Delaware Law.

 

51.
DenerveX Assets means (a) those assets of Medovex Corp. acquired by the Company pursuant to the terms of the Contribution
Agreement and (b) any additional assets acquired by the Company or any Subsidiary thereof in connection with the Business.

 

52.
DenerveX Devices means rotational ablation denervation devices used in ablation of soft tissues in spinal applications
for selective denervation in the treatment of facet joint syndrome.

 

    	A-5

    	 

    

 

53.
Depreciation means, for each Fiscal Year or other period, an amount equal to the depreciation, amortization or other cost
recovery deduction allowable for federal income tax purposes with respect to an asset for such Fiscal Year or other period; provided,
however, that if the Gross Asset Value of an asset differs from its adjusted tax basis for federal income tax purposes
at the beginning of such Fiscal Year or other period, Depreciation shall be an amount that bears the same ratio to such beginning
Gross Asset Value as the federal income tax depreciation, amortization or other cost recovery deduction with respect to such asset
for such Fiscal Year or other period bears to such beginning adjusted tax basis; and provided further that, if the adjusted
tax basis of an asset for federal income tax purposes at the beginning of such fiscal Year or other period is zero, Depreciation
shall be determined with reference to such beginning Gross Asset Value using any reasonable method selected by the Board of Managers.

 

54.
Disputed Items has the meaning set forth in Section 7.3(b).

 

55.
Disputed Items Notice has the meaning set forth in Section 7.3(a).

 

56.
Distribution means each distribution made by the Company to a Member (or deemed made pursuant to Section 4.6), whether
in cash, property or securities of the Company and whether by liquidating distribution, redemption, repurchase or otherwise; provided
that none of the following shall be a Distribution: (a) any recapitalization or exchange of securities of the Company, and
any subdivision (by unit split or otherwise) or any combination (by reverse unit split or otherwise) of any outstanding Units,
(b) any repurchase by the Company of any securities of the Company in connection with the termination of employment of an employee
of the Company or any Subsidiary; provided such repurchase was approved by the Board of Managers, (c) any repurchase of
Units pursuant to any right of first refusal or other repurchase right in favor of the Company under this Agreement, or (d) any
issuance of Units by the Company upon a conversion of its convertible Units by the holder of such convertible Units.

 

57.
Effective Date has the meaning set forth in the first paragraph of this Agreement.

 

58.
Electronic Transmission means any form of communication, not directly involving the physical delivery of paper (including
without limitation, electronic mail), that creates a record that may be (a) retrieved and reviewed by the recipient thereof, and
(b) retained or stored by the recipient electronically or printed or otherwise reproduced in paper form by such a recipient.

 

59.
Eligible Member means (a) the H-Cyte Member and each Investor Member, (b) any Transferee of Units of the H-Cyte Member
or any Investor Member (and any subsequent Transferees of such Transferees), in each case pursuant to Transfers made in accordance
with the terms of this Agreement, and (c) any other Member which the Board of Managers may from time to time designate as an Eligible
Member; provided that if the Board of Managers designates additional Person(s) as Eligible Member(s), it may place conditions
and restrictions on such Persons.

 

60.
Equity Agreement has the meaning set forth in Section 3.3.

 

    	A-6

    	 

    

 

61.
Equity Securities means, with respect to the Company, (a) additional Membership Interests or other equity interests in
the Company, Class A Units, Class B Units, Class C Units, and other Units created after the Effective Date, (b) obligations, evidences
of indebtedness or other securities or interests convertible or exchangeable into Units or other equity securities in the Company,
and (c) warrants, options, or other rights to purchase or otherwise acquire Units or other equity interests in the Company or
securities described in clause (b) above.

 

62.
Exempted Securities means (a) the Class A Units and Class B Units owned by the Members on the Effective Date, (b) up to
200,000 Class A Units issued by the Company after the Effective Date to key stakeholders approved by the Board of Managers (and
subject to Section 6.8(c), (c) up to 1,000,000 Class C Units issued by the Company after the Effective Date to investors
for cash consideration in accordance with Section 3.1, (d) up to 250,000 Class C Units issued to the H-Cyte Member upon
conversion of the Seller Note and (e) Equity Securities issued in connection with any Unit split, Unit dividend or recapitalization
of the Company.

 

63.
Fiscal Period means any interim accounting period within a Fiscal Year established by the Board of Managers and which is
permitted or required by Section 706 of the Code.

 

64.
Fiscal Quarter means each calendar quarter ending March 31, June 30, September 30 and December 31, or such other quarterly
accounting period as may be established by the Board of Managers.

 

65.
Fiscal Year has the meaning set forth in Section 9.1.

 

66.
Formation Date has the meaning set forth in the Background.

 

67.
Governmental Entity means any federal, state, provincial, municipal, foreign or local government, any political subdivision
thereof or any other executive, legislative, administrative, judicial, quasi-judicial or other governmental entity, department,
commission, court, board, bureau, agency or instrumentality.

 

68.
Gross Asset Value means, with respect to any Company asset, such asset’s adjusted basis for U.S. federal income tax
purposes, except that the initial Gross Asset Value of any asset contributed by a Member to the Company shall be the fair market
value (as determined by the Board of Managers) of such asset as determined at the time of the contribution. The Gross Asset Value
of all Company assets may be adjusted by the Board of Managers to equal their respective fair market values as determined by the
Board of Managers in accordance with the rules set forth in Section 1.704-l(b)(2)(iv)(f) of the Treasury Regulations as of: (i)
the date of the acquisition of any additional Units by any new or existing Member in exchange for more than a de minimis
Capital Contribution; (ii) the date of the distribution of more than a de minimis amount of Company property; (iii) the
acquisition of an additional interest in the Company by any new or existing Member (other than a de minimis interest) which
is acquired as consideration to that Member for the provision of services to or for the benefit of the Company acting in a Member
capacity or in anticipation of becoming a Member, (iv) the liquidation of the Company within the meaning of Regulations Section
1.704-1(b)(2)(ii)(g); or (v) an election under Section 734(b) of the Code or Section 743(b) of the Code but only as provided in
Regulations Section 1.704-1(b)(2)(iv)(m) and only to the extent not duplicative of adjustments made pursuant to clauses (i) through
(iv). The Gross Asset Value of any Company asset distributed to any Member shall be adjusted immediately prior to such distribution
to equal its fair market value. Depreciation shall be calculated by reference to Gross Asset Value, instead of tax basis, once
Gross Asset Value differs from tax basis.

 

    	A-7

    	 

    

 

69.
Gross Receipts means all cash receipts of the Company (inclusive of the Subsidiaries) from any source whatsoever, but calculated
to avoid any double counting of payments to or from the Company (inclusive of the Subsidiaries) or payments to and from reserves
established by the Board of Managers.

 

70.
H-Cyte Member has the meaning set forth in the Background.

 

71.
H-Cyte Representative has the meaning set forth in Section 5.3(b)(i).

 

72.
Initial Budget has the meaning set forth in Section 5.4.

 

73.
Initial Holder means, with respect to a particular Unit, the Person to which the Company initially issued such Unit. For
greater certainty, the Initial Holder of a Unit does not include a Transferee of such Unit.

 

74.
Initial Managers has the meaning set forth in Section 5.3(b).

 

75.
Investment as applied to any Person means (a) any direct or indirect purchase or other acquisition by such Person of any
notes, obligations, instruments, stock, securities or ownership interest (including partnership interests, limited liability company
interests or joint venture interests) of any other Person and (b) any capital contribution by such Person to any other Person.

 

76.
Investor Member means any Member holding Class A Units.

 

77.
IP License Agreement has the meaning set forth in Exhibit C.

 

78.
Key Person means each of the individuals identified on Exhibit F.

 

79.
Law Firm has the meaning set forth in Section 11.12.

 

80.
Major Decisions has the meaning set forth in Section 6.8.

 

81.
Majority in Interest means the Member(s) holding Units representing at least a majority of the Percentage Interests of
all the Members entitled to vote on the matter requiring approval.

 

82.
Manager and Managers have the meaning set forth in Section 5.1.

 

83.
Material Adverse Event means the occurrence of any military or terrorist attack, any pandemic, hurricane, flood, tornado,
earthquake or other natural disaster or any other force majeure event which has a material adverse effect on the assets, properties,
or financial condition of the Company and its Subsidiaries or the market within which the Company operates as a whole solely to
the extent such changes do not affect the Company in a materially disproportionate manner relative to other participants in the
industry in which the Company operates.

 

    	A-8

    	 

    

 

84.
Member means those Persons listed from time to time on the Schedule of Members and any Person admitted to the Company
as a member of the Company (within the meaning of the Delaware Law), but only for so long as such Person is shown on the Company’s
books and records as the owner of one or more Units. Whenever the context requires, references in this Agreement to a Member shall
include an assignee who does not become a Substituted Member whenever such reference relates solely to an economic interest in
the Company.

 

85.
Member Minimum Gain means an amount, with respect to each “partner nonrecourse debt” (within the meaning of
Treasury Regulation Section 1.704-2(b)(4)), equal to the Company Minimum Gain that would result if such partner nonrecourse debt
were treated as a nonrecourse liability (within the meaning of Treasury Regulation Sections 1.704-2(b)(3) and 1.752-1(a)(2)),
determined in accordance with Treasury Regulation Section 1.704-2(i).

 

86.
Membership Interest means, with respect to any Member, the ownership interest of the Member in the Company having the rights,
including rights in respect of allocations of Net Income and Net Loss and to receive distributions conferred by this Agreement,
which ownership interests are personal property affording only the rights and privileges as are expressly set forth in this Agreement
and under the Delaware Law. All Membership Interests are represented by Units.

 

87.
Minimum Gain means the partnership minimum gain determined pursuant to Treasury Regulation Section 1.704-2(d).

 

88.
Monthly Average Sales Report has the meaning set forth in Section 7.3(a).

 

89.
Net Income or Net Losses means, for each Fiscal Year or Fiscal Period, the taxable income or tax loss of the Company
as determined under Section 703(a) of the Code (including in such taxable income or tax loss all items of income, gain, loss or
deduction required to be stated separately pursuant to Section 703(a)(1) of the Code), adjusted to the extent the Board of Managers
determines that such adjustment is necessary to comply with the requirements of Section 704(b) of the Code and the Treasury Regulations
promulgated thereunder, but excluding all items of income, gain and expense specially allocated pursuant to this Agreement. If
the Company’s taxable income or tax loss for such period, as adjusted pursuant to the preceding sentence, is a positive
amount, such amount shall be the Company’s Net Income for such period; and if negative, such amount shall be the Company’s
Net Losses for such period.

 

90.
New Audit Rules has the meaning set forth in Section 9.4(a).

 

91.
New Securities means any (a) Equity Securities of the Company (including Class A Units, Class B Units or Class C Units),
whether or not currently authorized or (b) securities of any type whatsoever that are, or may by their terms become, convertible
or exchangeable into or exercisable for Equity Securities of the Company including Equity Securities that contain options or rights
to acquire any Equity Securities.

 

    	A-9

    	 

    

 

92.
Offer Notice has the meaning set forth in Section 7.2(a).

 

93.
Officer means those persons designated in this Agreement or by the Board of Managers pursuant to Section 5.9 to
conduct the daily business of the Company.

 

94.
Order means any order, injunction, judgment, decree, ruling, assessment, or arbitration award of any Governmental Entity
or arbitrator.

 

95.
Other Business has the meaning set forth in Section 6.6.

 

96.
Percentage Interest means the percentage by which each owner of a Unit shares in various allocations, Distributions, and
other rights (excluding voting rights) and obligations in accordance with the terms of this Agreement and the Delaware Law. The
Percentage Interest with respect to each Member shall be equal to the product of (a) a fraction, the numerator of which is the
number of Voting Units held by such Member and the denominator of which is the total number of Voting Units outstanding multiplied
by (b) 100. The Percentage Interest so determined shall be rounded to the nearest one-thousandth of a percent. The Percentage
Interests of the Members are set forth on the Schedule of Members, and are subject to adjustment from time to time in accordance
with this Agreement.

 

97.
Permitted Pledge means a pledge of Units by a Member to a lender providing financing to the Company and/or one or more
Subsidiaries pursuant to a loan approved by the Board of Managers.

 

98.
Permitted Transfer means (a) a Transfer by the H-Cyte Member to any of its Affiliates without consideration, (b) a Transfer
from one Investor Member to another Investor Member, or (c) a Transfer by a Member to a trust for the benefit of such Member or
any of such Member’s spouse or any lineal descendant (by birth or adoption) of such Member, provided that any transfer described
in clause (b)-(c) is without consideration, for estate planning purposes and so long as the transferor retains voting and investment
control over the transferred Units.

 

99.
Permitted Transferee means any Person who acquires the Units of a Member pursuant to a Permitted Pledge or Permitted Transfer.

 

100.
Person means any individual, partnership, corporation, limited liability company, limited liability partnership, unincorporated
association, trust or other entity.

 

101.
Prior Agreement has the meaning set forth in the Background.

 

102.
Proceeding has the meaning set forth in Section 5.13(d).

 

103.
Purchase Option has the meaning set forth in Section 7.3(c).

 

    	A-10

    	 

    

 

104.
Purchase Price has the meaning set forth in Section 7.3(d).

 

105.
Regulatory Allocations has the meaning set forth in Section 4.3(e).

 

106.
Regulatory Authority has the meaning set forth in Section 11.13.

 

107.
Related Party Agreement has the meaning set forth in Section 6.10(a).

 

108.
Sablowski has the meaning set forth in the Background.

 

109.
Sale of the Company means either (a) the sale, lease, transfer, conveyance or other disposition, in one transaction or
a series of related transactions (including by way of merger, consolidation, recapitalization, reorganization or sale of securities
of one or more of the Company’s Subsidiaries), to any Person that is not an Affiliate of the Company, for value, of all
or substantially all of the assets of the Company and/or its Subsidiaries on a consolidated basis or (b) a transaction or series
of transactions (including by way of merger, consolidation, recapitalization, reorganization or sale of securities by the holders
of securities of the Company) with any Person that is not an Affiliate of the Company, the result of which is that the Members
immediately prior to such transaction are (after giving effect to such transaction) no longer, in the aggregate, the “beneficial
owners” (as such term is defined in Rule 13d-3 and Rule 13d-5 promulgated under the Securities Exchange Act), directly or
indirectly through one or more intermediaries, of more than fifty percent (50%) of the voting power of the outstanding voting
securities of the Company. Notwithstanding the foregoing, a Sale of the Company shall not include any such transaction effected
by the issuance of voting securities by Company or any of its Subsidiaries without any subsequent redemptions of Equity Securities
of the Company.

 

110.
Securities Act means the Securities Act of 1933, as amended from time to time.

 

111.
Securities Exchange Act means the Securities Exchange Act of 1934, as amended from time to time.

 

112.
Seller has the meaning set forth in Section 7.3(c).

 

113.
Seller Note means that certain Secured Convertible Promissory Note dated as of the Effective Date and in the original principal
amount of $140,000, made by the Company to the order of the H-Cyte Member as partial consideration for the assets of Medovex Corp.
acquired by the Company pursuant to the terms of the Contribution Agreement.

 

114.
Specified Persons has the meaning set forth in Section 6.6.

 

    	A-11

    	 

    

 

115.
Subsidiaries means with respect to any Person, any corporation, limited liability company, partnership, association or
business entity of which (a) if a corporation, a majority of the total voting power of shares of stock entitled (without regard
to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned
or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination
thereof, or (b) if a limited liability company, partnership, association or other business entity (other than a corporation),
a majority of partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly,
by any Person or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall
be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity
(other than a corporation) if such Person or Persons shall be allocated a majority of limited liability company, partnership,
association or other business entity gains or losses or shall be or control the manager, managing member, managing director (or
a board comprised of any of the foregoing) or general partner of such limited liability company, partnership, association or other
business entity. For purposes hereof, references to a “Subsidiary” of any Person shall be given effect only at such
times that such Person has one or more Subsidiaries, and, unless otherwise indicated, the term “Subsidiary” refers
to a Subsidiary of the Company.

 

116.
Substituted Member means a Person admitted as a substitute Member pursuant to Section 7.6(b).

 

117.
Tax Distribution has the meaning set forth in Section 4.7.

 

118.
Taxing Jurisdiction means any federal, state, local, or foreign government that has the right to collect tax, interest
or penalties, however designated, on any Member’s share of the income or gain attributable to the Company.

 

119.
Transaction Documents means, collectively, this Agreement, the Contribution Agreements, and such other documents and agreements
entered in connection with the foregoing agreements.

 

120.
Transfer has the meaning set forth in Section 7.1. The terms “Transferee,” “Transferor,”
“Transferred,” and other forms of the word “Transfer” shall have the correlative meanings.

 

121.
Transferring Holder has the meaning set forth in Section 7.2(a).

 

122.
Treasury Regulation means the regulations promulgated by the United States Department of Treasury pursuant to and in respect
of provisions of the Code. All references herein to sections of the Treasury Regulations shall include any corresponding provisions
of succeeding, similar, substitute, proposed, or final Treasury Regulations.

 

123.
Triggering Event has the meaning set forth in Section 7.3(c).

 

124.
Unit means the units of Membership Interest in the Company representing a fractional part of the interests in Net Income,
Net Losses and Distributions of the Company held by all of the Members and Assignees; provided, that any class, group, or series
of Units issued shall have the relative rights, powers and obligations set forth in this Agreement. As of the Effective Date,
the outstanding Units are Class A Units and Class B Units.

 

125.
Unit Equivalents means (without duplication with any Units or other Unit Equivalents) rights, warrants, options, convertible
securities, exchangeable securities, indebtedness or other rights, in each case exercisable for or convertible or exchangeable
into, directly or indirectly, Units or securities exercisable for or convertible or exchangeable into Units, whether at the time
of issuance or upon the passage of time or the occurrence of some future event.

 

126.
Voting Units means collectively, the Class A Units, the Class B Units, the Class C-1 Units and the Class C-2 Units. For
avoidance of doubt, the Class C-3 Units are not Voting Units.

 

    	A-12

    	 

    

 

SCHEDULE
OF MEMBERS

(as
of April 2, 2021)

 

	Member; Address	 	Class A Units	 	 	Class B Units	 	 	Class C Units	 	 	Class C-2 Units	 	 	Class C-3 Units	 	 	Total Units	 	 	Percentage Interest	 	 	Capital Proceeds Percentage	 
	The Magnolia Trust 
21 Braeside Avenue 
Smithfield, NSW 2164 
Australia 
Attn: Christopher Athavle	 	 	375,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	375,000	 	 	 	24.83	%	 	 	24.83	%
	ValMedX, LLC 
c/o Manfred Sablowski 
9849 Windwood Drive 
Venice, Florida 34292	 	 	335,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	335,000	 	 	 	22.19	%	 	 	22.19	%
	Guy Beckerlegge 
1301 Trendy Building 
Sukhumvit soi 13 
Bangkok, Thailand 10110	 	 	300,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	300,000	 	 	 	19.87	%	 	 	19.87	%
	The Future Idea of Investment 
6 Grosvenor Street 
Brighton, Victoria 3186 
Australia 
Attn: Gary Tescher	 	 	50,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	50,000	 	 	 	3.31	%	 	 	3.31	%
	David Strang 
38A Pleasant Road 
Hawthorn East 
VIC 3123	 	 	50,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	50,000	 	 	 	3.31	%	 	 	3.31	%
	Medovex Corp. 
201 E Kennedy Blvd 
Suite 700 
Tampa, Florida 33602 
Attn: CEO	 	 	-	 	 	 	400,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	400,000	 	 	 	26.49	%	 	 	26.49	%
	TOTAL	 	 	1,110,000	 	 	 	400,000	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	1,510,000	 	 	 	100.00	%	 	 	100.00	%

 

    	 

    	 

    

 

EXHIBIT
A

 

Officers
as of the Effective Date

 

	Name	 	Title
	Christopher
    Athavle	 	Chief
    Executive Officer
	Manfred
    Sablowski	 	Vice
    President of Sales and Marketing
	Guy
    Beckerlegge	 	Vice
    President of Operations

 

    	 

    	 

    

 

EXHIBIT
B

 

Initial
Budget

 

Summary

 

	Profit and loss forecast	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Yr 0	 	 	 	 	 	 	 	 	 	 
	Year ending	 	Jun-21	 	 	Jun-22	 	 	Jun-23	 	 	Jun-24	 
	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 
	Sales proceeds	 	$	0	 	 	$	1,302,224	 	 	$	2,484,778	 	 	$	3,747,302	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Production costs	 	$	0	 	 	$	466,667	 	 	$	605,889	 	 	$	914,760	 
	stock cost	 	$	0	 	 	$	0	 	 	$	0	 	 	$	0	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gross Profit	 	$	0	 	 	$	835,557	 	 	$	1,878,889	 	 	$	2,832,542	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Start-up salaries	 	$	18,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	quality consultant	 	$	0	 	 	$	0	 	 	$	0	 	 	$	0	 
	Marketing costs	 	$	5,000	 	 	$	44,000	 	 	$	60,500	 	 	$	85,500	 
	Legal costs	 	$	25,000	 	 	$	12,000	 	 	$	24,000	 	 	$	24,000	 
	Freight - moulds	 	$	6,500	 	 	$	0	 	 	$	0	 	 	$	0	 
	Freight to units - to UK	 	$	5,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Storage	 	$	3,200	 	 	$	3,200	 	 	$	0	 	 	$	0	 
	audit on transfer of ISO certification	 	$	25,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	sterilisation of original units	 	$	33,360	 	 	$	0	 	 	$	0	 	 	$	0	 
	ETO validation - initial stock	 	$	50,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Success fee re CE mark	 	$	0	 	 	$	16,875	 	 	$	0	 	 	$	0	 
	Purchase of generators	 	$	0	 	 	$	0	 	 	$	96,000	 	 	$	96,000	 
	Purchase of dummy units	 	$	12,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Tooling testing and validation	 	$	15,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Man setup and ETO validation	 	$	31,240	 	 	$	62,480	 	 	$	0	 	 	$	0	 
	Purchase of stock from Nortec	 	$	250,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Purchase of parts from UK	 	$	28,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Purchase of spare parts	 	$	15,000	 	 	$	0	 	 	$	0	 	 	$	0	 
	Transfer to stock - finished goods	 	$	-311,360		 	$	0	 	 	$	0	 	 	$	0	 
	Transfer to stock - parts	 	$	-15,000		 	$	0	 	 	$	0	 	 	$	0	 
	Senior manager salaries	 	$	0	 	 	$	130,222	 	 	$	248,478	 	 	$	374,730	 
	Accountant	 	$	8,000	 	 	$	24,000	 	 	$	24,000	 	 	$	24,000	 
	Quality manager	 	$	13,500	 	 	$	44,625	 	 	$	45,000	 	 	$	45,000	 
	Company secretary	 	$	3,000	 	 	$	9,000	 	 	$	9,000	 	 	$	9,000	 
	Office costs	 	$	0	 	 	$	4,000	 	 	$	4,800	 	 	$	4,800	 
	Insurance	 	$	0	 	 	$	33,000	 	 	$	36,000	 	 	$	36,000	 
	Annual audit	 	$	0	 	 	$	0	 	 	$	50,000	 	 	$	50,000	 
	Clinical trials	 	$	0	 	 	$	105,000	 	 	$	45,000	 	 	$	0	 
	Travel and accommodation	 	$	0	 	 	$	15,000	 	 	$	36,000	 	 	$	36,000	 
	Legal fees re patent	 	$	0	 	 	$	0	 	 	$	40,000	 	 	$	40,000	 
	Grand avenue	 	$	2,708	 	 	$	8,124	 	 	$	8,124	 	 	$	8,124	 
	Royalty	 	$	0	 	 	$	38,133	 	 	$	149,087	 	 	$	224,838	 
	Stock price adjustment	 	$	0	 	 	$	58,458	 	 	$	0	 	 	$	0	 
	Generator testing	 	$	6,250	 	 	$	16,375	 	 	$	0	 	 	$	0	 
	EBITDA	 	$	-229,398		 	$	211,065	 	 	$	1,002,901	 	 	$	1,774,550	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cumulative net profit	 	$	-229,398		 	$	-18,333		 	$	984,567	 	 	$	2,759,117	 

 

	Summary Profit and loss	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Year ending	 	 	Jun-21	 	 	 	Jun-22	 	 	 	Jun-23	 	 	 	Jun-24	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Sales proceeds	 	$	0	 	 	$	1,302,224	 	 	$	2,484,778	 	 	$	3,747,302	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COGS	 	$	0	 	 	$	466,667	 	 	$	605,889	 	 	$	914,760	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gross Profit	 	$	0	 	 	$	835,557	 	 	$	1,878,889	 	 	$	2,832,542	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Overheads	 	$	229,398	 	 	$	624,493	 	 	$	875,988	 	 	$	1,057,992	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	EBITDA	 	$	-229,398		 	$	211,065	 	 	$	1,002,901	 	 	$	1,774,550	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Based on	 	 	7 months preparation 

                                                                                before first sale
	 	 	 	 	 	 	 

 

    	 

    	 

    

 

EXHIBIT
C

 

Approved
Related Party Arrangements

 

	1.	Intellectual
    Property License Agreement dated as of the Effective Date between the H-Cyte Member and the Company, with respect to the license
    by the Company of certain intellectual property from the H-Cyte Member for use in the Business (the “IP License Agreement”).

 

    	 

    	 

    

 

EXHIBIT
D

 

ADOPTION
AGREEMENT

 

This
Adoption Agreement (this “Adoption Agreement”) is executed by
the undersigned (the “Transferee”) pursuant to the terms of that certain Amended and Restated Limited Liability
Company Agreement of Medovex, LLC, a Delaware limited liability company (the “Company”), dated as of _____________,
2021 (the “LLC Agreement”), by and among the Company and its Members. Capitalized terms used but not defined
in this Adoption Agreement shall have the respective meanings ascribed to such terms in the LLC Agreement. By the execution of
this Adoption Agreement, the Transferee agrees as follows:

 

1.
Acknowledgement. Transferee acknowledges that Transferee is acquiring certain Units (the “Acquired Units”),
subject to the terms and conditions of the LLC Agreement.

 

2.
Agreement. Transferee (a) agrees that the Acquired Units acquired by Transferee shall be bound by and subject to the terms
of the LLC Agreement, and (b) hereby adopts the LLC Agreement with the same force and effect as if the Transferee were originally
a party thereto.

 

3.
Notice. Any notice required or permitted by the Agreement shall be given to Transferee at the address listed beside the
Transferee’s signature below.

 

[Signature
page follows.]

 

    	 

    	 

    

 

EXECUTED
AND DATED this ____ day of _______________, 20____.

 

	 	[Name
    of Transferee],
	 	 	 
	 	By:	      
	 	Name:	 
	 	Title:	 
	 	 	 
	 	Address:	 
	 	 
	 	 
	 	 
	 	 
	 	Fax:
    	

 

	Accepted
    and Agreed by the Company:	 
	 	 	 
	Medovex,
    LLC,	 
	a
    Delaware limited liability company	 
	 	      	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	  

 

    	 

    	 

    

 

EXHIBIT
E

 

Permitted
Outside Activities

 

	Individual	 	Outside
    Activities
	

        Christopher
        Athavle

        
	 	1.	Shareholder of Orthoprice
    (seller of knee prosthesis in Australia for B Braun).
	 	2.	Director of BTT
    Health GmbH (expected to terminate in April 2021)
	 	3.	Sales Agent for
    TikR (data storage/mining company)
	 	4.	Results Research
    Ortho Pty Ltd
	 	 	 
	Manfred Sablowski	 	1. 	Consultant to Intralink-Spine
    (product for treatment of degenerative disc disease)
	 	 	 
	

        Guy
        Beckerlegge

        
	 	1.	Consultant
    to Debx (Dutch chronic wound care company)
	 	2.	Co-founder of Recharge
    (bio-photonic device company) and serving as shareholder and advisor, but not involved in day to day business.
	 	3.	Consultant to Immunoheal
    – Singapore-based infection disease diagnostic company; also serving as consultant, but not involved in day to day business.

 

    	 

    	 

    

 

EXHIBIT
F

 

Key
Persons

 

	1.	Christopher
    Athavle
	2.	Manfred
    Sablowski
	3.	Guy
    Beckerlegge
	4.	Gary
    Tescher
	5.	David
    Strang

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]